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in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, 
as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
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a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1. PUBLIC HEALTH STATEMENT
 
This public health statement tells you about chlorfenvinphos and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal clean-up activities.  Chlorfenvinphos has been found in at least 1 of the 
1,428 current or former NPL sites.  However, it’s unknown how many NPL sites have been 
evaluated for this substance. As more sites are evaluated, the sites with chlorfenvinphos may 
increase. This is important because exposure to this substance may harm you and because these 
sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it by breathing, 
eating, or drinking the substance or by skin contact. 
If you are exposed to chlorfenvinphos, many factors determine whether you'll be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider the other chemicals you're exposed to and your age, sex, diet, family 
traits, lifestyle, and state of health. 
1.1 WHAT IS CHLORFENVINPHOS? 
Chlorfenvinphos is the common name of an organophosphorus insecticide used to control insect 
pests on livestock. It was also used to control household pests such as flies, fleas, and mites. 
This chemical is synthetic and does not occur naturally in the environment.  Chlorfenvinphos 




1. PUBLIC HEALTH STATEMENT 
The pure chemical (100% chlorfenvinphos) is a colorless liquid with a mild odor.  Commercial 
preparations commonly used in insecticides sold in stores were usually 90% chlorfenvinphos. 
Most of chlorfenvinphos was used in liquid form.  The substance easily mixes with acetone, 
ethanol, and propylene glycol. It is slowly broken down by water and is corrosive to metal. 
1.2	 WHAT HAPPENS TO CHLORFENVINPHOS WHEN IT ENTERS THE 
ENVIRONMENT? 
Chlorfenvinphos enters the environment from runoff after rainfall and leaching from hazardous 
waste sites. After it has leached, it may be present in the soil and underground water (wells).  It 
may be present in surface water (rivers and ponds) after it has run off the land.  From soil, it may 
also be washed into surface waters by rain. It may also move from soil to the air by evaporation 
or by being absorbed by plants. No information is available now to show that it can be found in 
fish or other freshwater animals, or in seafood, or in plants that are eaten by people. 
1.3	 HOW MIGHT I BE EXPOSED TO CHLORFENVINPHOS? 
Most cases of unintentional chlorfenvinphos poisoning have resulted from short exposures to 
very high concentrations of this substance. Usually this occurred when people unintentionally 
swallowed it. Workers involved in pesticide application, or dairy farming, cattle or sheep 
holding, or poultry production, may have inhaled, swallowed, or contaminated their skin with a 
large amount of the substance if they did not properly protect themselves when using it.  The 
most common way for people to be exposed to chlorfenvinphos is by eating imported 
agricultural products contaminated with it and by using pharmaceutical products that contain 
lanolin. Lanolin is a natural grease from sheep’s wool wax that is used as a base for many 
medications, cosmetic skin lotions, and creams that are rubbed on the skin to keep the skin from 
drying. Chlorfenvinphos used to control flies in animal buildings and holding pens can 
contaminate sheep’s wool.  If you live in areas surrounding hazardous waste disposal sites or 
treatment facilities for chlorfenvinphos, you could be exposed to it by contact with soils, runoff 
water, surface water, or groundwater contaminated by spills or leaks on the site or facility. 
People who work in the disposal of chlorfenvinphos or its wastes are more likely to be exposed.  
3 CHLORFENVINPHOS 
1. PUBLIC HEALTH STATEMENT 
You are most likely to be exposed to chlorfenvinphos if you live near chemical plants where it 
was manufactured, or near dairy or poultry farms, or cattle or sheep holding areas where it was 
used; or if you live near hazardous waste sites that contain it. 
1.4 HOW CAN CHLORFENVINPHOS ENTER AND LEAVE MY BODY? 
If you breathe air containing chlorfenvinphos, you may absorb it into your body through your 
lungs. If you eat food or drink water containing this substance, it may be absorbed from your 
stomach and intestines.  Chlorfenvinphos may also enter your body through your skin.  Once in 
the body, it is rapidly broken down and eliminated from the body, mostly when you urinate.  It 
does not build up in your tissues. 
1.5 HOW CAN CHLORFENVINPHOS AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.  One way to see if a chemical will hurt people 
is to learn how the chemical is absorbed, used, and released by the body; for some chemicals, 
animal testing may be necessary.  Animal testing may also be used to identify health effects such 
as cancer or birth defects. Without laboratory animals, scientists would lose a basic method to 
get information needed to make wise decisions to protect public health.  Scientists have the 
responsibility to treat research animals with care and compassion.  Laws today protect the 
welfare of research animals and scientists must comply with strict animal care guidelines.  
Chlorfenvinphos affects the nervous system.  In animals and people, high doses of the substance 
produce effects on the nervous system similar to those produced by high doses of muscarine and 
pure nicotine. Some mild symptoms of exposure are headache, dizziness, weakness, feelings of 
anxiety, confusion, runny nose, constriction of the pupils of the eye, and inability to see clearly. 
More severe symptoms may include nausea and vomiting, abdominal cramps, slow pulse, 
diarrhea, pinpoint pupils, difficulty in breathing, and passing out (fainting).  These signs and 
symptoms may start to develop within 30–60 minutes and reach their maximum effect after 
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6–8 hours. Very high exposure to chlorfenvinphos has killed people who swallowed it by 
accident or who swallowed large amounts of the substance to commit suicide.  We do not know 
if people who swallow small quantities of chlorfenvinphos over long periods of time will have 
permanent damage to their immune systems.  In almost all cases, complete recovery occurred 
when exposure stopped. There is no evidence that long-term exposure to small amounts of the 
chlorfenvinphos causes any other harmful health effects in people.  The substance has not been 
shown to cause birth defects or to prevent conception in people. The International Agency for 
Research on Cancer, the Environmental Protection Agency, and the National Toxicology 
Program have not yet studied chlorfenvinphos for cancer in people and animals.  In animal 
studies, high doses of chlorfenvinphos produced effects on the nervous system similar to those 
seen in people. 
1.6	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO CHLORFENVINPHOS? 
Most of the signs and symptoms resulting from chlorfenvinphos poisoning are due to the 
inhibition of an enzyme called “acetylcholinesterase” in the nervous system.  This enzyme is 
also found in your red blood cells and a similar enzyme (pseudocholinesterase) is found in blood 
plasma.  The most common test for exposure to many pesticides (including chlorfenvinphos) that 
contain the element phosphorus is to determine the level of cholinesterase activity in the red 
blood cells or plasma.  This test requires only a small amount of blood and can be done in your 
doctor's office.  It takes weeks for this enzyme to completely recover to normal levels following 
exposure; therefore, a valid test may be conducted a number of days following the suspected 
exposure. This test indicates only exposure to a chemical substance of this type.  It does not 
specifically show exposure to chlorfenvinphos. Other chemicals or disease conditions may also 
alter the activity of this enzyme.  There is a wide range of normal cholinesterase activity among 
individual people in the general population. If your normal or baseline value has not been 
established through a previous test, you might have to repeat the test several times to determine 
if your enzyme activity is recovering. 
Specific tests are available to identify chlorfenvinphos or its break-down products in your blood, 
body tissue, and urine. These tests are not usually available through your doctor's office and 
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require special equipment and sample handling.  If you need the specific test, your doctor can 
collect the sample and send it to a special laboratory for analysis.  Chlorfenvinphos is rapidly 
broken down to other chemicals and removed from the body (in urine), so this test must be done 
in the first few days after exposure to make sure that you have really breathed, swallowed, or got 
chlorfenvinphos on your skin. 
1.7	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). 
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals, then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other reasons. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. 
The federal government has set standards or guidelines to protect people from the possible 
harmful health effects of chlorfenvinphos.  These include regulated concentration limits for 
agricultural products, public right-to-know requirements about production and use of 
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chlorfenvinphos, and regulated quantities requiring emergency response procedures if an 
accidental release occurred. 
1.8 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or: 








* Information line and technical assistance 
Phone: (404) 639-6000 
Fax: (404) 639-6315 or 6324 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
* To order toxicological profiles, contact: 
National Technical Information Service
 




Phone: (800) 553-6847 or (703) 487-4650
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2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other 
interested individuals and groups with an overall perspective of the toxicology of chlorfenvinphos.  It contains 
descriptions and evaluations of toxicological studies and epidemiological investigations and provides 
conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near hazardous 
waste sites, the information in this section is organized first by route of exposure—inhalation, oral, and 
dermal; and then by health effect—death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects.  These data are discussed in terms of three exposure 
periods—acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. 
The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse­
effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  LOAELS have been 
classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological 
system and can lead to morbidity or mortality (e.g., acute respiratory distress or death).  "Less serious" effects 
are those that are not expected to cause significant dysfunction or death, or those whose significance to the 
organism is not entirely clear.  ATSDR acknowledges that a considerable amount of judgment may be 
required in establishing whether an end point should be classified as a NOAEL, "less serious" LOAEL, or 
"serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is 
indicative of significant dysfunction.  However, the Agency has established guidelines and policies that are 
used to classify these end points.  ATSDR believes that there is sufficient merit in this approach to warrant an 
attempt at distinguishing between "less serious" and "serious" effects.  The distinction between "less serious" 
effects and "serious" effects is considered to be important because it helps the users of the profiles to identify 
levels of exposure at which major health effects start to appear.  LOAELs or NOAELs should also help in 
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determining whether or not the effects vary with dose and/or duration, and place into perspective the possible 
significance of these effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures 
may differ depending on the user's perspective.  Public health officials and others concerned with appropriate 
actions to take at hazardous waste sites may want information on levels of exposure associated with more 
subtle effects in humans or animals (LOAEL) or exposure levels below which no adverse effects (NOAELs) 
have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may 
be of interest to health professionals and citizens alike. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been made 
for chlorfenvinphos. An MRL is defined as an estimate of daily human exposure to a substance that is likely 
to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. 
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most 
sensitive health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for acute, 
intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate methodology does 
not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an example, 
acute inhalation MRLs may not be protective for health effects that are delayed in development or are 
acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. 
As these kinds of health effects data become available and methods to assess levels of significant human 
exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in the 
interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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2.2.1 Inhalation Exposure 
2.2.1.1 Death 
There are no reports of deaths in humans exposed by acute-, intermediate-, or chronic-duration 
inhalation to chlorfenvinphos. 
No studies were located regarding lethality in animals after intermediate- or chronic-duration 
inhalation exposure to chlorfenvinphos. A study investigated whether the difference in the route of 
absorption or the mode of lethality is responsible for the higher lethality of the micron-sized (>1 µm) 
aerosols in male rats. The study reported 0, 60, and 100% mortality in rats at the 83, 144, and 
236 mg/m3 ambient air concentrations, respectively. The deaths occurred 3 and 4 hours after 
initiation of the exposure to micron-sized chlorfenvinphos aerosols. There was 0, 80, and 100% 
mortality in rats at the 254, 471, and 1,019 mg/m3 ambient air concentrations, respectively. The 
LC50 value calculated from the mortality of the rats was markedly increased by cannulation (from 
133 mg/m3 for non-cannulated to 489 mg/m3 for cannulated rats) for the micron-sized aerosol 
ambient air concentrations. However, there was essentially no difference in the LC50 values 
(509 mg/m3 for non-cannulated and 475 mg/m3 for cannulated rats) calculated from the mortality of 
the rats that were administered the more inhalable submicron-sized aerosols ambient air 
concentrations. These data indicate that the micron-sized aerosols were about 4 times more potent 
in producing lethality than the submicron-sized aerosols. This is also an indication that swallowed 
chlorfenvinphos contributed to the lethality; this was more evident for the less inhalable micron-
sized aerosol ambient air concentrations. Elapsed time from the start of exposure to death was not 
changed by the cannulation in both the micron-sized and the submicron-sized aerosols. The 
authors surmised that death from acute exposure to chlorfenvinphos aerosols probably derives 
from inhibition of acetylcholinesterase(AChE) activity (Takahashi et al. 1994).  In another study with 
rats, the acute lethality of chlorfenvinphos was unaffected in male rats in snout-only or whole body 
exposures (Tsuda et al. 1986). The LC50 for death in rats is shown in Table 2-1 and plotted in 
Figure 2-1. 
2.2.1.2 Systemic Effects 
No studies were located regarding the gastrointestinal, hematological, musculoskeletal, hepatic, 
renal, endocrine, dermal, ocular, or body weight effects in humans or animals following acute-, 
intermediate-, or chronic-duration inhalation exposure to chlorfenvinphos.  Existing human data on 
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substance are limited to chronic-duration exposure. Existing animal data on the respiratory and 
cardiovascular effects are limited to acute-duration exposure. 
The highest NOAEL value and all LOAEL values for adverse systemic effects in each reliable study 
for each species and duration category are shown in Table 2-1 and plotted in Figure 2-1. 
Respiratory Effects.  No studies were located regarding respiratory effects in humans after 
exposure to chlorfenvinphos for any duration category. 
Acute-duration exposure of rats to inhalation aerosol chlorfenvinphos ambient air concentrations 
produced cardiorespiratory changes in the treated rats at high ambient air concentrations. Male 
Fischer 344 rats exposed to the micron-sized (>1 µm) or submicron-sized (<1 µm) chlorfenvinphos 
aerosols for 4 hours suffered cardiorespiratory effects. Rats exposed to the lethal concentration of 
1,220 mg/m3 of the submicron-sized aerosols showed a progressive increase in blood pressure 
followed by an apnea during which the blood pressure was maximally increased. Rats exposed to 
390 mg/m3 of the micron-sized aerosols also exhibited cardiorespiratory changes similar to 
changes caused by the submicron-sized aerosols (data were not shown in the report). No 
significant qualitative difference was observed in cardiorespiratory changes between the micron-
sized and the submicron-sized aerosols, suggesting that the mode of lethality is not different 
between the two types of aerosols. A LOAEL of 390 mg/m3 for apnea was established in this study 
(Takahashi et al. 
1994). In a previous study (Takahashi et al. 1991), Sprague-Dawley rats exhibited similar signs at 
an intravenous dose of 16 mg/kg of chlorfenvinphos. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans 
after exposure to chlorfenvinphos for any duration category. 
Acute exposure of rats to inhalation aerosol chlorfenvinphos ambient air concentrations produced 
cardiorespiratory changes in the treated rats at high ambient air concentrations. Adult male 
Fischer 344 rats exposed to the micron-sized (>1 µm) or submicron-sized (<1 µm) chlorfenvinphos 
aerosols for 4 hours suffered cardiorespiratory effects. Rats exposed to the lethal concentration 
of 1,220 mg/m3 of the submicron-sized aerosols showed a progressive increase in blood pressure 
followed by apnea during which the blood pressure was maximally increased. Bradycardia was 
observed in the electrocardiograph (ECG) at the pressor period, which was characterized 
by a prolonged TP time without a change in PQ, QRS, and ST time. Rats exposed to 390 mg/m3 
of the micron-sized aerosols also exhibited cardiorespiratory changes similar to those 
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caused by the submicron-sized aerosols (data were not shown in the report). No significant 
qualitative difference was observed in cardiorespiratory changes between the micron-sized and the 
submicron-sized aerosols, suggesting that the mode of lethality is not different between the two 
types of aerosols. A LOAEL of 390 mg/m3 for progressive increased blood pressure and 
bradycardia was established in this study (Takahashi et al. 1994). 
Metabolic Effects. The information on the metabolic effects of chronic-duration inhalation 
exposure to chlorfenvinphos provides only inconclusive evidence.  Examinations of 
31 manufacturing workers who directly handled the chlorfenvinphos (and other similar compounds) 
for 19–53 years revealed significantly lowered NBT (nitroblue tetrazolium)-dye reduction in both 
stimulated and non-stimulated cells, as well as a significant decrease of the spontaneous E rosette 
formation (not influenced by exposure time) in the blood (early E rosettes, 52%; late E rosettes, 
57%) as compared to controls (early E rosettes, 57%; late E rosettes, 63%). No correlation was 
found between the spontaneous E rosette formation and acetylcholinesterase activity. The authors 
of this study concluded that depressed NBT-dye reduction and diminished spontaneous E rosette 
formation may be regarded as a probable mode of the effect of organophosphoric chemicals on 
metabolic and membrane damage to human cells. About half of the subjects in the study were 
smokers (Wysocki et al. 1987). However, the data from this study are not reliable for evaluating the 
inhalation toxicity of chlorfenvinphos because the workers were also concurrently exposed to 
greater concentrations of other known toxic substances. 
No studies were located regarding metabolic effects in animals after exposure to chlorfenvinphos 
for any duration category. 
2.2.1.3 Immunological and Lymphoreticular Effects 
No studies were located regarding the immunological and lymphoreticular effects in humans 
following acute- or intermediate-duration inhalation exposure to chlorfenvinphos. However, chronic-
duration inhalation exposure to organophosphoric pesticides caused a depression of immune 
responses and, consequently, produced damage to humoral mechanisms in humans.  Examination 
of 31 manufacturing workers who directly handled the organophosphoric pesticide chlorfenvinphos 
(and other compounds) for 19–53 years revealed significantly lowered NBT-dye reduction in 
both stimulated and non-stimulated cells, and a decreased percentage of phagocytic cells 
(P<0.001, 0.05, and 0.002, respectively) in pesticide workers occupationally exposed to an 
estimated average ambient chlorfenvinphos concentration of 0.21 mg/m3. These analyses 
parameters of the NBT test showed a positive linear correlation with the degree of 
acetylcholinesterase activity reduction. The exposure time had no effect on NBT reduction test 
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parameters, but there was a negative linear correlation with the phagocytic index of the NBT test 
(r = -0.4879, P<0.01). A significant decrease of the spontaneous E rosette formation (not 
influenced by exposure time) was found in the blood of the exposed workers (early E rosettes, 
52%; late E rosettes, 57%), as compared to controls (early E rosettes, 57%; late E rosettes, 63%). 
No correlation was found between the spontaneous E rosette formation and acetylcholinesterase 
activity. No significant differences were found in number of white blood cells, mainly neutrophils, in 
the two examined subgroups, but the absolute lymphocyte count in the peripheral blood of the 
exposed subjects was lower when compared to controls (1,941.9 versus 2,380 cells/mm3, P<0.05). 
The authors of this study concluded that depressed NBT-dye reduction and diminished 
spontaneous E rosette formation may be regarded as a probable mode of action of 
organophosphoric chemicals on metabolic and membrane damage to human cells. 
Acetylcholinesterase activity, which showed a time-independent positive linear relationship to 
lowered NBT-dye reduction in the subjects, was above 2 µmol in 17 of the subjects (with an 
average age of 38.5 years). Eighteen (58.1%) of the subjects examined showed symptoms of 
chronic bronchitis; seven (23.3%) subjects in the control group also had signs indicating previous 
(anamestic) chronic bronchitis. It is generally understood that chronic bronchitis stems from 
changes in humoral rather than cellular immune response. About half of the subjects were 
smokers. The maximal estimated airborne concentrations of substances in the workplace were: 
0.654 mg/m3 (formothion), 0.483 mg/m3 (sumithion), trace (DDVP), 0.21 mg/m3 (chlorfenvinphos), 
and 1.09 mg/m3 (malathion) (Wysocki et al. 1987). The data from this study are not reliable for 
evaluating the inhalation toxicity of chlorfenvinphos because the workers were also concurrently 
exposed to greater concentrations of other known immunotoxic substances. 
No studies were located regarding immunological and lymphoreticular effects in animals after 
acute-, intermediate-, or chronic-duration inhalation exposure to chlorfenvinphos. 
2.2.1.4 Neurological Effects 
No studies were located regarding neurological effects in humans after acute- or intermediate-
duration inhalation exposure to chlorfenvinphos. The single study that reported 
neurological effects in humans from inhalation exposure to chlorfenvinphos involved occupational 
exposure. A group of nine gardeners (pesticide mixers) who worked with the organo­
phosphates (dimethoate, formothion, isofenphos and occasionally chlorfenvinphos) for an 
unspecified duration complained of headaches. The gardeners had a mean difference (before 
and after exposure) of 0.56 nmol/mL for acetylcholinesterase and 2.67 nmol/mL for butyryl 
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cholinesterase. Since the symptoms could also result from exposure to the other 
organophosphates (dimethoate, formothion, isofenphos) to which the workers were also exposed, 
the role of chlorfenvinphos exposure in this incident is not certain. In addition, no data were given 
on air concentrations of the organophosphate pesticides (Kolmodin-Hedman and Eriksson 1987). 
No studies were located regarding neurological effects in animals after intermediate- or chronic-
duration inhalation exposure to chlorfenvinphos. Acute exposure of rats to aerosols of 
chlorfenvinphos produced neurological signs indicative of cholinergic response stemming from 
inhibition of acetylcholinesterase activity. Surviving adult male Fischer 344 rats (27 of 60) exposed 
to the micron-sized (>1 µm) or submicron-sized (<1 µm) chlorfenvinphos aerosols for 4 hours (83, 
130, 144, 236, 254, 322, 471, 623, 1,019, or 1,065 mg/m3) exhibited cholinergic signs: salivation, 
urination, exophthalmos, twitches, and tremors, at $83 mg/m3. The inhalation experiments were 
conducted using a nose-only inhalation chamber. (To examine the toxicological significance of 
swallowed chlorfenvinphos, a drain cannula was placed in the esophagus under pentobarbital 
sodium anesthesia.) Toxic signs were not assessed in detail during the exposure because the rats 
were in the animal holder. There were no differences in toxic signs between the micron-sized and 
the submicron-sized aerosols (Takahashi et al. 1994). 
All LOAEL values for neurological effects in each reliable study for each species and duration 
category are shown in Table 2-1 and plotted in Figure 2-1. 
No studies were located regarding the following health effects in humans or animals after acute-, 
intermediate-, or chronic-duration inhalation exposure to chlorfenvinphos: 
2.2.1.5 Reproductive Effects 
2.2.1.6 Developmental Effects 
2.2.1.7 Genotoxic Effects 
Other genotoxicity studies for chlorfenvinphos are described in Section 2.5. 
16 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
2.2.1.8 Cancer 
No studies were located regarding carcinogenic effects in humans or animals following inhalation 
exposure to chlorfenvinphos. 
2.2.2 Oral Exposure 
2.2.2.1 Death 
There are no reports of deaths in humans exposed by intermediate- or chronic-duration ingestion of 
chlorfenvinphos. A 16-month-old child who accidentally drank an unspecified amount of 
chlorfenvinphos, used for flea treatment in the home, died despite treatment in a hospital (Felthous 
1978). 
Chlorfenvinphos is extremely toxic to rodents and dogs by the oral route in acute doses. The oral 
LD50 values for rats, rabbits, and dogs have been estimated to be 9.7, 300, 50.5 mg/kg, respectively 
(Ambrose et al. 1970). An acute oral LD50 of 23 mg/kg was calculated from the mortality data of an 
unspecified number of male Wistar rats that were given varying doses of chlorfenvinphos in olive oil 
(Hutson and Logan 1986). Similarly, the acute oral LD50 of chlorfenvinphos in male rats as a single 
dose in olive oil was estimated to be 15.4 mg/kg. Animals that died from the effects of 
chlorfenvinphos did so within 12 hours of dosing; no further deaths were noted up to 72 hours after 
dosing. The chlorfenvinphos LD50 value for rats pretreated with dieldrin (0.2 mg/kg) was estimated 
to be 157 mg/kg; thus, dieldrin pretreatment induced a 10-fold protective effect against the acute 
toxicity of the organophosphate (Hutson and Wright 1980). After prolonged (105 minutes) 
exhibition of cholinergic signs, death occurred at the 20 mg/kg dose when Sprague-Dawley rats 
were orally administered single doses of 1.25, 5, or 20 mg/kg chlorfenvinphos (Takahashi et al. 
1991). In another study with Wistar rats, the acute oral LD50 was significantly decreased in rats fed 
a protein-deficient (4.5%) diet during the 60 days of administration. The 60-day rat LD50 value was 
reduced from a control value of 23.0 mg/kg to 7.4 mg/kg in males and 25.5 mg/kg to 10.2 mg/kg in 
females (Puzynska 1984). Pretreatment of male Fischer 344 rats with 15 mg/kg chlorfenvinphos 
followed by a further 15 mg/kg dose significantly reduced the male oral LD50 for chlorfenvinphos 
from a positive control value of 34.3 mg/kg to 105.6 mg/kg; about 3.08-fold (P<0.05). Deaths 
occurred between 2 hours and 1 day after oral administration of chlorfenvinphos (Ikeda et al. 1992). 
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Chlorfenvinphos appears to be less toxic to mice than to rats. In a lethality study with BDF1 mice of 
both sexes, the oral LD50 and maximum tolerated dose (MTD) for chlorfenvinphos (suspended in 
methylcellulose) were estimated to be 148 mg/kg and 109 mg/kg, respectively. The mice were 
evaluated 5 days after intragastric administration of the chlorfenvinphos doses (Kowalczyk-Bronisz 
et al. 1992). A mouse acute oral LD50 of 100–200 mg/kg for chlorfenvinphos was cited from an 
earlier study in which male CFI mice were used (Hutson and Logan 1986). 
A rabbit acute oral LD50 of >500–1,000 mg/kg for chlorfenvinphos was cited from an earlier study in 
which male New Zealand White rabbits were used (Hutson and Logan 1986). 
A dog acute oral LD50 of >5,000 mg/kg for chlorfenvinphos was cited from an earlier study in which 
female Beagle dogs were used (Hutson and Logan 1986). 
In prolonged exposures, no significant effect on mortality and survival was reported for rats and 
dogs given chlorfenvinphos in the diet at doses as high as 90 mg/kg/day for 12 weeks or 
24 mg/kg/day for 104 weeks (Ambrose et al. 1970). 
The LD50 values and doses associated with death in each species and duration category are shown 
in Table 2-2 and plotted in Figure 2-2. 
2.2.2.2 Systemic Effects 
No studies were located regarding the hematological, cardiovascular, gastrointestinal, 
musculoskeletal, hepatic, renal, endocrine, dermal, ocular, body weight, or other systemic effects in 
humans following acute-, intermediate-, or chronic-duration oral exposure to chlorfenvinphos. 
Existing human data on the respiratory and neurological effects are limited to acute-duration 
exposures. No studies were located regarding ocular effects in animals following acute-, 
intermediate-, or chronic-duration oral exposure to chlorfenvinphos. 
The highest NOAEL value and all LOAEL values for adverse systemic effects in each reliable study 
for each species and duration category are shown in Table 2-2 and plotted in Figure 2-2. 
Respiratory Effects.  No human studies were located that reported direct effects on the 
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ingestion of a mange-mite medication containing organic phosphate or intentional ingestion of the 
preparation Enolofos®, which contains 50% chlorfenvinphos, in suicide attempts reported in two 
clinical reports stemmed from central cholinergic disturbances (Cupp et al. 1975; Pach et al. 1987). 
In animal studies, no effects on the respiratory system were noted in rats and dogs orally 
administered chlorfenvinphos at doses as high as 100 mg/kg/day (rats) or 50 mg/kg/day (dogs) for 
12 weeks; or in rats at doses as high as 24 mg/kg/day for 104 weeks (Ambrose et al. 1970). 
Cardiovascular Effects.  Evidence from animal studies indicates that chlorfenvinphos is not 
directly toxic to the cardiovascular system but may modulate the function of the cardiovascular 
system via its effect on the central nervous system.  Relative heart-to-body weight ratios of 
weanling albino (Wistar) rats were not significantly altered when administered daily chlorfenvinphos 
doses of 0.27, 0.9, 2.7, 9, or 90 mg/kg/day (males): 0.3, 1, 3, 10, or 100 mg/kg/day (females) in the 
diet for 12 weeks. Similarly, no effects on relative heart-to-body weight ratios were reported for 
Wistar rats given chlorfenvinphos at doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 
24 mg/kg/day (females) in the diet for 104 weeks in another part of the same study (Ambrose et al. 
1970). However, cardiovascular function was not assessed in these studies. No gross or 
microscopic histopathology in heart tissues or changes in relative heart weights were evident in 
mongrel dogs administered daily chlorfenvinphos doses of 0.01, 0.1, 1, or 10 mg/kg/day (males) or 
0.05, 0.5, 5, or 50 mg/kg/day (females) for 12 weeks (Ambrose et al. 1970). However, 
cardiovascular function was not assessed in this study. Similarly, no effects on heart-to-body 
weight ratios were reported for Beagle dogs given chlorfenvinphos at doses of 0.3, 2, or 
10 mg/kg/day (males), or 1.5, 10, 50 mg/kg/day (females) in the diet for 104 weeks in another part 
of the same study (Ambrose et al. 1970). 
A study concluded that the alteration of brain and liver activities of the aromatic amino acid 
transferases may be due to the inhibitory effect of chlorfenvinphos on noradrenaline 
(norepinephrine) activity (Puzynska 1984). In other studies, chlorfenvinphos was shown to 
independently inhibit noradrenaline (norepinephrine) activity in vivo in rats rapidly (3 hours) at doses 
as low as 4 mg/kg (Brzezinski 1978; Osumi et al. 1975). On this basis, it has been postulated that 
chlorfenvinphos may also act via central noradrenergic mechanisms, disturbing the dynamic 
equilibrium between the rate of formation and utilization of noradrenaline (norepinephrine). It was 
postulated that this action via central noradrenergic mechanisms by chlorfenvinphos may be 
responsible for the changes in blood pressure observed in other studies after chlorfenvinphos 
intoxication (Brzezinski 1978). 
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Gastrointestinal Effects.  No gross or microscopic histopathology was evident in the 
gastrointestinal tract of rats and dogs given oral doses of up to 100 mg/kg/day (female rats) or 
50 mg/kg/day (female Beagle dogs) chlorfenvinphos for 12 weeks (Ambrose et al. 1970). 
Similarly, no gross or microscopic histopathology was evident in the stomach, or small and large 
intestine of weanling albino (Wistar) rats of both sexes chronically (104 weeks) given daily dietary 
chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day 
(females) (Ambrose et al. 1970). 
Hematological Effects.  Information on the hematological effects from oral exposure to 
chlorfenvinphos is limited. Investigations conducted to evaluate the serological effects of 
chlorfenvinphos on 4 groups of rabbits of both sexes at a doses of 10 mg/kg for 90 days found 
significant increases of hemolysin and hemagglutinin serum titer, as compared to controls. 
Hemagglutinin and hemagglutinin IgG titer were increased by 16 and 18%, respectively, while 
hemolysin and hemolysin IgG titer were elevated by 66 and 102%, respectively (Roszkowski 
1978). In a 104-week oral study in Beagle dogs, no effects were reported on monitored 
hematological parameters (hemoglobin, hematocrit, total/differential leucocyte counts) at doses of 
10 mg/kg/day for male dogs and 50 mg/kg/day for female dogs (Ambrose et al. 1970). Similarly, 
no effects were seen on monitored hematological parameters (hemoglobin, hematocrit, 
total/differential leucocyte counts) in rats orally administered chlorfenvinphos (21 mg/kg/day, 
males; 24 mg/kg/day, females) for 104 weeks (Ambrose et al. 1970). 
Musculoskeletal.  In animal studies, no gross or microscopic histopathology changes in the 
musculoskeletal system were observed in dogs orally administered chlorfenvinphos at doses as 
high as 50 mg/kg/day (females) for 12 weeks, or in rats at doses as high as 24 mg/kg/day 
(females) for 104 weeks (Ambrose et al. 1970). 
Hepatic Effects.  The limited information on the hepatic effects of chlorfenvinphos indicates that 
the substance is not significantly hepatotoxic by the oral route in acute- or intermediate-duration 
exposure. No changes in liver weight (relative to body weight) were reported in Fischer 344 rats 
given a single oral chlorfenvinphos dose of 15 mg/kg. However, P-450 activity was increased by 
30%. Aminopyrine-N-demethylase and aniline hydroxylase activities were also increased by 40 
and 27%, respectively (Ikeda et al. 1991). Mature Wistar rats of both sexes were kept on 
diets containing 4.5% of casein (low-protein diet), 26% of casein (optimal-protein diet), or 
standard (Murigran) diet and 30 mg/kg/day of chlorfenvinphos for 30 days to evaluate the 
effects of oral chlorfenvinphos exposure on serum activity of sorbitol dehydrogenase (SDH), 
and on brain and liver activities of the aromatic amino acids transferases L-phenylalanine 
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aminotransferase (Phen AT), L-tyrosine aminotransferase (Tyr AT), and L-tryptophan 
aminotransferase (Try AT). Both male and female rats exhibited disturbances in the activities of 
these enzymes. Chlorfenvinphos significantly decreased the activities of Phen AT (females = 
41%, P<0.01), Tyr AT (females = 30, P<0.01), and Try AT (males = 20%, females = 42%, P<0.01) 
in the brain of the rats. Concomitantly, chlorfenvinphos significantly increased the activities of 
Phen AT (males = 37%, females = 54%, P<0.01), Tyr AT (males = 75, female = 150%, P<0.001)), 
and Try AT (males = 109%, females = 62%, P<0.001) in the liver of the rats, and developed a rise 
in the activity of sorbitol dehydrogenase (SDH) in serum (4.5% protein diet, males = NS, females = 
94%; standard diet, males = 51%, females = 105%). There was also a 32% decrease in serum 
glucose-6-phosphate isomerase in females. In general, these changes were more pronounced in 
female rats fed standard Murigran diet. However, no changes in protein levels were reported in 
the study (Puzynska 1984). 
In other animal studies, no gross or microscopic histopathology in liver tissues was evident in 
weanling albino (Wistar) rats administered daily chlorfenvinphos doses of 0.27, 0.9, 2.7, 9, or 
90 mg/kg/day (males) or 0.3, 1, 3, 10, or 100 mg/kg/day (females) in the diet for 12 weeks 
(Ambrose et al. 1970). In a chronic study (104 weeks) in which this strain of rats (both sexes) was 
given daily dietary chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 
24 mg/kg/day (females), increased relative liver weights were observed in males at the 
7 mg/kg/day dose level. No gross or microscopic histopathology in the liver tissues examined or 
changes in relative liver weights were reported at any dose level (Ambrose et al. 1970). Hepatic 
function was not assessed in this study. 
No gross or microscopic liver histopathology or changes in relative liver weights were evident in 
mongrel dogs administered daily chlorfenvinphos doses of 0.01, 0.1, 1, or 10 mg/kg/day (males) or 
0.05, 0.5, 5, or 50 mg/kg/day (females) for 12 weeks (Ambrose et al. 1970). Similarly, no gross or 
microscopic liver histopathology or significant changes in relative kidney weights were evident in 
Beagle dogs (2/sex) fed daily dietary chlorfenvinphos doses of 0.3, 2, or 10 mg/kg/day (males), or 
1.5, 10, or 50 mg/kg/day (females) for 104 weeks. No adverse effects on liver function as 
indicated by alterations in serum bromosulfalein (BSP), serum glutamic oxaloacetic transaminase 
(SGOT), and serum alkaline phosphatase (SAP) or in blood urea nitrogen (BUN) levels were 
reported for the test animals (Ambrose et al. 1970). 
Renal Effects.  The relative kidney weight ratios of weanling albino (Wistar) rats administered 
daily chlorfenvinphos doses of 0.27, 0.9, 2.7, 9, or 90 mg/kg/day (males), or 0.3, 1, 3, 10, or 
100 mg/kg/day (females) in the diet for 12 weeks were significantly and irreversibly decreased at 
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the 2.7 mg/kg/day (males) and 3 mg/kg/day (females) dose levels (Ambrose et al. 1970). 
However, no quantitative data on the reduction of relative kidney weight were provided in this 
study. No gross or microscopic histopathology in the kidney and urinary bladder tissues examined 
or changes in relative kidney weights were evident in Wistar rats of both sexes given daily dietary 
chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day 
(females) in a chronic study (104 weeks) (Ambrose et al. 1970). Renal function was not assessed 
in either study. 
No gross or microscopic histopathology in kidney tissues or changes in relative kidney weights 
were evident in mongrel dogs administered daily chlorfenvinphos doses of 0.01, 0.1, 1, or 
10 mg/kg/day (males) or 0.05, 0.5, 5, or 50 mg/kg/day (females) for 12 weeks (Ambrose et al. 
1970). Similarly, no gross or microscopic renal histopathology or significant changes in relative 
kidney weights were evident in Beagle dogs fed daily dietary chlorfenvinphos doses of 0.3, 2, or 
10 mg/kg/day (males), or 1.5, 10, or 50 mg/kg/day (females) for 104 weeks (Ambrose et al. 1970). 
However, renal function was not assessed in these studies. 
Endocrine Effects.  A significant increase (>300%) in plasma corticosterone was observed at 
1 and 3 hours and in plasma aldosterone from 1 to 6 hours after treatment of male Wistar rats with 
a single chlorfenvinphos dose of 6.15 mg/kg (50% LD50) by stomach tube. Maximal increase in 
plasma corticosteroid levels occurred within 1 hour, while the brain cholinesterase activity was 
only slightly inhibited at that time. The authors surmised that changes in plasma corticosteroids 
are not related to the decrease of cholinesterase activity in the brain (Osicka-Koprowska et al. 
1984). The toxicological significance of these findings is unknown. 
No gross or microscopic histopathology was evident in endocrine organs (pancreas, thyroid, 
adrenal, pituitary) of weanling albino (Wistar) rats or Beagle dogs given oral doses of up to 
100 mg/kg/day (female rats) or 50 mg/kg/day (female Beagle dogs) chlorfenvinphos for 12 weeks 
(Ambrose et al. 1970). Similarly, no gross or microscopic histopathology was evident in endocrine 
organs (pancreas, thyroid, adrenal, pituitary) of weanling albino (Wistar) rats of both sexes 
chronically (104 weeks) given daily dietary chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day 
(males) or 0.8, 2.4, 8, or 24 mg/kg/day (females) (Ambrose et al. 1970). 
Dermal Effects.  No adverse changes were observed in the skin of weanling albino 
(Wistar) rats of both sexes given oral doses of up to 100 mg/kg/day (female rats) chlorfenvinphos 
for 12 weeks (Ambrose et al. 1970). Similarly, no adverse changes were observed in the skin of 
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weanling albino (Wistar) rats of both sexes chronically (104 weeks) given daily dietary 
chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day 
(females) (Ambrose et al. 1970). 
Body Weight Effects.  A significant but slightly reversible depression on growth was observed at 
9 mg/kg/day (males) or 10 mg/kg/day (females) in weanling albino (Wistar) rats.  The rats were 
administered daily chlorfenvinphos doses of 0.27, 0.9, 2.7, 9, or 90 mg/kg/day (males) or 0.3, 1, 3, 
10, or 100 mg/kg/day (females) in the diet for 12 weeks (Ambrose et al. 1970). In an 
accompanying chronic study (104 weeks) in which this strain of rats (both sexes) was given daily 
dietary chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 
24 mg/kg/day (females), no consistent difference in body weight gains in males was evident at any 
dose level tested, as compared to undosed controls. However, chlorfenvinphos exposure caused 
a significant decrease in body weight gain in females in the 8 and 24 mg/kg/day dose groups from 
the 26th week until near the end of the study. The decreased body weight gain became 
statistically insignificant at the end of the study (Ambrose et al. 1970). In another rat study, body 
weight gains in adult female albino (Wistar) rats were unaffected following orally administered 
Birlane® (chlorfenvinphos) at a dose of 0 or 2.4 mg/kg/day in the diet for 10 days or 0 or 
0.8 mg/kg/day in the diet for 30 days (Barna and Simon 1973). 
Likewise, no significant effect on body weight was observed in mongrel dogs following dietary 
chlorfenvinphos doses of 0.01, 0.1, 1, or 10 mg/kg/day (males), or 0.05, 0.5, 5, or 50 mg/kg/day 
(females) for 12 weeks (Ambrose et al. 1970). In a chronic study (104 weeks) in which Beagle 
dogs were given daily dietary chlorfenvinphos doses of 0.3, 2, or 10 mg/kg/day (males), or 1.5, 10, 
or 50 mg/kg/day (females), no significant changes in body weight were evident at any dose level 
tested, as compared to undosed controls (Ambrose et al. 1970). 
Metabolic Effects.  In animal studies, pairs of Carworth Farm E strain male rats orally 
administered a single [14C]chlorfenvinphos dose of 2.5 or 13.3 mg/kg in olive oil (with or without 
prior monooxygenase induction with dieldrin) exhibited minimal changes in the metabolic profiles 
(Hutson and Wright 1980). 
Other Systemic Effects.  No significant effect on food consumption was observed in 
weanling albino (Wistar) rats administered daily chlorfenvinphos doses of 0.27, 0.9, 
2.7, 9, or 90 mg/kg/day (males) or 0.3, 1, 3, 10, or 100 mg/kg/day (females) in the diet for 
12 weeks (Ambrose et al. 1970). In a chronic study (104 weeks) in which weanling albino 
(Wistar) rats of both sexes were given daily dietary chlorfenvinphos doses of 0.7, 2.1, 7, 
or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day (females), no consistent 
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difference in food consumption was evident at any dose level tested, as compared to undosed 
controls (Ambrose et al. 1970). In dog studies, no significant effect on food consumption was 
observed in mongrel dogs given dietary chlorfenvinphos doses of 0.01, 0.1, 1, or 10 mg/kg/day 
(males) or 0.05, 0.5, 5, or 50 mg/kg/day (females) for 12 weeks (Ambrose et al. 1970). Similarly, 
no significant changes in food consumption were evident at any dose level tested in a chronic 
study (104 weeks) in which Beagle dogs were given daily dietary chlorfenvinphos doses of 0.3, 2, 
or 10 mg/kg/day (males) or 1.5, 10, or 50 mg/kg/day (females) (Ambrose et al. 1970). 
2.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding the immunological and lymphoreticular effects in humans 
following acute-, intermediate-, or chronic-duration oral exposure to chlorfenvinphos. 
The limited information on the immunological and lymphoreticular effects of chlorfenvinphos 
indicates that the substance is moderately immunotrophic to the rodent immune system in oral 
exposures. The gastrointestinal absorption of glucose was increased by 30% over control values 
in adult female albino (Wistar) rats orally administered Birlane® (chlorfenvinphos) at a dose of 0 or 
2.4 mg/kg/day in the diet for 10 days. Similarly, gastrointestinal absorption of glucose was 
increased by 12% over control values following orally administered Birlane® (chlorfenvinphos) at a 
dose of 0 or 0.8 mg/kg/day in the diet of Wistar rats for 30 days. The changes in glucose and Na+ 
absorption were not considered statistically significant (P>0.05) by the investigators (Barna and 
Simon 1973). It has been observed in other studies that an increased metabolic activity of 
neutrophils and monocytes during phagocytosis is accompanied by higher consumption of glucose 
and oxygen. Hydrogen peroxide is then derived from the pentose cycle, NAD-, and 
NADP-oxidase action (Kolanoski 1977 as cited in Wysocki et al. 1977). The relationship between 
increased gastrointestinal absorption of glucose and increased glucose utilization is not clear. 
In an intermediate-duration dietary study with albino (Wistar) rats, there was a significant and 
irreversible reduction in relative spleen weight of female rats given $3 mg/kg/day 
chlorfenvinphos for 12 weeks. However, no gross or microscopic histopathology was e 
vident in the spleen and bone marrow tissues of the rats upon examination (Ambrose et al. 
1970). In dogs, relative spleen weights were unaffected following dietary doses of 10 mg/kg/ 
day (males) or 50 mg/kg/day (females) to mongrel dogs for 12 weeks.  In addition, no gross or 
microscopic histopathology was evident in the spleen and bone marrow tissues of the 
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dogs upon examination (Ambrose et al. 1970). No quantitative data on the reduction of relative 
spleen weights were provided in these studies. 
A study was undertaken to evaluate selected serological and cytoimmunological reactions in 
rabbits subjected to a long-term poisoning with subtoxic oral doses (10 mg/kg in a soya oil solution 
with a small amount of food) of chlorfenvinphos for 90 days (shortened chronic poisoning). Both 
control group (soya oil) and treatment group rabbits were immunized with sheep red blood cells 
6 days prior to ending the experiment. Chlorfenvinphos treatment significantly elevated serum 
hemagglutinin level (16%) and hemolysin activity (66%, P<0.05) and increased the number of 
nucleated lymphoid cells producing hemolytic antibody to sheep erythrocytes as compared to 
controls (treated 906, P<0.05 and controls 618). Spleen cytomorphology changes, manifested 
mainly as transformation of primary follicles into secondary ones with well developed germinal 
centers, were also observed (Roszkowski 1978). After 90 days of oral intoxication of C57BL/6 
mice and (C57BL/6 x DBA/2)F1 (BDF1/Iiw) hybrid mice (6–8-weeks-old) with chlorfenvinphos 
(suspended in 1% methylcellulose solution), a dose-related decrease in number of hemolysin­
producing cells was observed. Plaque-forming cells (PFC) were 58% at the 6 mg/kg dose group 
and 85% at the 3 mg/kg dose level, as compared to control values. Chlorfenvinphos treatment 
also caused reduction in E rosettes-forming cell numbers by 30% at the 6 mg/kg dose level, 25% 
at the 3 mg/kg dose level, and 45% at the 6 mg/kg dose level. Spleen colonies were stimulated as 
evidenced by the increase of endogenous spleen colonies; and exogenous spleen colonies 
(CFU-S) increased 190% at the 1.5 mg/kg dose level, 137% at the 6 mg/kg dose level, 162% at 
1.5 mg/kg dose level, and 70% at the 6 mg/kg dose level, respectively. When the IgM PFC 
number was tested 3 weeks later, after the exposure to chlorfenvinphos in the small dose 
(1.5 mg/kg), an increase (about 40%) in plaque number was observed. There was a 50% 
reduction in thymus weight at the 1.5 mg/kg dose level, as compared to controls, as well as 
significant involution of the thymus. IgM levels returned to normal values, indicating the reversible 
nature of the immunotrophic effect of chlorfenvinphos (Kowalczyk-Bronisz et al. 1992). The 
LOAEL of 1.5 mg/kg/day, based on adverse immunologic/lymphoreticular effects in this study, was 
used to derive an intermediate oral MRL of 0.002 mg/kg/day for chlorfenvinphos. 
In a chronic-duration (104 weeks) dietary study in which weanling albino (Wistar) rats of both 
sexes were given daily dietary chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) 
or 0.8, 2.4, 8, or 24 mg/kg/day (females), no histopathological changes in the spleen or bone 
marrow were evident at any dose level tested, as compared to undosed controls. In addition, no 
changes in absolute or relative spleen weights were reported (Ambrose et al. 1970). Likewise, no 
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histopathological changes in the spleen or bone marrow were evident in Beagle dogs given daily 
dietary chlorfenvinphos doses of 0.3, 2, or 10 mg/kg/day (males) or 1.5, 10, or 50 mg/kg/day 
(females) for 104 weeks. In addition, no changes in absolute or relative spleen weights were 
reported (Ambrose et al. 1970). 
The highest NOAEL values and all reliable LOAEL values for immunological and lymphoreticular 
effects in each species and duration category are presented in Table 2-2 and plotted in Figure 2-2. 
2.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans following intermediate- or 
chronic-duration oral exposure to chlorfenvinphos.  In humans, chlorfenvinphos inhibits 
cholinesterase activity in the central and peripheral nervous system when ingested in acute-
duration exposures (Cupp et al. 1975; Pach et al. 1987). A 16-year-old white male mistakenly 
took a full swallow of a mange-mite medication (identified as Dermaton® which contains 25% 
organophosphate, like chlorfenvinphos, as an active ingredient) prescribed by a veterinarian for 
his dog. Approximately 90 minutes later, he was hospitalized with symptoms of abdominal 
cramps, nausea, vomiting, generalized weakness, cold dry skin, constricted pupils, fine 
generalized muscular twitching, and apprehension. On physical examination, his blood pressure 
was 152/102, pulse was 96 and irregular, respiration was 24, and rectal temperature was 94.2 EF. 
While in the emergency room, gastric lavage of 4 L was done and 1 mg of atropine given 
intravenously. On transfer to the intensive care unit, respiration had increased in rate and depth, 
skin was warm and slightly diaphoretic, muscle twitching had increased, and he complained of 
double vision. Emesis persisted. The patient developed hypothermia which lasted for 2 hours. 
Four and one-half hours after admission, the patient was listless and apathetic, but oriented. 
Blood analysis showed plasma and erythrocyte cholinesterase levels of 0.3 and 1.1 µmol/minute, 
respectively. Twenty-four hours later, plasma and erythrocyte cholinesterase levels were 0.8 and 
12.7 µmol/minute, respectively. He was given 1 g of pralidoxime intravenously over a 15-minute 
period, repeated in 1 hour. Forty-eight hours after admission, signs of improvement were evident. 
The patient was discharged 5 days after admission without residual effects (Cupp et al. 1975). 
Another clinical report described anticholinesterase symptoms (unconsciousness, absence of 
tendon reflexes, 80% reduction of erythrocyte acetylcholinesterase activity, 100% reduction in 
plasma pseudocholinesterase activity, respiratory failure, bronchial tree hypersecretion) in a 
29-year-old male patient hospitalized 3 hours after a suicide attempt during which he drank about 
50 mL of the preparation ‘Enolofos®, which contains 50% chlorfenvinphos (Pach et al. 1987). 
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The existing information on neurological effects in animals following acute-, intermediate-, and 
chronic-duration oral exposures to chlorfenvinphos indicates that the substance causes 
disruptions in the central and peripheral nervous system in rats manifested as cholinesterase 
inhibition (Barna and Simon 1973; Osicka-Koprowska et al. 1984; Takahashi et al. 1991) and 
interference with noradrenaline (norepinephrine) activity in central adrenergic mechanisms 
(Brzezinski 1978; Osumi et al. 1975). Inhibition of acetylcholinesterase activity results in 
accumulation of acetylcholine at muscarinic and nicotinic receptors leading to peripheral and 
central nervous system effects. These effects usually appear within a few minutes to a few hours 
after exposure depending on the extent of exposure.  When chlorfenvinphos was evaluated for 
acute lethality in animals, death occurred within 12 hours in tested rats, rabbits, and dogs and was 
usually preceded by the characteristic signs of cholinergic response—salivation, lacrimation, 
muscle fasciculation, diarrhea, emesis, tremors, irregular respiration, and prostration (Ambrose et 
al. 1970, Ikeda et al. 1992). 
In acute-duration studies, brain cholinesterase activity was strongly inhibited in male Fischer 344 
rats (8 weeks old) that were orally treated with 30 mg/kg chlorfenvinphos or pretreated with 
15 mg/kg for 24 hours before treatment with 30 mg/kg chlorfenvinphos. This was accompanied by 
clinical anticholinesterase symptoms which included salivation, fasciculation, lacrimation, tremors, 
irregular respiration, and prostration which resulted in deaths 1–24 hours after administration of 
the chlorfenvinphos doses. Although chlorfenvinphos pretreatment did not change the nature of 
these symptoms, it aggravated the inhibition of brain cholinesterase activity (Ikeda et al. 1992). 
Plasma and erythrocyte cholinesterase activities were inhibited by 52 and 30%, respectively, at 
the only tested Birlane® (chlorfenvinphos) dietary dose of 2.4 mg/kg/day administered to adult 
female albino (Wistar) rats for 10 days (Barna and Simon 1973). The LOAEL of 2.4 mg/kg/day 
from the 10-day dosing protocol of this study, based on adverse neurological effects in rats was 
used to derive an acute oral MRL of 0.002 mg/kg/day for chlorfenvinphos. 
Brain and erythrocyte acetylcholinesterase, and plasma pseudocholinesterase activities were 
reduced by $90% and 50%, respectively, following acute oral treatment of male Sprague-Dawley 
rats with chlorfenvinphos. Rats administered chlorfenvinphos orally attained maximum inhibition 
of cholinesterase activity in less than two hours. The rats also exhibited cholinergic signs that 
included fasciculations, twitches, convulsions, chromodacryorrhea, exophthalmos, gasping, 
lacrimation, prostration, salivation, Straub tail reflex, and urination.  The clinical signs lasted for 
8 hours. No effects were observed at the 1.25 mg/kg dose level (Takahashi et al. 1994). 
Cholinesterase activity in the brain of male Wistar rats was unaffected 3 hours after oral 
administration of 1 mg/kg of chlorfenvinphos. However, at doses of 2 and 4 mg/kg, oral 
chlorfenvinphos produced marked decreases in the brain cholinesterase activity to 38 and 18% of
40 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
control (P<0.001), respectively. The maximum inhibition occurred 3 hours after administration, after 
which the cholinesterase activity elevated gradually. Activity in the brain decreased steadily with time 
and, at 72 hours, still remained 67% of control. Erythrocyte acetylcholinesterase activity also 
decreased after 4 mg/kg of chlorfenvinphos; the lowest level (20%, P<0.001) was attained 3 hours 
after treatment (Osumi et al. 1975). 
Acute oral exposure to chlorfenvinphos was also associated with reversible sleep disturbance in male 
Wistar rats. Single oral chlorfenvinphos doses up to 1 mg/kg did not affect the awake-sleep cycle in 
the rats, but spontaneous electroencephalogram (EEG) showed a prominent arousal pattern and 
appearance of slow wave sleep and parasleep was markedly depressed in doses over 2 mg/kg. The 
duration of arousal pattern was proportional to the doses but, nonetheless, the awake-sleep cycle 
returned to control values on the second day; a rebound increase in parasleep occurred on the third 
day at doses over 4 mg/kg. Atropine at a dose of 2 mg/kg (administered to one rat 2 hours after 
chlorfenvinphos administration) was antidotal to the chlorfenvinphos-induced disturbance of EEG 
arousal pattern, depressing the EEG arousal pattern without affecting cholinesterase activity in the 
brain. As a positive control, physostigmine, a reversible cholinesterase inhibitor, in doses of 0.05 and 
0.1 mg/kg, produced an increase in wakefulness during the first hour. Thereafter, the arousal pattern 
was reduced, and slow wave sleep and parasleep patterns increased, as compared with the control, 
3–5 hours after the administration of chlorfenvinphos. According to these investigators, appearance of 
EEG arousal pattern after treatment with chlorfenvinphos is indicative of central cholinergic activation. 
A LOAEL of 2 mg/kg with a NOAEL of 1 mg/kg for 38% decrease in brain cholinesterase activity and 
reversible sleep disturbances was determined in this study (Osumi et al. 1975). This study was not 
used to calculate an acute oral MRL because it was deemed less appropriate because of the gavage 
(oral) route of administration. An oral feeding study is preferred for this purpose by ATSDR. 
In intermediate-duration studies, plasma and erythrocyte cholinesterase activities were inhibited by 
36 and 3%, respectively, at a chlorfenvinphos dose of 0.8 mg/kg/day following dietary administration of 
0 or 0.8 mg/kg/day Birlane® (chlorfenvinphos) to adult female albino (Wistar) rats for 30 days (Barna 
and Simon 1973). However, the change in erythrocyte acetylcholinesterase activity was not 
considered significant and therefore, this study was not used to derive an intermediate MRL. Similarly, 
the change in plasma pseudocholinesterase was not used to derive an intermediate MRL because 
while the inhibition of plasma pseudocholinesterase may have some physiological significance, 
alteration in the levels of this enzyme is generally regarded more as a biomarker of exposure to 
organophosphate compounds than as an adverse neurological effect. In other intermediate rat 
studies, mature rats of both sexes kept on diets containing 4.5% 
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of casein (low-protein diet), 26% of casein (optimal-protein diet), or standard (Murigran) diet for 
30 days exhibited depressed cholinesterase activities following oral exposure to chlorfenvinphos. 
These alterations consisted of significant inhibition in pseudocholinesterase activity in the serum (4.5% 
protein diet: males = 97%, females = 96%; standard diet: males = 87%, females = 93%) and brain 
(4.5% protein diet: males = 83%, females = 87%; standard diet: males = 58%, females = 39%), with 
more pronounced effects in the brain of female rats fed low-protein diets (87%). The activity of this 
enzyme returned to normal values 14 days after dosing (Puzynska 1984). Blood and plasma 
cholinesterase activity was depressed at $9 mg/kg/day (males) or $10 mg/kg/day (females), with a 
NOAEL of 2.7 mg/kg/day (males) or 3 mg/kg/day (females) following dietary administration of 
chlorfenvinphos doses of 0.27, 0.9, 2.7, 9, or 90 mg/kg/day (males), or 0.3, 1, 3, 10, or 100 mg/kg/day 
(females) in the diet to weanling albino (Wistar) rats for 12 weeks. No gross or microscopic 
histopathology was evident in the brain tissues examined (Ambrose et al. 1970). Similarly, plasma 
cholinesterase activity was consistently depressed, while erythrocyte cholinesterase activity was 
sporadically depressed in all dose groups in mongrel dogs administered daily chlorfenvinphos doses 
of 0.01, 0.1, 1, or 10 mg/kg/day (males) or 0.05, 0.5, 5, or 50 mg/kg/day (females) in the diet for 
12 weeks. No gross or microscopic histopathology was evident in the brain and spinal cord tissues 
examined (Ambrose et al. 1970). Due to incomplete reporting of this study, it was not clear if there 
was a NOAEL for the inhibition of erythrocyte cholinesterase activity. No quantitative data on the 
depression of plasma or erythrocyte cholinesterase activity were provided in this study. 
In another intermediate-duration study, whole blood cholinesterase activity in Sprague-Dawley rats 
was markedly inhibited at 3 and 6 months of exposure following exposure to 10.5 mg/kg/day 
chlorfenvinphos (0.9 and 0.6x10-6 mol/minute; control, 2.4 and 1.9x10-6 mol/minute, respectively, 
P<0.001). After 3 and 6 months of exposure to chlorfenvinphos, plasma cholinesterase activity was 
also markedly inhibited (0.4 and 0.4x10-6 mol/minute; control, 1.9 and 1.6x10-6 mol/minute, 
respectively; P<0.001). After 3–6 months, all 36 Sprague-Dawley rats in this study had repetitive and 
increasingly diminishing muscle fiber depolarization when given double stimuli. The greatest 
reduction in peak depolarization occurred with an interval of 4 muscle action potential amplitude (ms) 
and a large but slightly smaller reduction at 7 ms. These phases probably coincide with refractoriness 
of some muscle fibers due either to repetitive activity (at 4 ms) or reflex activity (at 7 ms). Double and 
repetitive stimulation at rates even as low as 0.5 Hz reduced or abolished the prolonged negative 
potential and repetitive activity. These abnormalities became more marked with time, even on 
constant dosing. Spike potentials were recorded between the direct response and reflex responses 
with latency similar to the repetitive activity potential. These electrophysiological abnormalities may be 
attributable to acetylcholinesterase inhibition at neuromuscular junctions (Maxwell and LeQuesne 
1982). 
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In chronic-duration studies, chlorfenvinphos significantly inhibited both plasma and erythrocyte cholin­
esterase activities in a dose-dependent manner in weanling albino (Wistar) rats fed daily 
chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day 
(females) mg/kg/day in the diet for 104 weeks. Plasma and erythrocyte cholinesterase activities were 
inhibited by 48% in females and 45% in males in the first week of treatment and by 20% in females 
and 33% in males in the fourth week of treatment, respectively, at the lowest dose tested 
(0.7 mg/kg/day for males and 0.8 mg/kg/day for females). No gross or microscopic histopathology 
was evident in the brain tissue examined (Ambrose et al. 1970). The LOAEL of 0.7 mg/kg/day, based 
on adverse neurological effects in rats in this study, was used to derive a chronic oral MRL of 
0.0007 mg/kg/day for chlorfenvinphos. 
Similarly, chlorfenvinphos significantly inhibited both plasma and erythrocyte cholinesterase activities 
in Beagle dogs fed daily chlorfenvinphos doses of 0.3, 2, or 10 mg/kg/day (males), or 1.5, 10, or 
50 mg/kg/day (females) in the diet (moist) for 104 weeks.  Plasma cholinesterase activities were 
significantly inhibited at all dietary levels through week 39 of the study; 49% inhibition at ambient air 
concentrations of 0.3 mg/kg/day (males) and 1.5 mg/kg/day (females) groups.  During the first 
12 weeks, erythrocyte cholinesterase activity was significantly and consistently inhibited (36%) only in 
the 10 mg/kg/day (males) and 50 mg/kg/day (females) dose groups. No gross or microscopic 
histopathology was evident in the brain and spinal cord tissues examined (Ambrose et al. 1970). 
Besides its cholinergic action, chlorfenvinphos may also act via central noradrenergic mechanisms in 
rats by accelerating the noradrenaline (norepinephrine) turnover in the brain in vivo. Three hours after 
oral administration of 4 mg/kg of chlorfenvinphos, the brain noradrenaline (norepinephrine) level of 
male Wistar rats was reversibly decreased by 16% (Osumi et al. 1975). In another study with male 
Wistar rats, 13 mg/kg of oral chlorfenvinphos decreased cerebral noradrenaline (norepinephrine) level 
by 20% as compared to the control rats. Other rats that received oral chlorfenvinphos 30 minutes after 
pretreatment with disulfiram injection (400 mg/kg intraperitoneally) as positive controls exhibited a 50% 
decrease of cerebral noradrenaline (norepinephrine); the level was observed in time intervals of 
1–3 hours, peaking at 89% decrease after 6 hours. Based on these observations, it was suggested 
that chlorfenvinphos accelerates the rate of noradrenaline (norepinephrine) disappearance from the rat 
brain in vivo. Thus, besides being a cholinergic agent, chlorfenvinphos may also act via central 
noradrenergic mechanisms, disturbing the dynamic equilibrium between the rate of formation and 
utilization of noradrenaline (norepinephrine). It was postulated that this action via central 
noradrenergic mechanisms by chlorfenvinphos may be responsible for the changes in blood pressure 
observed in other studies after chlorfenvinphos intoxication (Brzezinski 1978). 
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Sprague-Dawley rats fed chlorfenvinphos doses of 10.5 mg/kg/day for 1 year had repetitive and 
increasingly diminishing muscle fiber depolarization when given double stimuli. The greatest 
reduction in peak depolarization occurred with an interval of 4 muscle action potential amplitude (ms) 
and a large but slightly smaller reduction at 7 ms. These phases probably coincide with refractoriness 
of some muscle fibers due either to repetitive activity (at 4 ms) or reflex activity (at 7 ms). These 
electrophysiological abnormalities may be attributable to acetylcholinesterase inhibition at 
neuromuscular junctions (Maxwell and LeQuesne 1982). 
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are presented in Table 2-2 and plotted in Figure 2-2. 
2.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans following acute-, intermediate-, or 
chronic-duration oral exposure to chlorfenvinphos. 
No studies were located regarding reproductive effects in animals following acute-duration oral 
exposure to chlorfenvinphos. The limited information on the reproductive toxicity of chlorfenvinphos 
indicates that chlorfenvinphos may interfere with the reproductive competence of rats. In a 3­
generation reproductive study, chlorfenvinphos induced adverse reproductive effects (decreased 
fertility and maternal body weight gain) at a LOAEL of 2.7 mg/kg/day in albino (Wistar) rats given 
chlorfenvinphos at a doses of 2.7, 9, or 27 mg/kg/day (males) or 3, 10, or 30 mg/kg/day (females) in 
the diet for 11 weeks. The chlorfenvinphos dosed rats were mated for 20 days to produce an F/1a 
generation and remated, 10 days after weaning of the F/1a pups, to produce an F/1b generation. 
Each generation was fed the chlorfenvinphos doses for 11 weeks before mating. The study reported 
decreased maternal body weights of 3, 5, and 11%, respectively, for F/0 parental generation animals 
fed 0, 3, or 10 mg/kg/day; 9, 2, and 19%, respectively, for F/1 parental generation animals fed 0, 3, or 
10 mg/kg/day; and 14 and 10%, respectively, for F/2 parental generation animals fed 0 or 3 mg/kg/day 
chlorfenvinphos. The changes in maternal body weight gain were not considered significant. 
However, fertility (pregnancy/mating x 100) was decreased by 49% in the F/1b parents at the 
10 mg/kg/day dose level. In the F/2b parents, fertility was decreased by 50% at the 3 mg/kg/day dose 
level and by 84% in the 10 mg/kg/day dose level. No gross or microscopic histopathology was evident 
in male and female gonads examined. No adverse effects on gestation were noted at any exposure 
levels (Ambrose et al. 1970). 
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In intermediate-duration studies, chlorfenvinphos had no effect on relative testes weight at any of the 
doses tested in weanling albino (Wistar) rats administered daily chlorfenvinphos doses of 
90 mg/kg/day (males) or 100 mg/kg/day (females) in diet for 12 weeks. No gross or microscopic 
histopathology was evident in any of the gonads (Ambrose et al. 1970). 
In chronic-duration studies, no gross or microscopic gonad histopathology in either sex or changes in 
the relative weights of the testes in males were reported in albino (Wistar) rats administered daily 
chlorfenvinphos doses of 21 mg/kg/day (males) or 24 mg/kg/day (females) in the diet for 104 weeks 
(Ambrose et al. 1970). Similarly, no gross or microscopic gonad histopathology in either sex or 
changes in the relative weights of the testes in males were reported in mongrel dogs administered 
daily chlorfenvinphos doses of 0.01, 0.1, 1, or 10 mg/kg/day (males) or 0.05, 0.5, 5, or 50 mg/kg/day 
(females) in the diet for 12 weeks (Ambrose et al. 1970). Reproductive function was not evaluated in 
these studies. 
The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species and 
duration category are presented in Table 2-2 and plotted in Figure 2-2. 
2.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans following acute-, intermediate-, or 
chronic-duration oral exposure to chlorfenvinphos. 
No studies were located regarding developmental effects in animals following acute-duration oral 
exposures in animals. Oral chlorfenvinphos interfered with development in intermediate- and chronic-
duration exposures as well as multigenerational studies in animals. Weanling albino (Wistar) rats 
administered daily dietary doses of chlorfenvinphos (0.27, 0.9, 2.7, 9, or 90 mg/kg/day for males; 0.3, 
1, 3, 10, or 100 mg/kg/day for females) for 12 weeks exhibited slightly reversible but significant 
depression of growth at doses of 9 mg/kg/day (males) or 10 mg/kg/day (females).  No quantitative data 
on the depression of growth were provided in the study (Ambrose et al.1970). In a chronic feeding 
study (104 weeks) in which weanling albino (Wistar) rats were given chlorfenvinphos in the diet at 
doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day (females) for 104 weeks, 
chlorfenvinphos significantly decreased body weight gain of females at the 8 and 24 mg/kg/day 
ambient air concentrations from the 26th week till towards the end of the study.  The decrease in body 
weight gain was not statistically significant at the end of the study. An increased relative liver weight 
was observed in males at the 7 mg/kg/day dose level, but no other signs of hepatopathology were 
45 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
reported. No consistent differences in body weight gains in males, survival of the test animals, food 
consumption, or mortality were evident at any dose level tested, as compared to undosed controls. No 
gross or microscopic histopathology was evident in any of the tissues (heart, lungs, liver, kidney, 
urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, skin, bone marrow, 
pancreas, thyroid, adrenal, pituitary) examined to indicate teratogenicity. No changes in organ-to-body 
weight were observed in the heart and kidney (Ambrose et al. 1970). Dietary exposure to 
chlorfenvinphos exposure caused decreases in viability and lactational indices in a 3-generation 
reproductive study with albino (Wistar) rats. In this study, the rats were given chlorfenvinphos in the 
diet at doses of 2.7, 9, or 27 mg/kg/day (males) or 3, 10, or 30 mg/kg/day (females) for 11 weeks. The 
chlorfenvinphos-dosed rats were mated for 20 days to produce an F/1a generation and remated 
10 days after weaning of the F/1a pups to produce an F/1b generation. Each generation was fed the 
chlorfenvinphos doses for 11 weeks before mating.  The pup viability index (pups surviving 
5 days/pups born alive x 100) decreased by 66% for F/1b pups at a maternal dose of 10 mg/kg/day. 
No offspring in the 27 mg/kg/day (males) or 30 mg/kg/day (females) dose group survived beyond the 
F1 generation. The lactation index was also decreased by 46% in the F/1b offsprings at the 
10 mg/kg/day dose level. No gross or microscopic histopathology was evident in any of the tissues 
examined. There were no gross signs of teratogenicity (Ambrose et al. 1970). 
The highest NOAEL values and all reliable LOAEL values for developmental effects in each species 
and duration category are presented in Table 2-2 and plotted in Figure 2-2. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in animals after oral exposure to chlorfenvinphos. 
Other genotoxicity studies are discussed in Section 2.5. 
2.2.2.8 Cancer 
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2.2.3 Dermal Exposure 
2.2.3.1 Death 
No studies were located regarding death in humans after acute-, intermediate-, or chronic-duration 
dermal exposure to chlorfenvinphos. 
The dermal LD50 values in rabbits for undiluted chlorfenvinphos and emulsifiable concentrate have 
been estimated to be 400 and 1,087 mg/kg, respectively (Ambrose et al. 1970). 
2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, hepatic, 
musculoskeletal, hepatic, renal, endocrine, dermal, ocular, body weight, metabolic, or other systemic 
effects in humans or animals following acute-, intermediate-, or chronic-duration dermal exposure to 
chlorfenvinphos. 
2.2.3.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans or animals 
after acute-, intermediate-, or chronic-duration dermal exposure to chlorfenvinphos. 
2.2.3.4 Neurological Effects 
No studies were located regarding neurological effects in humans after intermediate-, or chronic-
duration dermal exposure to chlorfenvinphos. Dermally-applied chlorfenvinphos formulations 
significantly inhibited plasma cholinesterase activity in healthy human male volunteers without prior 
occupational exposure to the substance. Three different chlorfenvinphos formulations were used in 
this study: 80% weight per volume (w/v) emulsifiable concentrate (EC), mainly chlorfenvinphos and 
emulsifiers; 24% w/v EC, mainly isometric trimethyl benzenes with 4½% w/v emulsifiers; 25% w/w 
wettable powder (WP), mainly colloidal silica, florisil, triphenylphosphate, sodium triphosphates, 
empicol LZ and tamal. The formulations were administered separately in single applications to the 
forearm skin of 9 adult human males for periods up to 4 hours in doses of 4–10 mg chlorfenvinphos/kg 
body weight. The 80% EC and 25% EC formulations had no effect on cholinesterase activity levels in 
the volunteers. Only plasma and erythrocyte cholinesterase activities 
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of volunteers who received a single application of the 24% emulsifiable concentrate (5 and 10 mg 
chlorfenvinphos/kg body weight equivalent to a dermal dose of 5 mg/cm2) were inhibited. Plasma 
and erythrocyte cholinesterase were inhibited by 53–76% and 9%, respectively (Hunter 1969). 
No studies were located regarding neurological effects in animals after intermediate- or chronic-
duration dermal exposure to chlorfenvinphos. Acute-duration dermal exposure of laboratory animals 
to chlorfenvinphos resulted in the depression of plasma cholinesterase without clinical symptoms. 
Two dogs of unspecified sex treated with a daily dose of 0.3% chlorfenvinphos applied topically to the 
spinal area from head to tail for 7 days (3 consecutive days, 1 day skipped, then 4 consecutive days) 
suffered 28% depression in plasma cholinesterase activity by day 8. No clinical signs resulting from 
cholinesterase depression were observed in any of the dogs (Vestweber and Kruckenberg 1972). 
2.2.3.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals after acute-, 
intermediate-, or chronic-duration dermal exposure to chlorfenvinphos. 
2.2.3.6 Developmental Effects 
No studies were located regarding developmental effects in humans after acute-, intermediate-, or 
chronic-duration dermal exposure to chlorfenvinphos. 
2.2.3.7 Genotoxic Effects 
No studies were located regarding genotoxic effects of chlorfenvinphos in humans or animals following 
dermal exposure. 
Other genotoxicity studies for chlorfenvinphos are described in Section 2.5. 
2.2.3.8 Cancer 
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2.3 TOXICOKINETICS 
The absorption of chlorfenvinphos after inhalation exposure in humans or animals is unknown due to 
lack of data. Ingested chlorfenvinphos is rapidly absorbed in humans. In animals, oral 
chlorfenvinphos is also well absorbed to an extent of $67.1–72.5% of the administered dose. 
Although no information on the dermal absorption of chlorfenvinphos in animals is available, dermally 
applied chlorfenvinphos formulations were rapidly and extensively absorbed in humans; the rate and 
extent of absorption was dependent on solvents used in the preparation. 
In humans, absorbed chlorfenvinphos is widely distributed and has been detected in compartments 
that include serum, cervical mucus, follicular and sperm fluids, and milk at levels of up to 0.42 µg/kg for 
environmental exposures and 15 ng/mL in an acute poisoning case. The distribution of absorbed 
chlorfenvinphos in animals is unknown because of lack of data. 
In humans, absorbed chlorfenvinphos is extensively metabolized via oxidative dealkylation by liver 
microsomal fractions. Based on human and animal data, the mechanism for oxidative dealkylation of 
chlorfenvinphos proceeds initially via monooxygenation of the alpha-carbon atom of the alkoxy group 
to produce an unstable hemiacetal which breaks down by oxidative O- and N-alkylation mechanisms 
to acetaldehyde and 2-chloro-1-(2,4-dichlorophenyl) vinylethylhydrogen phosphate. Acetophenone 
produced in the succeeding step is reduced to the alcohol and conjugated by glutathione transferases. 
Data from animal studies suggest that electrophilic metabolic intermediates or epoxides may be 
produced in the metabolism of chlorfenvinphos. 
The elimination or excretion of chlorfenvinphos in humans and animals after inhalation or dermal 
exposures is unknown due to lack of data. In humans, ingested chlorfenvinphos is rapidly removed 
from the blood and passed into the tissues. Chlorfenvinphos has been detected in human sperm fluid 
and milk samples. In animals, ingested chlorfenvinphos is rapidly eliminated via the urine (70–90%), 
feces (about 16%), and expired air (0.5%). 
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2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
No studies were located regarding absorption of chlorfenvinphos after inhalation exposure in humans 
or animals. 
2.3.1.2 Oral Exposure 
A 29-year-old male was hospitalized with severe respiratory distress and bronchial tree 
hypersecretion. The patient had ingested about 50 mL of the preparation Enolofos®, which contains 
50% chlorfenvinphos, in a suicide attempt. The concentration of chlorfenvinphos in the serum was 
300 ng/mL upon admission. This is the only known human chlorfenvinphos poisoning case in which 
hemoperfusion intervention was employed. The mean clearance of chlorfenvinphos during 
hemoperfusion was low (68 mL/min) and only 0.42 mg of the poison was recovered. The poison level 
in the serum was low (15 ng/mL) immediately before the procedure, and gradually rose in successive 
blood samples indicating that chlorfenvinphos passes fairly easily from the tissues into blood.  This 
may be related to secondary resorption from the digestive tract. The highest value of clearance was 
observed in the fourth hour of hemoperfusion, in contrast to the observations during hemoperfusion 
performed for other drug poisoning, when the value of the clearance was lowest in the last hour. The 
serum chlorfenvinphos levels decreased temporarily within a few hours even prior to the beginning of 
hemoperfusion, either due to rapid inactivation or to rapid passage into the tissues where the 
organophosphates accumulate (Pach et al. 1987). 
In animal studies, a total of 67.1–72.5% of the administered radioactivity was recovered from the urine 
of pairs of Carworth Farm E strain male rats administered [14C]chlorfenvinphos orally at doses of 2.5 or 
13.3 mg/kg in olive oil (with or without prior monooxygenase induction with dieldrin). This is suggestive 
of gastrointestinal absorption of $67.1–72.5% (Hutson and Wright 1980). 
2.3.1.3 Dermal Exposure 
A study conducted to assess the potential dermal absorption of chlorfenvinphos for humans (since the 
most likely route of entry is through the skin in occupational exposures) applied the substance to the 
forearm skin of nine healthy human male volunteers who had no prior occupational exposure to the 
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substance. Three different chlorfenvinphos formulations were used in this study: 80% w/v EC, mainly 
chlorfenvinphos and emulsifiers; 24% w/v EC, mainly isometric trimethyl benzenes with 4.5% w/v 
emulsifiers; 25% weight per weight (w/w) wettable powder, mainly colloidal silica, florisil, 
triphenylphosphate, sodium triphosphates, empicol LZ and tamal.  The formulations were administered 
separately in single applications to the forearm skin of nine adult human males for periods up to 
4 hours in doses of 4–10 mg chlorfenvinphos/kg body weight. The 80% EC formulation was applied at 
doses of 4, 5, 10, or 10 mg/kg body weight for periods of 4, 3.7, 3.8, or 4 hours on approximate skin 
areas of 36, 38, 320, or 336 cm2, respectively. The 24% EC formulation was applied at doses of 5, 5, 
10, 10, or 10 mg/kg body weight for periods of 4, 3.8, 4.1, 4, or 4 hours on approximate skin areas of 
272, 420, 800, 600, or 880 cm2, respectively. The 25% WP formulation was applied at doses of 5 or 
5 mg/kg body weight for periods of 4.2 or 3.8 hours on approximate skin areas of 80 or 70 cm2, 
respectively. The extent and ease of absorption or permeability factor of the applied doses depended 
on the formulation, relating to solvents in the preparation. The dermal absorption of the 80% EC 
formulation was 1.43, 1.81, 0.06, or 0.32 mg/cm2/hour, corresponding to applied doses of 4, 5, 10, or 
10 mg/kg body weight for periods of 4, 3.7, 3.8, or 4 hours on approximate skin areas of 36, 38, 320, 
or 336 cm2, respectively. The dermal absorption of the 24% EC formulation was 0.18, 0.12, 0.14, 
0.20, or 0.08 mg/cm2/hour corresponding to applied doses of 5, 5, 10, 10, or 10 mg/kg body weight for 
periods of 4, 3.8, 4.1, 4, or 4 hours on approximate skin areas of 272, 420, 800, 600, or 880 cm2, 
respectively. The dermal absorption of the 25% wettable powder formulation was 0.35 mg/cm2/hour 
corresponding to applied doses of 5 mg/kg body weight for periods of 4.2 hours on approximate skin 
areas of 80 cm2. Concentrations of intact chlorfenvinphos of 14.4, 12.0, or 0.5 µg/L were found 
24 hours post-exposure in the blood of volunteers for whom chlorfenvinphos absorption rates of 0.20, 
0.14, or 0.08 mg/cm2/hour, respectively, had been estimated. Concentrations of intact chlorfenvinphos 
of 22, 3.8, <2.8, 2.9, 2.6, 0.2, or <0.7 µg/L were found 8 hours later in the blood of volunteers for whom 
chlorfenvinphos absorption rates of 1.81, 1.43, 0.32, 0.18, 0.12, and 0.06 mg/cm2/hour, respectively, 
had been estimated (Hunter 1969). 
No studies were located regarding absorption of chlorfenvinphos after dermal exposure in animals. 
2.3.2 Distribution 
2.3.2.1 Inhalation Exposure 
As an organophosphorus compound, chlorfenvinphos is not expected to accumulate in the body 
tissues because of its expected short half-life. However, chlorfenvinphos was found in some of the 
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41 specimens of cervical mucus, follicular and sperm fluids, and human milk that were examined in 
Germany. Chlorfenvinphos levels of 13.66, 1.69, 2.02, and 1.89 µg/kg were detected in 4 of the 
11 samples of cervical mucus. Chlorfenvinphos levels of 0.42 µg/kg were detected in 1 of the 
10 sperm fluid samples and 1 of the 10 human milk samples, respectively. The detection of 
chlorfenvinphos in the cervical mucus, which showed the highest levels, was unexpected because it 
was believed to be the most unlikely site for accumulation in the body. It was suggested that a 
connection exists between the activities of the cervical glands of the endocervix and the appearance of 
some pesticides in the cervical mucus which might show a new way for accumulation. Accordingly, 
the data indicate that organophosphorus environmental pollutants, like chlorfenvinphos, can appear in 
the human reproductive organs, exposing even germ-cells and, thus, present a risk of interference with 
the process of reproduction (Wagner et al. 1990). Since the data were generated from environmental 
exposure, the combined route of exposure may include inhalation. 
No studies were located regarding the distribution of chlorfenvinphos after inhalation exposure in 
animals. 
2.3.2.2 Oral Exposure 
Although chlorfenvinphos is a hydrophilic substance, it has hitherto not been widely found in human 
tissues because it is not expected to persist in these tissues. As an organophosphorus compound, 
chlorfenvinphos is not expected to accumulate in the body tissues because of its expected short half-
life. However, chlorfenvinphos was found in some of the 41 specimens of cervical mucus, follicular 
and sperm fluids, and human milk that were examined. Chlorfenvinphos levels of 13.66, 1.69, 2.02, 
and 1.89 µg/kg were detected in 4 of the 11 samples of cervical mucus. Chlorfenvinphos levels of 
0.42 µg/kg were detected in 1 of the 10 sperm fluid samples and 1 of the 10 human milk samples, 
respectively. The detection of chlorfenvinphos in the cervical mucus, which showed the highest levels, 
was unexpected because it is the most unlikely compartment for accumulation in the body. It was 
suggested that a connection exists between the gland’s activities and the appearance of some 
pesticides in the cervical mucus, which might show a new way for accumulation. Accordingly, these 
data indicate that new environmental pollutants, like chlorfenvinphos, can appear in the human organs, 
exposing even germ-cells and, thus, present a risk of adverse effects on reproduction (Wagner et al. 
1990). Since the data were generated from environmental exposure, the combined route of exposure 
possibly include oral. 
A 29-year-old male was hospitalized with severe respiratory distress and bronchial tree 
hypersecretion. The patient had ingested about 50 mL of the preparation Enolofos®, which contains 
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50% chlorfenvinphos, in a suicide attempt. The concentration of chlorfenvinphos in the serum was 
300 ng/mL upon admission. This is the only human chlorfenvinphos poisoning case in which 
hemoperfusion intervention was employed. The mean clearance of chlorfenvinphos during 
hemoperfusion was low (68 mL/minute) and only 0.42 mg of the poison was recovered. The poison 
level in the serum was low (15 ng/mL) immediately before the procedure, and gradually rose in 
successive blood sampling indicating that chlorfenvinphos passes fairly easily from the tissues into 
blood. This may be related to secondary resorption from the digestive tract. The highest value of 
clearance was observed in the fourth hour of hemoperfusion, in contrast to the observations during 
hemoperfusion performed for other drug poisoning, when the value of the clearance was lowest in the 
last hour. The serum chlorfenvinphos levels decreased temporarily within a few hours even prior to 
the beginning of hemoperfusion, either due to rapid inactivation or to rapid passage into the tissues 
where the organophosphates accumulate (Pach et al. 1987). 
No studies were located regarding the distribution of chlorfenvinphos in animals after oral exposure. 
2.3.2.3 Dermal Exposure 
No studies were located regarding the distribution of chlorfenvinphos after dermal exposure in humans 
or animals. 
Although chlorfenvinphos is a hydrophilic substance, it has hitherto not been widely found in human 
tissues because it is not expected to persist in these tissues. As an organophosphorus compound, 
chlorfenvinphos is not expected to accumulate in the body tissues because of its expected short half-
life. However, chlorfenvinphos was found in some of the 41 specimens of cervical mucus, follicular 
and sperm fluids, and human milk that were examined. Chlorfenvinphos levels of 13.66, 1.69, 2.02, 
and 1.89 µg/kg were detected in 4 of the 11 samples of cervical mucus. Chlorfenvinphos levels of 
0.42 µg/kg were detected in 1 of the 10 sperm fluid samples and 1 of the 10 human milk samples, 
respectively. The detection of chlorfenvinphos in the cervical mucus, which showed the highest levels, 
was unexpected because it is the most unlikely compartment for an accumulation in the body. It was 
suggested that a connection exists between the gland activities and the appearance of some 
pesticides in the cervical mucus, which might show a new way for accumulation. Accordingly, this 
data indicate that new environmental pollutants, like chlorfenvinphos, can appear in the human organs, 
contacting even germ-cells and, thus, present risk of adverse effects on reproduction (Wagner et al. 
1990). Since the data were generated from environmental exposure, the combined route of exposure 
possibly includes dermal. 
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2.3.3 Metabolism 
An adapted scheme for the mammalian metabolic pathway of chlorfenvinphos (Akintonwa 1984; 
Akintonwa 1985; Akintonwa and Itam 1988; Hunter et al. 1972; Hutson and Millburn 1991; Hutson and 
Wright 1980) is presented in Figure 2-3. 
2.3.3.1 Inhalation Exposure 
No studies were located regarding the metabolism of chlorfenvinphos after inhalation exposure in 
humans or animals. 
2.3.3.2 Oral Exposure 
In humans, the rates of chlorfenvinphos de-ethylation by liver microsomal fractions are 
0.36 nmol/minute per mg protein (range 0.11–0.82) without induction and 1.03 nmol/minute per nmol 
of cytochrome P-450 (range 0.42–1.78) with induction (Hutson and Logan 1986). 
In animal studies, pairs of Carworth Farm E strain male rats administered [14C]chlorfenvinphos orally at 
doses of 2.5 or 13.3 mg/kg in olive oil (with or without prior monooxygenase induction with dieldrin) 
exhibited minimal changes in the metabolic profiles. Urine samples were collected at 12 and 32 hours 
and analyzed by chromatography for metabolites of chlorfenvinphos using authentic standards: 
de-ethylchlorfenvinphos or 2-chloro-1-(2’,4’-dichlorophenyl) vinylethylhydrogen phosphate, 
1-(2',4'-dichlorophenyl) ethanol, 1-(2',4'-dichlorophenyl) ethanediol, 2,4-dichloromandelic acid, and 
2,4-dichlorobenzoyl glycine. The metabolites 2-chloro-1-(2,4-dichlorophenyl) vinylethylhydrogen 
phosphate, 1-(2,4-dichlorophenyl) ethanol, 1-(2,4-dichlorophenyl) ethanediol, 2,4-dichloromandelic 
acid, and 2,4-dichlorobenzoyl glycine were identified in the urine by this method. Increased 
monooxygenase induction (dieldrin pretreatment) favored the production of the glucuronide of 
1-(2,4-dichlorophenyl) ethanol and decreased yield of 2,4-dichloromandelic acid and 2,4-dichloro­
benzoyl glycine at a low dose level. At the high dose level, an increased yield of 1-(2,4-dichlorophenyl) 
ethanol, an increase in the relative yield of 2,4-dichloromandelic acid and 2,4-dichlorobenzoyl glycine, 
and a doubling in the relative yield of de-ethylchlorfenvinphos occurred with a concomitant reduction in 
the relative yields of the glucuronides. The authors suggested that the relatively low amount of 
radioactivity eliminated within 0–32 hours via the urine of high-dose rats was probably due to limited 
absorption/metabolism. The results support the conclusion that the effect of enzyme induction on the 
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metabolism of substrates of that enzyme are dose-dependent with respect to enzyme saturation. 
Therefore, alterations in metabolism are not necessarily a consequence of enzyme induction alone 
(Hutson and Wright 1980). The tissue distribution of organophosphoric ester metabolizing enzymes 
in the livers of mammalian species has been suggested to be an important factor in accounting for 
species specificity of the toxicity of some phosphate triester anticholinesterase agents, including 
chlorfenvinphos. These enzymes were identified as microsomal monooxygenases, esterases, and 
glutathione-s-transferases. The acute oral LD50 values of chlorfenvinphos for the rat, mouse, rabbit, 
and dog which have been estimated as 10, 100, 500, and 12,000 mg/kg, respectively, correlated 
fairly well with the relative rates of chlorfenvinphos O-dealkylation and relative in vivo 
chlorfenvinphos-induced decreases in the rates of hexobarbital metabolism in these species. The 
relative rates of dealkylation in the rat, mouse, rabbit, and dog have been estimated as 1, 8, 24, and 
80, respectively. The relative rates of chlorfenvinphos-induced decreases in hexobarbital metabolism 
in the rat, mouse, rabbit, and dog have been estimated as 4, 17, 5, and 1, respectively (Hansen 
1983). 
An investigator in an earlier study had suggested that the enzyme system responsible for this 
reaction was found to be microsomal and required molecular oxygen and NADPH2 for activity. The 
activity of this enzyme system in isolated washed rat, mouse, and dog liver microsomes had rates of 
product formation of 0.02, 0.65, and 2.00 nmol (per mg of microsomal protein per minute), 
respectively. The activity of this enzyme system in isolated washed rabbit liver microsomes had a 
rate of product formation similar to the other species used in this study. The maximum specific 
activity of liver microsomes with respect to the dealkylation of chlorfenvinphos achieved in dieldrin-
pretreated and phenobarbital-pretreated mice was 3.6 nmol at 1.6 mg/kg daily for 62 weeks and 
6.0 nmol at 12 mg/kg daily for 40 weeks, respectively.  The maximum specific activity of liver 
microsomes with respect to the dealkylation of chlorfenvinphos achieved in dieldrin-pretreated and 
phenobarbital-pretreated dogs was 4.1 nmol (per mg of microsomal protein per minute) at 2.0 mg/kg 
daily for 4 weeks and 9.2 nmol (per mg of microsomal protein per minute) at 20 mg/kg daily for 
4 weeks, respectively. The activity of the enzyme system oxygen: NADPH2 oxidoreductase (with 
chlorfenvinphos as substrate) in isolated washed monkey liver microsomes had a rate of product 
formation of 1.00 nmol (per mg of microsomal protein per minute).  The maximum specific activity of 
liver microsomes with respect to the dealkylation of chlorfenvinphos achieved in dieldrin-pretreated 
monkeys given oral chlorfenvinphos doses of 0.03 mg/kg/day for 6.15 years was 1.8 nmol (per mg of 
microsomal protein per minute). The mechanism of this reaction has been proposed to be mediated 
by oxidative dealkylation of chlorfenvinphos to the relatively nontoxic metabolite, 2-chloro­
1-(2,4-dichlorophenyl) vinyl ethylhydrogen phosphate and acetaldehyde.  The enzyme system was 
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readily inducible, especially in the rat, by the administration of phenobarbital or dieldrin.  The 
maximum specific activity of liver microsomes with respect to the dealkylation of chlorfenvinphos 
achieved in dieldrin-pretreated and phenobarbital-pretreated rats was 12.4 nmol at 8 mg/kg/day for 
4 weeks and 5.7 nmol at 14 mg/kg/day for 4 weeks, respectively. A 600-fold increase in specific 
activity was observed in the liver of dieldrin-pretreated rats. In rats pretreated with dieldrin at 
200 ppm in the diet for 12 days, the acute LD50 for chlorfenvinphos was increased by a factor of 6–8 
(Donninger 1971). 
A quantitative study of the species distribution of phosphate esterases and glutathione S-alkyl 
transferase found that these enzymes are significantly less in quantity in the pig than in all the other 
species studied, suggesting a significantly varied distribution among some mammalian species. The 
author of the study concluded that the distribution of these enzymes is an important factor in 
accounting for the species specificity of at least some anticholinesterase agents and that the 
glutathione-dependent alkyl transferase is predominantly a methyl transferase. The contribution of 
these two enzyme systems to the detoxification of any particular phosphate triester is dependent on 
the structure and solubility of the molecule (Donninger 1971). 
These findings were confirmed by three other reports.  In the report by Hutson and Millburn (1991), 
the oral LD50 values for rat, mouse, rabbit, and dog are 10–30 mg/kg, 150, 500, and >5,000 mg/kg, 
respectively. The oral LD50 in the rabbit has been reported to be as high as >12,000 mg/kg in some 
studies. The difference in toxicity in rats and dogs was found to be due to differences in several 
pharmacokinetic and pharmacodynamic factors. These factors include differences in the rates of 
absorption and metabolism, bioavailability in blood, and rates of uptake by the brain, as well as the 
sensitivity of brain cholinesterase to the phosphorylating action of the compound. In studies using 
rats and dogs, the most important reaction in detoxification is the conversion of chlorfenvinphos to 
de-ethylchlorfenvinphos by oxidative de-ethylation.  The reaction is catalyzed by a hepatic 
microsomal monooxygenase, probably cytochrome P-450. The relative rates of de-ethylation in liver 
slices were 1, 8, 24, and 88 for the rat, mouse, rabbit, and dog, respectively. Thus, an excellent 
inverse correlation between oral LD50 and rate of de-ethylation was established. Also evidence for 
the significance of the reaction in vivo was provided from experiments in which rats were protected 
7-fold from the action of chlorfenvinphos by pre-treatment with dieldrin in the diet for 12 days.  This 
treatment induces cytochrome P-450 microsomal monooxygenase and, thus, chlorfenvinphos 
de-ethylation. However, the author cautioned that species differences in toxicity response are often 
multi-factorial, and metabolism can be a minor component (Hutson and Millburn 1991). 
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In the second report, Ikeda et al. (1991) found the metabolism of chlorfenvinphos in kidney subcellular 
fractions and in the serum of Fischer 344 rats (orally pretreated with chlorfenvinphos followed by oral 
treatment with a similar chlorfenvinphos dose or 50 mg/kg phenobarbital in 24 hours), with or without 
the NADPH-generating system, to be negligible. Metabolism of chlorfenvinphos in the liver subcellular 
fraction without the NADPH-generating system was also practically negligible. However, when the 
NADPH-generating system was added to the liver subcellular fraction, chlorfenvinphos metabolism 
increased significantly (203% in the 9,000 g fraction and 178% in the microsomes) in the 
chlorfenvinphos-pretreated animals and in the phenobarbital-pretreated animals (565%). Additionally, 
chlorfenvinphos pretreatment increased cytochrome P-450 content (30%) in the hepatic microsomal 
fraction; phenobarbital pretreatment caused a 180% increase. Hepatic microsomal cytochrome 
b5 content and cytochrome P-450 reductase activity were also increased by chlorfenvinphos and 
phenobarbital pretreatment (121 and 130%, respectively, for chlorfenvinphos, and 126 and 139%, 
respectively, for phenobarbital). Both chlorfenvinphos and phenobarbital pretreatment significantly 
increased protein content (P<0.001) in the microsomal fraction. Chlorfenvinphos treatment did not 
increase liver weight (relative to body weight). Increases were also noted in cytochrome P-450-linked 
activities such as aminopyrine N-demethylase (40%) and aniline hydroxylase (27%) content in the 
hepatic microsomal fraction and hexobarbital sleeping time and zoxazolamine paralysis time. Both 
chlorfenvinphos and phenobarbital are potent inducers of cytochrome P-450, which is involved in the 
metabolic detoxication of chlorfenvinphos. Thus, the authors concluded that the increase in hepatic 
chlorfenvinphos metabolism may be due to the induction of the hepatic cytochrome P-450 system 
caused by the single oral short-term treatment with chlorfenvinphos. Also this induction may be one of 
the reasons for the decrease in plasma chlorfenvinphos concentration which may be responsible for 
the reduction in toxicity of subsequent exposure to chlorfenvinphos (Ikeda et al. 1991). 
The third report was a theoretical analysis that predicted the mammalian biotransformation products 
based on the recognition of the structure of chlorfenvinphos, understanding of Types I and II 
metabolism of foreign compounds, and mechanistic biochemistry (Akintonwa 1984). This analysis 
also acknowledged that cytochrome P-450 monooxygenase (an inducible enzyme) is the relevant 
enzyme which mediates the biotransformation of chlorfenvinphos via oxidative dealkylation of to the 
relatively nontoxic metabolite, 2-chloro-1-(2,4-dichlorophenyl) vinyl ethylhydrogen phosphate or 
de-ethylchlorfenvinphos. Thirteen metabolites of chlorfenvinphos were predicted for mammals from 
theoretical biotransformation as justified by the known structure of chlorfenvinphos and understanding 
of biochemical reactions of monooxygenation, reduction, hydrolysis, glucuronidation, glutathione­
S-transferase conjugation, and amino acid conjugation. The 13 metabolites predicted are: 2-chloro­
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1-(2’,4’-dichlorophenyl) vinyldiethyl phosphate; acetaldehyde; 2-chloro-1-(2’,4’-dichlorophenyl) vinyl­
ethylhydrogen phosphate; 2,4-dichlorophenacylchloride; 2-chloro-1-(2’,4’-dichlorophenyl) ethanol; 
2,4-dichloromandelic acid; 2,4-dichloromandelic acid ester glucuronide; 2,4-dichloroacetophenone; 
1-(2',4’-dichlorophenyl) ethanol; 1-(2’,4’-dichlorophenyl) ethanediol; 1-(2’,4’-dichlorophenyl) ethanediol­
2-glucuronide; 1-hydroxy-1-(2’,4’-dichlorophenyl) acetyl glycine; and 1-(2’,4’-dichlorophenyl) 
ethanediol. 2-Chloro-1-(2’,4’-dichlorophenyl) vinylethylhydrogen phosphate, 2,4-dichloromandelic acid, 
1-(2’,4’-dichlorophenyl) ethanediol-2-glucuronide, and 1-(2’,4’-dichlorophenyl) ethanediol are predicted 
specifically for the dog and rat. 1-Hydroxy-1-(2’,4’-dichlorophenyl) acetyl glycine (the glycine conjugate 
of 2,4-dichloromandelic acid) was not confirmed in the rat while 2,4-dichlorohippuric acid was present 
in the dog, but not in the rat. While the theoretical or predictive approach to metabolite identification 
elucidates all the possible mechanistic pathways in the derivation of each metabolite and identifies all 
toxic or hazardous intermediates, only actual experimentation, which begins with theoretical prediction, 
can provide species differences in the proportion of metabolites and the toxicity of these metabolites. 
Thus, the theoretical approach to chlorfenvinphos metabolism in mammals effectively reveals that the 
monooxygenation of the vinyl group would produce an unstable epoxide (2-hydroxyl groups attached 
to a carbon) to yield 2,4-dichlorophenyl glyoxylate and 2,4-dichlorobenzoic acid through 
decarboxylation and oxygenation. The author of this study postulated that the 2,4-dichlorobenzoyl 
glycine (2,4-dichlorohippuric acid) was produced in the rat by this mechanism. The production of 
electrophilic metabolic intermediates or epoxides in the metabolism of chlorfenvinphos, which could 
react with nucleophilic cellular components (DNA, RNA, and proteins) leading to carcinogenesis, was 
considered unlikely by this theoretical approach (Akintonwa 1984). 
2,4-Dichlorophenacyl chloride, an intermediary metabolite of chlorfenvinphos and dimethylvinphos, is 
excreted from mammals mainly as 1-(2,4-dichlorophenyl)ethyl glucuronide (Hutson et al. 1977).  The 
authors assumed that this arose via the reductive dechlorination of the phenacyl halide to the 
acetophenone, which was then reduced to the alcohol and conjugated. A further investigation of the 
proposed reductive dechlorination step (using subcellular fractions of rat liver) led the authors to 
conclude that it is likely that the mechanism of reaction is a nucleophilic attack by sulphur (of the 
second GSH) on sulphur (of the chlorfenvinphos/GSH conjugate), with the expulsion of the phenacyl 
anion as the leaving group. The enzyme may be regarded as one of the glutathione transferases 
(Hutson et al. 1977). 
An assay developed for determining monooxygenase activity in human fetal livers, as a measure of 
the rate of decrease in substrate (Supona®, chlorfenvinphos) concentration, was found reliable for 
incubations at 37 EC for periods up to 10 minutes. Incubations in excess of 10 minutes were 
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unreliable due to an unexpected increase in E246 nm readings. The investigators concluded that 
hydrolysis, rather than monooxygenation, of chlorfenvinphos, was probably responsible for the 
observed increase in readings. Using 5- and 10-minute incubations, specific activity values for 
monooxygenase in whole liver homogenates of 13- and 16-week-old human fetuses were determined 
to be 6.47±0.84 and 5.26±0.46 µg/mg, respectively; no monooxygenase activity could be detected in 
whole liver homogenates of 24-week-old fetuses. The authors concluded that, similar to in vivo 
observations, the mechanism for oxidative dealkylation of chlorfenvinphos proceeds initially via 
monooxygenation of the alpha-carbon atom of the alkoxy group to produce an unstable hemiacetal 
which breaks down by oxidative O- and N-alkylation mechanisms to acetaldehyde and 2-chloro­
1-(2,4-dichlorophenyl) vinylethylhydrogen phosphate (Akintonwa and Itam 1988). 
2.3.3.3 Dermal Exposure 
No studies were located regarding metabolism of chlorfenvinphos after dermal exposure in humans or 
animals. 
2.3.4 Elimination and Excretion 
2.3.4.1 Inhalation Exposure 
No studies were located regarding excretion of chlorfenvinphos after inhalation exposure in humans or 
animals. 
2.3.4.2 Oral Exposure 
A male patient, aged 29, was admitted to the hospital 3 hours after a suicide attempt during which he 
drank about 50 mL of the preparation Enolofos® which contains 50% chlorfenvinphos. The 
concentration of chlorfenvinphos in the serum was 300 ng/mL upon admission. In this, the only 
human chlorfenvinphos poisoning in which hemoperfusion intervention was employed, the mean 
clearance of chlorfenvinphos during hemoperfusion was low, 68 mL/minute; and only 0.42 mg of the 
poison was recovered. The level of the poison in the serum was low (15 ng/mL) immediately before 
the procedure and gradually rose in successive blood sampling. At all times in successive blood 
samples during the procedure, there was an increase of chlorfenvinphos level in the serum, indicating 
that chlorfenvinphos passes fairly easily from the tissues into blood. This may be related to secondary 
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resorption from the digestive tract. The highest value of clearance was observed in the fourth hour of 
hemoperfusion, in contrast to the observations during hemoperfusion performed for other drug 
poisoning, when the value of the clearance was lowest in the last hour. The serum chlorfenvinphos 
levels decreased temporarily within a few hours even prior to the beginning of hemoperfusion, either 
due to rapid inactivation or to rapid passage into the tissues where the organophosphates accumulate 
(Pach et al. 1987). 
In animal studies, pairs of Carworth Farm E strain male rats administered [14C]chlorfenvinphos orally at 
doses of 2.5 or 13.3 mg/kg in olive oil (with or without prior monooxygenase induction with dieldrin) 
eliminated about 50% of the administered radioactivity in the urine in the first 12 hours, 9–13% in the 
next 12 hours, 3.5–6% in the subsequent 16 hours, and 4.2–5% in the final 42 hours of monitoring. A 
total of 67.1–72.5% of the administered radioactivity was recovered from the urine. Only 15.2–16.9% 
of the administered radioactivity was eliminated in the urine in the first 12 hours, 2.5–8.2% in the next 
12 hours, 6.1–6.6% in the subsequent 18 hours, and 0.7–1.4% in the final 42 hours of monitoring. 
Only 26.2–31.7% of the total dose was recovered in the urine in the high-dose animals. Dieldrin 
pretreatment resulted in a more rapid elimination as well as a greater percentage elimination of the 
administered [14C]chlorfenvinphos doses (Hutson and Wright 1980). All of the Birlane® 
(chlorfenvinphos) dose of 0.8 mg/kg/day administered in the diet for 30 days to 2 groups of adult 
female albino (Wistar) rats was removed from the body (excreted or metabolized) in 4 days. The dose 
was excreted mostly in the urine (70–90%) and feces (about 16%) with minor amounts (0.5%) in 
expired air (Barna and Simon 1973). 
2.3.4.3 Dermal Exposure 
No studies were located regarding excretion of chlorfenvinphos after dermal exposure in humans or 
animals. 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake 
and disposition of chemical substances to quantitatively describe the relationships among critical 
biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue 
dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the 
concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue 
following various combinations of route, dose level, and test species (Clewell and Andersen 1985). 
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Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-
response function to quantitatively describe the relationship between target tissue dose and toxic end 
points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and 
target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses 
(Andersen et al. 1987; Andersen and Krishnan 1994). These models are biologically and 
mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical 
substances from high to low dose, from route to route, between species, and between subpopulations 
within a species. The biological basis of PBPK models results in more meaningful extrapolations than 
those generated with the more conventional use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan 
and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical 
substance-specific physicochemical parameters, and species-specific physiological and biological 
parameters. The numerical estimates of these model parameters are incorporated within a set of 
differential and algebraic equations that describe the pharmacokinetic processes. Solving these 
differential and algebraic equations provides the predictions of tissue dose. Computers then provide 
process simulations based on these solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. 
The adequacy of the model is, therefore, of great importance, and model validation is essential to the 
use of PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 
1994). PBPK models provide a scientifically-sound means to predict the target tissue dose of 
chemicals in humans who are exposed to environmental levels (for example, levels that might occur at 
hazardous waste sites) based on the results of studies where doses were higher or were administered 
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If PBPK models for chlorfenvinphos exist, the overall results and individual models are discussed in 
this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
A physiologically based pharmacokinetic (PBPK) analysis used data from a study with 8-week old 
Fischer 344 rats as a model to study the mechanism of protection by initial chlorfenvinphos exposure 
against the toxicity of a subsequent exposure. The analysis concluded that, contrary to expectation, 
the body burden of chlorfenvinphos decreased after the initial exposure upon subsequent challenge 
exposure. The model predicted that decreased body burden of oral chlorfenvinphos dose might be 
due to the decrease in the plasma concentration after a challenge with chlorfenvinphos. In the rat 
study on which the model is based, the acute oral toxicity of chlorfenvinphos was reduced by the oral 
pretreatment of rats with chlorfenvinphos after a subsequent challenge dose. This was accompanied 
by reduction in brain cholinesterase, liver, and plasma concentrations of chlorfenvinphos (by one-third 
and 4–10 times, respectively). Unbound fractions of chlorfenvinphos in blood and liver were estimated 
by the in vitro experiments and pretreatment did not change the unbound fraction of chlorfenvinphos. 
The authors stated that, according to the PBPK model, the decrease in body burdens of the oral 
chlorfenvinphos dose may be caused mainly by an increase in intrinsic clearance of chlorfenvinphos 
by the liver and a decrease in the partition coefficient of chlorfenvinphos between the emergent blood 
and he liver. The increase in the intrinsic clearance was suggested to be related to the metabolic 
induction of P-450 observed in vitro. Additionally, pretreatment decreased the absorption rate 
constant of the oral chlorfenvinphos dose. Essentially, this is responsible for the protection afforded 
against toxicity of subsequent exposure to chlorfenvinphos (Ikeda et al. 1992). 
2.4 MECHANISMS OF ACTION 
2.4.1 Pharmacokinetic Mechanisms 
The level of activity of cholinesterases in the livers of mammalian species and the distribution of these 
enzymes have been suggested to be important factors in accounting for species specificity of some 
phosphate triester anticholinesterase agents, including chlorfenvinphos. These factors may account 
for the great variation in the toxicity of chlorfenvinphos among different animal species. The acute oral 
LD50 values of chlorfenvinphos for the rat, mouse, rabbit, and dog are 10, 100, 500, and 1,200 mg/kg, 
respectively. The relative conversion rates of chlorfenvinphos (by O-dealkylation) to the diester by 
liver slices from the rat, mouse, rabbit, and dog were 1, 8, 24, and 80 hours, respectively; these values 
correlate well with the published acute oral LD50 values for the species. The enzyme system 
responsible for this reaction was found to be microsomal and required molecular oxygen and NADPH2 
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for activity.  The activity of this enzyme system in isolated rat, mouse, and dog liver (washed) 
microsomes had rates of product formation of 0.02, 0.65, and 2.00 nmol (per mg of microsomal 
protein per minute), respectively. The activity of this enzyme system in isolated washed rabbit liver 
microsomes had a rate of product formation similar to that of other species used in this study. 
The maximum specific activity of liver microsomes with respect to the dealkylation of chlorfenvinphos 
achieved in dieldrin-pretreated and phenobarbital-pretreated mice was 3.6 nmol at 1.6 mg/kg/day for 
62 weeks and 6.0 nmol at 12 mg/kg/day for 40 weeks, respectively. The maximum specific activity of 
liver microsomes with respect to the dealkylation of chlorfenvinphos achieved in dieldrin- and 
phenobarbital-pretreated dogs was 4.1 nmol (per mg of microsomal protein per minute) at 
2.0 mg/kg/day for 4 weeks and 9.2 nmol (per mg of microsomal protein per minute) at 20 mg/kg/day 
for 4 weeks, respectively. The activity of the enzyme system oxygen: NADPH2 oxidoreductase (with 
chlorfenvinphos as substrate) in isolated washed monkey liver microsomes had a rate of product 
formation of 1.00 nmol (per mg of microsomal protein per minute).  The maximum specific activity of 
liver microsomes with respect to the dealkylation of chlorfenvinphos achieved in dieldrin-pretreated 
monkeys given oral chlorfenvinphos doses of 0.03 mg/kg/day for 6.15 years was 1.8 nmol (per mg of 
microsomal protein per minute). It has been proposed that the mechanism of this reaction is mediated 
by oxidative dealkylation of chlorfenvinphos to the relatively nontoxic metabolite, 2-chloro­
1-(2,4-dichlorophenyl) vinyl ethylhydrogen phosphate and acetaldehyde.  The enzyme system was 
readily inducible, especially in the rat, by the administration of phenobarbital or dieldrin. 
The maximum specific activity of liver microsomes with respect to the dealkylation of chlorfenvinphos 
achieved in dieldrin- and phenobarbital-pretreated rats was 12.4 nmol at 8 mg/kg/day for 4 weeks and 
5.7 nmol at 14 mg/kg/day for 4 weeks, respectively. A 600-fold increase in specific activity was 
observed in the liver of dieldrin-pretreated rats; in rats pretreated with dieldrin at 200 ppm in the diet for 
12 days, the acute LD50 for chlorfenvinphos was increased by a factor of 6–8. A quantitative study of 
the species distribution of phosphate esterases and glutathione S-alkyl transferase found that these 
enzymes are significantly less in the pig than all the other species studied, suggesting a significantly 
varied distribution among some mammalian species. The author of the study concluded that the 
distribution of these enzymes is an important factor in accounting for the species specificity of at least 
some anticholinesterase agents and that the glutathione-dependent alkyl transferase is predominantly 
a methyl transferase; the contribution of these two enzyme systems to the detoxification of any 
particular phosphate triester is dependent on the structure and solubility of the molecule (Donninger 
1971). 
65 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
These findings were confirmed by two other reports. In one, the oral LD50 values for rat, mouse, 
rabbit, and dog were 10–30, 150, 500, and >5,000 mg/kg, respectively; it can be >12,000 mg/kg in 
the rabbit. The difference in toxicity in rats and dogs was found to be due to rates of absorption and 
metabolism, bioavailability in blood, and rates of uptake by the brain and sensitivity of brain 
cholinesterase to the phosphorylating action of the compound. In studies using rats and dogs, the 
most important reaction in detoxification is the conversion of chlorfenvinphos to 
de-ethylchlorfenvinphos by oxidative de-ethylation.  The reaction is catalyzed by a hepatic 
microsomal monooxygenase, probably cytochrome P-450. The relative rates of de-ethylation in liver 
slices were 1, 8, 24, and 88 for the rat, mouse, rabbit, and dog, respectively. Thus, an excellent 
inverse correlation between oral LD50 and rate of de-ethylation was established. Also evidence for 
the significance of the reaction in vivo was provided from experiments in which rats were protected 
7-fold from the action of chlorfenvinphos by pre-treatment with dieldrin in the diet for 12 days.  This 
treatment induces cytochrome P-450 microsomal monooxygenase and, thus, chlorfenvinphos 
de-ethylation. The de-ethylation was induced about 40-fold (measured in vitro) relative to cytochrome 
P-450 concentration. However, the author cautioned that species differences in toxicity response are 
often multi-factorial, and metabolism can be a minor component (Hutson and Millburn 1991). 
In the second report, the metabolism of chlorfenvinphos in kidney subcellular fraction and in the 
serum of Fischer 344 rats (orally pretreated with chlorfenvinphos followed by an oral treatment with a 
similar chlorfenvinphos dose or 50 mg/kg phenobarbital in 24 hours), with or without the NADPH-
generating system, was found to be negligible. Metabolism of chlorfenvinphos in the liver subcellular 
fraction without the NADPH-generating system was also practically negligible. However, when the 
NADPH-generating system was added to the liver subcellular fraction, chlorfenvinphos metabolism 
increased significantly (203% in the 9,000 g fraction and 178% in the microsomes) in the 
chlorfenvinphos-pretreated animals and in the phenobarbital-pretreated animals (565%). 
Additionally, chlorfenvinphos pretreatment increased cytochrome P-450 content (30%) in the hepatic 
microsomal fraction; phenobarbital pretreatment caused a 180% increase. Hepatic microsomal 
cytochrome b5 content and cytochrome P-450 reductase activity were also increased by 
chlorfenvinphos and phenobarbital pretreatment (121 and 130%, respectively, for chlorfenvinphos 
and 126 and 139%, respectively, for phenobarbital). Both chlorfenvinphos and phenobarbital 
pretreatment significantly increased protein content (P<0.001) in the microsomal fraction. 
Chlorfenvinphos treatment did not increase liver weight (relative to body weight). Increases were 
also noted in cytochrome P-450-linked activities such as aminopyrine N-demethylase (40%) and 
aniline hydroxylase (27%) content in the hepatic microsomal fraction and hexobarbital sleeping time 
and zoxazolamine paralysis time. Both chlorfenvinphos and phenobarbital are potent inducers of 
cytochrome P-450, which is involved in the metabolic detoxication of chlorfenvinphos. Thus, the 
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authors concluded that the increase in hepatic chlorfenvinphos metabolism may be due to the 
induction of the hepatic cytochrome P-450 system caused by the single oral short-term treatment. 
Also this induction may be one of the reasons for the decrease in plasma chlorfenvinphos 
concentration, which may be responsible for the reduction in toxicity of subsequent exposure to 
chlorfenvinphos (Ikeda et al. 1991). 
Some of the major sites and enzyme systems involved in the detoxication of direct-acting neurotoxic 
organophosphates, like chlorfenvinphos, are NADPH-P-450, GSH transferase, FAD-monooxygenase 
and esterases; the most important of these is monooxygenase. The major activation step for 
microsomal monooxygenases is of critical importance for the toxicity of organophosphate compounds 
like chlorfenvinphos. According to this study, the relative rates of chlorfenvinphos O-dealkylation in 
rats, mice, rabbits, and dogs are 1, 8, 24, and 88, respectively. These rates correlated well with the 
oral LD50 values for these species, which were given as 10, 100, 500, and 12,000 mg/kg for rats, 
mice, rabbits, and dogs, respectively. According to the author, the potential for oxidative 
O-dealkylation in the P-450 pathway varies widely with species, with activity toward chlorfenvinphos 
correlating well with species selectivity. The author concluded that the biotransformation of delayed 
neurotoxicants will certainly influence relative potencies, but the distinction between a delayed 
neurotoxicant and the neurotoxicity of organophosphate compounds, which is mainly limited to acute 
effects, depends more heavily on pharmacodynamic than pharmacokinetic considerations. Thus, the 
pharmacokinetics of delayed neurotoxicants differ from the pharmacokinetics of neurotoxic 
organophosphates, like chlorfenvinphos (Hansen 1983). 
2.4.2 Mechanisms of Toxicity 
Most chlorfenvinphos toxicity results from the inhibition of cholinesterase activity in the central and 
peripheral nervous system when administered by the oral (Cupp et al. 1975; Pach et al. 1987) or 
inhalation route in acute-duration exposures in humans (Kolmodin-Hedman and Eriksson 1987), and 
when administered by the oral (Barna and Simon 1973; Osicka-Koprowska et al. 1984; Takahashi et 
al. 1991) or dermal route in acute-duration exposures in animals. Inhibition of cholinesterase activity 
results in accumulation of acetylcholine at muscarinic and nicotinic receptors leading to peripheral 
and central nervous system effects. These effects usually appear within a few minutes to a few hours 
after exposure depending on the extent of exposure. The enzyme is responsible for terminating the 
action of the neurotransmitter acetylcholine in the synapse of the pre- and post-synaptic nerve 
endings or in the neuromuscular junctions. On arrival of a nerve impulse at the synaptic gutter 
between the pre- and post-synaptic nerve endings or effector muscle fiber endplates, there is a 
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release of acetylcholine from the pre-synaptic terminals. At the post-synaptic nerve ending, 
acetylcholine acts as a chemical mediator to perpetuate the action potential. However, the action of ­
acetylcholine does not persist long as it is hydrolyzed by the enzyme, acetylcholinesterase, and 
rapidly removed. 
As an anticholinesterase organophosphate, chlorfenvinphos inhibits the activity of the 
acetylcholinesterase enzyme by reacting with the esteratic sites of the enzyme to form a stable 
phosphorylated complex which is incapable of destroying acetylcholine at the synaptic gutter between 
the pre- and post-synaptic nerve endings in the central and peripheral nervous system or 
neuromuscular junctions of skeletal muscles, resulting in the accumulation of acetylcholine at these 
sites. This leads to continuous or excessive stimulation of cholinergic fibers in the post-ganglionic 
parasympathetic nerve endings, neuromuscular junctions of the skeletal muscles, resulting in 
hyperpolarization of nerve or muscle fibers and receptor desensitization until hydrolysis of the 
phosphorylated cholinesterase occurs. In some cases, a dealkylation and stabilization of the 
phosphorylated enzyme (“aging”) occurs such that hydrolysis can no longer take place and the 
enzyme is irreversibly inhibited. In such cases, return of acetylcholinesterase activity parallels the 
time required to resynthesize this enzyme. 
In the parasympathetic system, stimulation of postganglionic fibers on the effector organs is mimicked 
by muscarine, and the receptors for the transmitters are called muscarinic receptors. They are found 
primarily in smooth muscle, the heart, and the exocrine glands.  Stimulation of these receptors by 
inhibition of acetylcholinesterase activity produces signs and symptoms of cholinergic poisoning that 
include bronchoconstriction and increased bronchial secretions, increased salivation and lacrimation, 
exophthalmos, increased sweating, increased gastrointestinal tone and peristalsis, nausea, vomiting, 
abdominal cramps, diarrhea, hypotension and bradycardia that can lead to heart block, involuntary 
urination caused by contraction of the smooth muscle of the bladder, and constriction of the pupils or 
miosis. 
At the autonomic ganglia and neuromuscular junctions, stimulation of transmission is mimicked by the 
action of nicotine, and the receptors are called nicotinic receptors. Inhibition of acetylcholinesterase 
activity leads to abnormal continuous or excessive stimulation of the receptor muscle fibers, causing 
weakness of the muscles, involuntary twitching, fasciculations, cramps, and eventual paralysis of the 
muscles. Paralysis of the respiratory muscles leads to respiratory failure and death. The central 
nervous system effects are due to accumulation of acetylcholine at various cortical, subcortical, and 
spinal levels (primarily in the cerebral cortex, hippocampus, and extrapyramidal motor system). 
Accumulation of acetylcholine in the central nervous system causes tension, anxiety, restlessness, 
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insomnia, headache, emotional instability, neurosis, excessive dreaming and nightmares, apathy, 
drowsiness, confusion, slurred speech, tremor, ataxia, convulsions, depression of respiratory and 
circulatory centers, and coma. The most likely cause of death in fatal organophosphate poisoning is 
paralysis associated with respiratory failure (Cupp et al. 1975; Klaassen et al. 1986; Shankar; 
Takahashi et al. 1991; Williams and Burson 1985). 
The results of pretreatment of New Zealand white rabbits with 0.007 mg/kg oxotremorine, a direct 
agonist of muscarinic receptors, followed by treatment with 0.5 mg/kg chlorfenvinphos by hypothalamic 
infusion suggests that the chlorfenvinphos is neither an agonist nor antagonist of the muscarinic 
receptors in the rabbit hypothalamus. No overt changes in behavior or changes in hippocampal EEG 
were observed in the rabbits following infusion with 0.5 mg/kg chlorfenvinphos (Gralewicz et al. 1995). 
Organophosphate-induced hypotension (reported for chlorfenvinphos only in rats receiving intravenous 
doses) (Takahashi et al. 1991) has been suggested to be due to factors other than inhibition of 
cholinesterase activity (Kojima et al. 1992). A study concluded that the alteration of brain and liver 
activities of the aromatic amino acid transferases may be due to the inhibitory effect of chlorfenvinphos 
on noradrenaline (norepinephrine) activity (Puzynska 1984). In other studies, chlorfenvinphos was 
shown to independently inhibit noradrenaline (norepinephrine) activity in vivo in rats rapidly (3 hours) at 
doses as low as 4 mg/kg (Brzezinski 1978; Osumi et al. 1975).  On this basis, it has been postulated 
that chlorfenvinphos may also act via central noradrenergic mechanisms, disturbing the dynamic 
equilibrium between the rate of formation and utilization of noradrenaline (norepinephrine).  This action 
via central noradrenergic mechanisms by chlorfenvinphos may be responsible for the changes in 
blood pressure observed in other studies after chlorfenvinphos intoxication (Brzezinski 1978). 
It has also been suggested that the cholinergic action of organophosphates like chlorfenvinphos may 
interfere with the pathways controlling the secretory activity of the anterior pituitary lobe and the 
adrenal cortex whose hormones influence the activities of many enzymes, including aromatic amino 
acid transferases (Puzynska 1984). Interference with the secretory activity of the adrenal cortex may 
lead to a disruption in the normal activities of one or more components of the renal blood pressure 
regulatory systems (Klaassen et al. 1986). 
2.4.3 Animal-to-Human Extrapolations 
In one study, the rates of chlorfenvinphos de-ethylation by human liver microsomal fractions are 
0.36 nmol/minute per mg protein (range 0.11–0.82) without induction and 1.03 nmol/minute per nmol 
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of cytochrome P-450 (range 0.42–1.78) with induction. The rates of chlorfenvinphos de-ethylation by 
liver microsomal fractions are 0.62 nmol/minute/mg protein (range 0.36–0.93) and 
1.30 nmol/minute/nmol cytochrome P-450 (range 0.81–1.74) for uninduced rabbits. The rabbit is 
considered relatively resistant to the acute toxic action of chlorfenvinphos, with an LD50 of 
500–1,000 mg/kg (provided in another study). These results demonstrate that human hepatic 
cytochrome P-450 is almost as active as that of rabbits. However, the authors stressed that these 
results refer to the total cytochrome P-450 complement of the cells and take no account of the several 
forms known to exist which differ from species to species, or of the environmental factors, and the 
other factors involved in the acute toxicity of chlorfenvinphos in humans. Based on the findings in this 
study, it appears that humans may de-ethylate chlorfenvinphos more like rabbits or mice than like rats 
(Hutson and Logan 1986). 
2.5 RELEVANCE TO PUBLIC HEALTH 
Overview
Chlorfenvinphos is an insecticide that was broadly used in the United States in both agriculture and 
control of pests in residential dwellings, gardens, and on household pets from 1963 until 1991, when 
all products containing chlorfenvinphos as an active ingredient were canceled (REFS 1995). 
The absorption of chlorfenvinphos after inhalation exposure in humans or animals is unknown due to 
lack of data. Ingested and dermally contacted chlorfenvinphos is rapidly absorbed in humans and 
animals; the rate of absorption is dependent on the solvent in which the substance is dissolved. In 
humans, absorbed chlorfenvinphos is widely distributed and has been detected in compartments that 
include serum, cervical mucus, follicular and sperm fluids, and milk.  It is extensively metabolized via 
oxidative dealkylation by liver microsomal fractions.  Data from animal studies suggest that 
electrophilic metabolic intermediates or epoxides may be produced in the metabolism of 
chlorfenvinphos. There is no information on the elimination or excretion of chlorfenvinphos in humans 
and animals after inhalation or dermal exposures; however, ingested chlorfenvinphos is rapidly 
eliminated via the urine and feces, and expired air in animals. In humans, ingested chlorfenvinphos is 
rapidly removed from the blood and passed into the tissues; chlorfenvinphos has been detected in 
human sperm fluid and milk samples. 
As an anticholinesterase organophosphate, the principal toxic effect of chlorfenvinphos is the inhibition 
of cholinesterase activity in the central and peripheral nervous system when administered by the oral 
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or inhalation route in acute-duration exposures in humans and the inhibition of cholinesterase activity 
in the central and peripheral nervous system when administered by the oral, or dermal route in acute-
duration exposures. Inhibition of cholinesterase activity results in the accumulation of acetylcholine at 
acetylcholine receptors leading to cholinergic responses in the peripheral (muscarinic and nicotinic) 
and central nervous system and neuromuscular junctions. Severe inhibition of acetylcholinesterase 
activity often leads to cholinergic symptoms in humans and laboratory animals, which include 
excessive glandular secretions (salivation, lacrimation, rhinorrhea, miosis), exophthalmos, 
bronchoconstriction, vasodilation, hypotension, diarrhea, nausea, vomiting, urinary incontinence, and 
bradycardia.  Tachycardia, mydriasis, fasciculations, cramping, twitching, muscle weakness, and 
muscle paralysis are associated with nicotinic receptor stimulation.  Central nervous system toxicity 
may be mediated by either muscarinic or nicotinic receptors and includes respiratory depression, 
anxiety, insomnia, headache, apathy, drowsiness, dizziness, loss of concentration, confusion, tremors, 
convulsions, and coma. In non-fatal exposures, the effects are transient and recovery is rapid and 
complete following cessation of exposure. In sufficiently high doses, chlorfenvinphos exposure has 
resulted in death of humans, rats, and mice. These effects usually occur within a few minutes to a few 
hours after dosing, depending on the extent of exposure. In addition, chlorfenvinphos may interfere 
with the activity of noradrenaline (norepinephrine) in central adrenergic mechanisms in animals. 
The greatest potential for significant exposure to this compound is found in occupational settings (i.e., 
manufacture and application of chlorfenvinphos). Currently, the most common exposure scenario for 
the general population comes from home use of imported foods and lanolin-containing pharmaceutical 
products. Workers involved in disposal of chlorfenvinphos-contaminated wastes are at a higher risk of 
exposure. Populations potentially at higher risk of exposure are: people living in the vicinity of plants 
where chlorfenvinphos was manufactured; people living near dairy farms, cattle or sheep holding 
areas, or poultry producing-facilities where chlorfenvinphos was used; and populations living near 
hazardous waste sites containing chlorfenvinphos. No association has been reported between 
chlorfenvinphos toxicity and low-level environmental contamination. 
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Minimal Risk Levels for Chlorfenvinphos
Inhalation MRLs.  
Inhalation MRLs for acute-, intermediate-, or chronic-duration exposure to chlorfenvinphos have not 
been calculated because adequate data for developing these MRLs are not available. The available 
human reports involve mixed exposures. The available animal studies reported serious effects. 
A human study reported immunological effects at a LOAEL of 0.21 mg/m3 following prolonged 
occupational exposure to chlorfenvinphos by the inhalation route. However, the subjects of this study 
were also concurrently exposed to greater concentrations of other potentially immunotoxic substances 
such as formothion, sumithion, and malathion (Wysocki et al. 1987). In another human study, a group 
of nine gardeners (pesticide mixers) exposed to unknown concentrations of a mixture of pesticides 
(chlorfenvinphos, dimethoate, formothion, isofenphos), complained of headaches and had a mean 
difference (before and after exposure) of 0.56 nmol/mL for acetylcholinesterase and 2.67 nmol/mL for 
butyrylcholinesterase (Kolmodin-Hedman and Eriksson 1987). However, since these symptoms could 
also result from exposure to the other organophosphate pesticides in the mixture, the etiology for 
these symptoms is uncertain. Therefore the study was not useful for developing inhalation MRLs. 
The available inhalation animal studies reported only serious effects (mortality, apnea, salivation, 
urination, exophthalmos, twitches, and tremors) (Takahashi et al. 1994; Tsuda et al. 1986) following 
exposure to chlorfenvinphos. Therefore, the data from these studies are not appropriate for use in the 
calculation of MRLs. 
Oral MRLs. 
An MRL of 0.002 mg/kg/day has been developed for acute-duration oral exposure (14 days or 
less) to chlorfenvinphos. 
This MRL for chlorfenvinphos is based on a LOAEL of 2.4 mg/kg/day for neurological effects (38% 
erythrocyte cholinesterase inhibition) in female rats (Barna and Simon 1973). In the study, two groups 
of adult female albino (Wistar) rats weighing 208 g were orally administered Birlane® (chlorfenvinphos) 
at dose of 0 or 2.4 mg/kg/day in the diet for 10 days. The study was designed to investigate the 
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effects of oral chlorfenvinphos on body weight increase, the gastrointestinal absorption of glucose, 
Na+, and Ca2+, and the effects of oral chlorfenvinphos on plasma and erythrocyte cholinesterase 
activity levels. Plasma cholinesterase activity was inhibited by 52%, and erythrocyte cholinesterase 
activity level was inhibited by 30% at a dose of 2.4 mg/kg/day (the only dose tested). Gastrointestinal 
absorption of glucose was increased by 30% over control values while Na+ absorption was decreased 
by 32% below control values. Gastrointestinal absorption of Ca2+ and body weight increases were 
unaffected by chlorfenvinphos exposure. These changes in the gastrointestinal absorption of glucose, 
but Na+ were not considered statistically significant (P>0.05) by the investigators. 
The central nervous system is the principal target of chlorfenvinphos toxicosis.  Chlorfenvinphos, an 
anticholinesterase organophosphate, inhibits cholinesterase activity in the central and peripheral 
nervous system in humans and animals (Cupp et al. 1975; Gralewicz et al.1990; Hunter 1969; Maxwell 
and LeQuesne 1982; Osumi et al. 1975; Osicka-Koprowska et al. 1984; Pach et al. 1987; Takahashi 
et al. 1991; Vestweber and Kruckenberg 1972). Chlorfenvinphos also inhibits noradrenaline 
(norepinephrine) activity in the central nervous system in animals (Brzezinski 1978; Osumi et al. 1975). 
Human subjects exposed to large acute doses of chlorfenvinphos exhibited severe cholinergic signs. 
These cholinergic signs were relieved by the administration of atropine and/or pralidoxime, indicating 
cholinesterase inhibition etiology (Cupp et al. 1975; Pach et al. 1987). In rats, low to moderate doses 
(2.4–30 mg/kg) of oral chlorfenvinphos significantly inhibited cholinesterase activities in a number of 
tissues: the brain, erythrocyte, and plasma (Barna and Simon 1973; Osicka-Koprowska et al. 1984; 
Puzynska 1984). An acute-duration oral study also found alterations in noradrenaline 
(norepinephrine) level in rat brain following exposure to chlorfenvinphos. A chlorfenvinphos dose of 
13 mg/kg decreased noradrenaline (norepinephrine) levels in rat brains by 20%, as compared to 
control rats. According to the investigators, chlorfenvinphos accelerated the rate of NA disappearance 
from the brain (Brzezinski 1978). 
Therefore, it is appropriate to base the acute oral MRL for chlorfenvinphos on cholinesterase inhibition. 
It should be noted that a study by Osumi et al. (1975) which determined a NOAEL of 1 mg/kg/day and 
a LOAEL of 2 mg/kg/day for 38% inhibition of brain cholinesterase in rats was not used to calculate an 
acute oral MRL because it was deemed less appropriate due to the gavage (oral) route of 
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An MRL of 0.002 mg/kg/day has been developed for intermediate-duration oral exposure 
(15–364 days) to chlorfenvinphos. 
The MRL is based on a LOAEL of 1.5 mg/kg/day for adverse immunological/lymphoreticular effects in 
mice (Kowalczyk-Bronisz et al. 1992). In this study male and female inbred C57BL/6 mice and 
(C57BL/6 x DBA/2)F1 (BDF1/Iiw) hybrid mice (6–8 weeks old) were orally dosed with chlorfenvinphos 
(suspended in 1% methylcellulose solution) and evaluated for 5 days for the effect of chlorfenvinphos 
exposure on the mouse immune system. The mice were exposed to oral chlorfenvinphos doses of 0, 
1.5, 3, or 6 mg/kg (0, 1/100, 1/50, or 1/25 LD50) daily for 3 months; the control group was given 1% 
methylcellulose. Then exposed and control mice were immunized by intraperitoneal injections of 
0.2 mL 10% sheep red blood cells. The IgM-PFC (plaque-forming or antibody-producing cells) 
number in spleen cell suspension was tested on day 4 after immunization and the procedure 
repeated 3 weeks after the exposure to chlorfenvinphos had been ceased. Exposed and control 
groups were subjected to immunological tests and hematological examinations.  Lymphatic organs 
were histologically examined. A dose-related decrease in the number of hemolysin-producing cells 
was observed: plaque-forming cells (PFC) were 58% at the 6 mg/kg dose group and 85% at the 
3 mg/kg dose level as compared to control values. Chlorfenvinphos treatment also caused reduction 
in the number of E rosette-forming cells by 30% at the 6 mg/kg dose level and by 25% at the 3 mg/kg 
dose level. Increases in Interlukin-1 (Il-1) activity and delayed-type hypersensitivity (DTH) reaction 
were observed 24 hours after challenge. Spleen colonies were stimulated, as evidenced by the 
increase of endogenous spleen colonies and exogenous spleen colonies (CFU-S). CFU-S increased 
190% at the 1.48 mg/kg dose level; 137% at the 6 mg/kg dose level; 162% at 1.5 mg/kg dose level; 
and 70% at the 6 mg/kg dose level. When the IgM PFC number was tested 3 weeks later, after the 
exposure to chlorfenvinphos in the small dose (1.5 mg/kg), an increase (about 40%) in number of 
plaques was observed. There was a 50% reduction in thymus weight at the 1.5 mg/kg dose level, 
compared to controls; significant involution of the thymus was also noted. 
In other studies, adverse immunologic/lymphoreticular effects have been associated with exposure to 
oral chlorfenvinphos. In an intermediate-duration dietary study with albino (Wistar) rats, there was a 
significant and irreversible reduction in relative spleen weight of female rats given $3 mg/kg/day 
chlorfenvinphos for 12 weeks (Ambrose et al. 1970). A study was undertaken to evaluate selected 
serological and cytoimmunological reactions in rabbits subjected to a long-term poisoning with 
subtoxic oral doses (10 mg/kg in a soya oil solution with a small amount of food) of chlorfenvinphos 
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hemolysin activity (66%, P<0.05), and also increased the number of nucleated lymphoid cells 
producing hemolytic antibody to sheep erythrocytes, compared to controls (treated 906, P<0.05 and 
controls 618). Spleen cytomorphology changes, manifested mainly as transformation of primary 
follicles into secondary ones with well developed germinal centers, were also observed (Roszkowski 
1978). 
Therefore, it is appropriate to base the intermediate oral MRL for chlorfenvinphos on immunological 
effects. 
An MRL of 0.0007 mg/kg/day has been derived for chronic-duration oral exposure (365 days or 
more) to chlorfenvinphos. 
This MRL for chlorfenvinphos was developed from a LOAEL of 0.7 mg/kg/day for adverse neurological 
effects in rats (Ambrose et al. 1970). In this study, four matched groups of weanling albino (Wistar) 
rats were culled to a narrow starting weight range and fed daily GC-4072 (technical chlorfenvinphos) 
doses of 0, 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0, 0.8, 2.4, or 8, or 24 mg/kg/day (females) in the 
diet for 104 weeks. An additional group of non-littermate rats were administered 21 mg/kg/day (males) 
or 24 mg/kg/day (females) chlorfenvinphos for 104 weeks. Plasma and erythrocyte cholinesterase 
(ChE) activity levels were obtained from 4 rats of each sex per dose group at 1, 4, 8, and 12 weeks. 
At 13 weeks, 4 rats/sex/dose group were sacrificed for histopathologic examination. The rats in the 
21 mg/kg/day (males) and 24 mg/kg/day (females) were sacrificed on the 95th week, and all other 
dose group animals were sacrificed on the end of the study (104 weeks). At each autopsy, relative 
organ weights were determined for heart and kidneys. All animals sacrificed in moribund condition, as 
well as those sacrificed at week 13, 95, and 104 weeks were examined grossly and microscopically, 
and organs (heart, lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, 
skeletal muscle, skin, bone marrow, pancreas, thyroid, adrenal, pituitary) from these animals were 
histopathologically examined. Chlorfenvinphos significantly decreased body weight gain of females at 
the 8 and 24 mg/kg/day dose groups from the 26th week until near the end of the study, although the 
decreased body weight gain became statistically insignificant at the end of the study. Increased 
relative liver weights were observed in males at the 7 mg/kg/day dose level, but no other signs of 
hepatopathology were reported. Compared to undosed controls, no consistent differences in body 
weight gains in males, survival of the test animals, food consumption, or mortality were evident at any 
dose level tested. No gross or microscopic histopathology was evident in any of the organs (heart, 
lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, skin, 
bone marrow, pancreas, thyroid, adrenal, pituitary) and tissues examined. No changes in 
organ-to-body weight were observed in the heart, kidney, spleen and testes. 
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Although the neurological effects of prolonged human exposure to low oral doses of chlorfenvinphos 
are not known due to a lack of studies, clinical reports of accidental and intentional acute exposure to 
relatively high doses of chlorfenvinphos-containing organic phosphate products indicate that 
neurological effects, mediated by cholinesterase inhibition (Cupp et al. 1975; Pach et al. 1987), may 
be the most sensitive toxicological consequences of human exposure to chlorfenvinphos.  Similarly, 
chlorfenvinphos significantly inhibited both plasma and erythrocyte cholinesterase activities in Beagle 
dogs fed daily chlorfenvinphos doses of 0.3, 2, or 10 mg/kg/day (males), or 1.5, 10, or 50 mg/kg/day 
(females) in the diet (moist) for 104 weeks. Plasma cholinesterase activities were significantly 
inhibited at all dietary levels through week 39 of the study; 49% inhibition was noted at the 
0.3 mg/kg/day (males) and 1.5 mg/kg/day (females) dose levels.  Erythrocyte cholinesterase activity 
was significantly and consistently inhibited (36%) during the first 12 weeks only in the 10 mg/kg/day 
(males) and 50 mg/kg/day (females) dose levels (Ambrose et al. 1970). 
Death.  Data are not available to estimate the lethal dose of chlorfenvinphos by any route or for any 
duration of exposure in humans. However, one study reported the death of a 16-year-old victim 
following unintentional ingestion of an unspecified amount of chlorfenvinphos (Felthous 1978). In 
animal studies, the acute inhalation LC50 for rat is estimated as 130 mg/m3 (Tsuda et al. 1986). The 
acute oral LD50 for technical chlorfenvinphos for both sexes of rat is variously estimated as 15.4 mg/kg 
(Hutson and Wright 1980); 22.8 mg/kg (Hutson and Logan 1986); 34.3 mg/kg (Ikeda et al. 1992); and 
9.7 mg/kg/day (Ambrose et al. 1970). The acute oral LD50 values for male and female rats have been 
given as 23 mg/kg and 25.5 mg/kg, respectively (Puzynska 1984). Chlorfenvinphos appears to be 
less acutely toxic to mice than to other experimental animals, with estimated LD50 values of 148 mg/kg 
(male) and 109 mg/kg (female) (Kowalczyk-Bronisz et al. 1992). The LD50 for rabbits has been 
estimated to be 300 mg/kg (Ambrose et al. 1970) and 500–1,000 mg/kg (Hutson and Logan 1986); the 
estimated LD50 for dogs is 50.5 mg/kg/day (Ambrose et al. 1970). 
The dermal LD50 values for undiluted chlorfenvinphos and emulsifiable concentrate for rabbits have 
been estimated as 400 and 1,087 g/kg, respectively (Ambrose et al. 1970). No reports of human 
deaths resulting from dermal exposure to chlorfenvinphos were located, but evidence from non-lethal 
human data and animal studies (Hunter 1969; Vestweber and Kruckenberg 1972) indicates that 
human lethality by this route of exposure is unlikely. 
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Systemic Effects.
Respiratory Effects. No studies were located regarding respiratory effects in humans following 
acute-, intermediate- or chronic-duration inhalation, oral, or dermal exposure to chlorfenvinphos. 
Respiratory effects were noted in two clinical reports of human ingestion: accidental ingestion of a 
mange-mite medication containing organic phosphate; and intentional ingestion in a suicide attempt of 
the preparation Enolofos®, which contains 50% chlorfenvinphos. In both cases, effects stemmed from 
central cholinergic disturbances (Cupp et al. 1975; Pach et al. 1987). Animal data indicate that acute-
duration inhalation exposure to high doses of chlorfenvinphos (16–390 mg/m3) may be accompanied 
by transient apnea (Takahashi et al. 1991, 1994). No effects on the respiratory system were noted in 
rats and dogs orally administered chlorfenvinphos at doses as high as 100 mg/kg/day (rats) or 
50 mg/kg/day (dogs) for 12 weeks; or in rats at doses as high as 24 mg/kg/day for 104 weeks 
(Ambrose et al. 1970). Due to inadequate data, it is unknown whether human exposure to 
environmental concentrations of chlorfenvinphos could result in adverse respiratory effects. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans 
following acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to 
chlorfenvinphos. Animal data indicate that acute-duration inhalation exposure to high doses of 
chlorfenvinphos (16–390 mg/m3) may be preceded by an initial hypotension followed by steadily 
increasing hypertension and abnormal cardiac conductivity (Takahashi et al. 1991, 1994). Evidence 
from animal studies also indicates that oral chlorfenvinphos is not directly toxic to the cardiovascular 
system, but may modulate the function of the cardiovascular system via its effect on the central 
nervous system (Ambrose et al. 1970; Klaassen et al. 1986; Puzynska 1984). Although this route of 
exposure may not be relevant to human exposure to chlorfenvinphos, Sprague-Dawley rats also 
exhibited similar signs at a dose of 16 mg/kg following intravenous administration of the 
chlorfenvinphos (Takahashi et al. 1991). Due to inadequate data, it is unknown whether human 
exposure to environmental concentrations of chlorfenvinphos could result in adverse cardiovascular 
effects. 
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
following acute-, intermediate-, or chronic-duration oral exposure to chlorfenvinphos. Acute- and 
intermediate-duration oral exposures to chlorfenvinphos increased gastrointestinal absorption of 
glucose, while decreasing the gastrointestinal absorption of Na+; however, Ca2+ absorption was 
unaffected in adult Wistar rats. These changes in glucose and Na+ absorption were not considered 
statistically significant (P>0.05) by the investigators (Barna and Simon 1973). Weanling albino 
(Wistar) rats of both sexes chronically administered daily dietary chlorfenvinphos doses of 
21 mg/kg/day (males) or 24 mg/kg/day (females) exhibited no gross or microscopic histopathology in 
77 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
the stomach or small and large intestine at autopsy (Ambrose et al. 1970). Based on the available 
information, human exposure to chlorfenvinphos at hazardous waste sites is not likely to result in any 
significant adverse gastrointestinal effects. 
Hematological Effects. The hematological effects from inhalation exposure to chlorfenvinphos are 
not known due to lack of data in humans and laboratory animals. Similarly, the hematological effects 
of oral chlorfenvinphos exposure are not certain because of limited and inconclusive data in animals. 
Uncorroborated investigations conducted on 4 groups of male and female rabbits (13 each) at a dose 
of 10 mg/kg for 90 days to evaluate the serological effects of chlorfenvinphos reported significant 
increases of hemolysin and hemagglutinin serum titers as compared to controls. Hemagglutinin and 
hemagglutinin IgG titers were increased by 16 and 18%, respectively, while hemolysin and hemolysin 
IgG titers were elevated by 66 and 102%, respectively (Roszkowski 1978). However, no effects were 
observed on monitored hematological parameters in rats and Beagle dogs given oral chlorfenvinphos 
(up to 24 mg/kg/day for rats and 50 mg/kg/day for dogs) for 104 weeks (Ambrose et al. 1970). Due to 
the lack of data on the hematological effects of chlorfenvinphos in humans and scarcity of data in 
animals, the hematological effects of human exposure to chlorfenvinphos are uncertain. 
Musculoskeletal Effects.  No studies were found regarding musculoskeletal effects in humans or 
animals following inhalation or dermal exposure to chlorfenvinphos. In animal oral studies, no effects 
on the musculoskeletal system were noted in dogs orally administered chlorfenvinphos at doses as 
high as 50 mg/kg/day (females) for 12 weeks; or in rats at doses as high as 24 mg/kg/day (females) 
for 104 weeks (Ambrose et al. 1970). Therefore, adverse musculoskeletal effects in humans from 
exposure to chlorfenvinphos at hazardous waste sites are not likely. 
Hepatic Effects. Based on the currently available data, chlorfenvinphos exposure at environmental 
levels is not likely to present risk of liver injury to humans. No hepatic effects were reported in humans 
from exposure to chlorfenvinphos by any route.  Although chlorfenvinphos proved to be 
porphyrinogenic in tissue culture without induction and markedly porphyrinogenic with induction 
(Koeman et al. 1980), no such evidence was found in the currently available in vivo studies. The 
limited information on the hepatic effects of chlorfenvinphos indicates that the substance is not 
significantly hepatotoxic by the oral route in acute-, intermediate-, or chronic-duration exposures. 
While no changes in liver weight (relative to body weight) were reported in Fischer 344 rats given a 
single oral chlorfenvinphos dose of 15 mg/kg, P-450 activity was increased by 30%.  Aminopyrine­
N-demethylase and aniline hydroxylase activities were also increased by 40 and 27%, respectively 
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(Ikeda et al. 1991). Although intermediate oral administration of doses of chlorfenvinphos induced 
alterations in serum sorbitol dehydrogenase and brain and liver levels of aromatic amino acids 
transferases L-phenylalanine aminotransferase, L-tyrosine aminotransferase, and L-tryptophan 
aminotransferase in mature Wistar rats (Puzynska 1984), no gross or microscopic histopathology in 
liver tissues was evident in weanling albino (Wistar) rats administered daily dietary chlorfenvinphos 
doses of 90 mg/kg/day (males) or 100 mg/kg/day (females) or in mongrel dogs given daily dietary 
doses of 10 mg/kg/day (males) or 50 mg/kg/day (females) for 12 weeks. However, relative liver 
weights were significantly and irreversibly decreased in the rats at a dose of 2.7 mg/kg/day (males) or 
3 mg/kg/day (females) (Ambrose et al. 1970). In chronic (104 weeks) feeding studies, increased 
relative liver weights were observed in males at a dose of 7 mg/kg/day following dietary administration 
of chlorfenvinphos to both sexes. No liver histopathological or adverse liver function effects were 
reported in Beagle dogs fed daily dietary chlorfenvinphos doses of 10 mg/kg/day (males) or 
50 mg/kg/day (females) for 104 weeks (Ambrose et al. 1970). 
Renal Effects. No studies were located regarding renal effects in humans or animals following acute-, 
intermediate-, or chronic-duration oral exposure to chlorfenvinphos.  In one study, no gross or 
microscopic histopathology in kidney tissues was evident in weanling albino (Wistar) rats administered 
daily dietary chlorfenvinphos doses of 90 mg/kg/day (males) or 100 mg/kg/day (females), or in mongrel 
dogs given daily dietary doses of 10 mg/kg/day (males) or 50 mg/kg/day (females) for 12 weeks. 
However, relative kidney weights were significantly and irreversibly decreased in the rats at a dose of 
2.7 mg/kg/day (males) or 3 mg/kg/day (females) (Ambrose et al. 1970). In chronic (104 weeks) 
feeding studies, no gross or microscopic histopathology in the kidney and urinary bladder tissues 
examined or changes in relative kidney weights were evident in this strain of rats following daily doses 
of 21 mg/kg/day (males) or 24 mg/kg/day (females) (Ambrose et al. 1970). No kidney 
histopathological or adverse kidney function effects were reported in Beagle dogs fed daily dietary 
chlorfenvinphos doses of 10 mg/kg/day (males) or 50 mg/kg/day (females) for 104 weeks (Ambrose et 
al. 1970). Renal function was not assessed in these studies. Due to the lack of adequate data on the 
renal effects on chlorfenvinphos in humans and animals, the renal effects of human exposure to 
chlorfenvinphos are not known. 
Endocrine Effects. There are no reports of endocrine effects in humans exposed by acute-, 
intermediate-, or chronic-duration ingestion of chlorfenvinphos. No studies were located regarding 
endocrine effects in animals after intermediate- or chronic-duration oral exposure to this insecticide. 
Although a significant increase (>300%) of plasma corticosterone was observed at 1 and 3 hours, and 
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of plasma aldosterone from 1 to 6 hours after treatment of male Wistar rats with a single 
chlorfenvinphos dose of 6.15 mg/kg (50% LD50) by stomach tube (Osicka-Koprowska et al. 1984), the 
toxicological significance of these findings and relevance to human health are unknown. 
Dermal Effects. No studies were found regarding dermal effects in humans or animals following 
inhalation or dermal exposure to chlorfenvinphos. In animal oral studies, no adverse changes were 
seen in the skin of weanling albino (Wistar) rats of both sexes given oral doses of up to 100 mg/kg/day 
(female rats) chlorfenvinphos for 12 weeks (Ambrose et al. 1970). Similarly, no adverse changes were 
seen in the skin of weanling albino (Wistar) rats of both sexes chronically (104 weeks) given daily 
dietary chlorfenvinphos doses of 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day 
(females) (Ambrose et al. 1970). Therefore, adverse dermal effects in humans from exposure to 
chlorfenvinphos at hazardous waste sites are not likely. 
Ocular Effects. No studies were located regarding ocular effects in humans or animals following 
acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to chlorfenvinphos. 
Consequently, it is not known whether human exposure to environmental concentrations of 
chlorfenvinphos could result in adverse ocular effects. 
Body Weight Effects. No studies were located regarding body weight effects in humans following 
acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to chlorfenvinphos.  In 
animal studies, acute-duration exposure of adult rats to oral Birlane® (chlorfenvinphos) at a dose of 
2.4 mg/kg/day in the diet for 10 days did not affect body weight increases. Body weight increases 
were also unaffected following oral doses of 0.8 mg/kg/day in the diet for 30 days (Barna and Simon 
1973). Similarly, no body weight changes were seen in mongrel dogs exposed to dietary 
chlorfenvinphos at a dose of 10 mg/kg/day (males) or 50 mg/kg/day (females) for 12 weeks (Ambrose 
et al. 1970). However, oral exposure of weanling rats for the same duration was associated with a 
significant but slightly reversible depression on growth, observed at a dose of 9 mg/kg/day (males) or 
10 mg/kg/day (females). In an accompanying chronic-duration oral study (104 weeks), 
chlorfenvinphos also significantly and reversibly decreased body weight gain of female weanlings at 
dose levels of $8 mg/kg/day. Beagle dogs given daily dietary chlorfenvinphos doses of 10 mg/kg/day 
(males) or 50 mg/kg/day (females) for the same duration (104 weeks) exhibited no significant changes 
in body weight (Ambrose et al. 1970). Based on the available information, human exposure to 
environmental concentrations of chlorfenvinphos is not likely to result in any significant adverse body 
weight effects. 
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Metabolic Effects.  Occupational exposure to airborne chlorfenvinphos significantly lowered NBT-dye 
reduction in both stimulated and non-stimulated cells, and caused a significant decrease of the 
spontaneous E rosette formation (not influenced by exposure time) in the blood (early E rosettes, 52%; 
late E rosettes, 57%). The authors of this study concluded that this may be regarded as a probable 
mechanism by which organophosphoric chemicals interfere with metabolism and cause membrane 
damage in human cells. About half of the subjects in the study were smokers (Wysocki et al. 1987). 
In animal studies, Carworth Farm E strain male rats orally administered a single [14C]chlorfenvinphos 
dose of 2.5 or 13.3 mg/kg in olive oil (with or without prior monooxygenase induction with dieldrin) 
exhibited minimal changes in the metabolic profiles (Hutson and Wright 1980). However, the gastro­
intestinal absorption of glucose was increased by 30% over control values, while Na+ absorption was 
decreased by 32% below control values in adult female albino (Wistar) orally administered Birlane® 
(chlorfenvinphos) at a dose of 2.4 mg/kg/day in the diet for 10 days, although, Ca2+ absorption was 
unaffected. Similarly, oral chlorfenvinphos increased glucose absorption 12% while decreasing Na+ 
absorption by 23% at a dose of 0.8 mg/kg/day in the diet to this strain of rats for 30 days. Gastro­
intestinal absorption of Ca2+ was, likewise, unaffected by chlorfenvinphos exposure in this intermediate 
exposure to oral chlorfenvinphos. The changes in glucose and Na+ absorption were not considered 
statistically significant (P>0.05) by the investigators (Barna and Simon 1973). The LOAEL of 
2.4 mg/kg/day from the 10-day dosing protocol of this study, based on adverse neurological effects in 
rats was used to derive an acute oral MRL of 0.002 mg/kg/day for chlorfenvinphos. 
Evidence from rat studies indicates that the alteration of brain and liver activities of the aromatic amino 
acid transferases by chlorfenvinphos may be due to the inhibitory effect of the substance on 
noradrenaline (norepinephrine) activity, since noradrenaline (norepinephrine) has been shown to affect 
amino acid transferase (L-tyrosine aminotransferase) activity in another study (Puzynska 1984). 
Based on the available information, human exposure to environmental concentrations of 
chlorfenvinphos is not likely to result in any significant adverse metabolic effects. 
Other Systemic Effects. No studies were located regarding other systemic effects in humans 
following acute-, intermediate-, or chronic-duration inhalation, oral, or dermal systemic effects from 
exposure to chlorfenvinphos. In animal studies, no significant effect on food consumption was evident 
in weanling albino (Wistar) rats administered daily dietary chlorfenvinphos doses of 90 mg/kg/day 
(males) or 100 mg/kg/day (females) or in mongrel dogs given daily dietary doses of 10 mg/kg/day 
(males) or 50 mg/kg/day (females) for 12 weeks. Similarly, in chronic (104 weeks) feeding studies, no 
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significant effect on food consumption was evident in rats and Beagle dogs following daily doses of 
21 mg/kg/day (males) or 24 mg/kg/day (females) and 10 mg/kg/day (males) or 50 mg/kg/day 
(females), respectively (Ambrose et al. 1970). Based on the available information, human exposure to 
environmental concentrations of chlorfenvinphos is not likely to result in any significant adverse effects 
on food consumption effects. 
Immunological and Lymphoreticular Effects.  Only one study was located that reported 
immunological effects in humans. In this report, occupational exposure to inhaled chlorfenvinphos for 
an average of 15 years was associated with damage to humoral mechanisms in humans.  The 
subjects exhibited significant decrease of the spontaneous E rosette formation and lowered absolute 
lymphocyte count in the peripheral blood. However, the subjects were also concurrently exposed to 
greater concentrations of other potentially immunotoxic substances such as formothion, sumithion, and 
malathion (Wysocki et al. 1987). In animal studies, the gastrointestinal absorption of glucose was 
increased by 30% over control values in adult female albino (Wistar) rats orally administered Birlane® 
(chlorfenvinphos) at a dose of 0 or 2.4 mg/kg/day in the diet for 10 days. Similarly, gastrointestinal 
absorption of glucose was increased by 12% over control values following orally administered Birlane® 
(chlorfenvinphos) at a dose of 0 or 0.8 mg/kg/day in the diet to this strain of rats for 30 days. However, 
the changes in glucose and Na+ absorption were not considered statistically significant (P>0.05) by the 
investigators (Barna and Simon 1973). It has been observed in other studies that an increased 
metabolic activity of neutrophils and monocytes during phagocytosis is accompanied by higher 
consumption of glucose and oxygen. Hydrogen peroxide is then derived from the pentose cycle, 
NAD-, and NADP-oxidase action (Kolanoski 1977 as cited in Wysocki et al. 1977). However, the 
relationship between increased gastrointestinal absorption of glucose and increased glucose utilization 
is not clear. In other animal studies, rabbits orally exposed to chlorfenvinphos for 90 days also 
exhibited significantly elevated serum hemagglutinin level (16%) and hemolysin activity (66%, P<0.05) 
as well as increased numbers of nucleated lymphoid cells producing hemolytic antibodies to sheep 
erythrocytes. Spleen cytomorphology changes, manifested mainly as transformation of primary 
follicles into secondary ones with well developed germinal centers, were also observed (Roszkowski 
1978). Intermediate-duration dietary exposure of rats resulted in a significant and irreversible 
reduction in relative spleen weight of female rats given $3 mg/kg/day chlorfenvinphos for 12 weeks. 
However, no gross or microscopic histopathology was evident in the spleen and bone marrow tissues 
of the rats upon examination (Ambrose et al. 1970). No histopathological changes in the spleen or 
bone marrow or changes in absolute or relative spleen weights were noted in rats or Beagle dogs of 
both sexes given dietary chlorfenvinphos doses of 21 mg/kg/day (males) or 24 mg/kg/day (females), or 
10 mg/kg/day (males) or 50 mg/kg/day (females), respectively, for 104 week (Ambrose et al. 1970). 
C57BL/6 mice and (C57BL/6 x DBA/2)F1 (BDF1/Iiw) hybrid mice (6–8 weeks old) orally exposed to 
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chlorfenvinphos for 90 days exhibited a reversible reduction in the number of E rosette-forming cells as 
well as a dose-related decrease in the number of hemolysin-producing cells, reduction in the number 
of plaque-forming cells, increases in Interlukin-1 activity and DTH reaction, stimulation of spleen 
colonies, and disturbance in humoral immune factors (immunoglobulins) at a LOAEL of 1.5 mg/kg 
(Kowalczyk-Bronisz et al. 1992). The LOAEL of 1.5 mg/kg/day, based on adverse 
immunolymphoreticular effects in this study, was used to derive an intermediate oral MRL of 
0.002 mg/kg/day for chlorfenvinphos. While the existing human inhalation study and the animal oral 
studies provide some indication that chlorfenvinphos exposure is associated with immunological 
changes, these changes were not consistent with depressive effect on immune reactions. Thus, the 
changes reported in these studies may simply be immunological mobilizations of the organisms to 
xenobiotics as opposed to damage to the major histocompatibility complex.  Consequently, it is not 
certain that human inhalation or oral exposure to chlorfenvinphos can result in immune dysfunction. 
Neurological Effects.  No studies were located regarding neurological effects in humans after 
acute- or intermediate-duration inhalation exposure to chlorfenvinphos, or after intermediate- or 
chronic-duration dermal exposure. Chlorfenvinphos inhibits cholinesterase activity in the central and 
peripheral nervous system of humans and animals (Ambrose et al. 1970; Barna and Simon 1973; 
Cupp et al. 1975; Gralewicz et al. 1989a, 1989b, 1990; Hunter 1969; Maxwell and LeQuesne 1982; 
Osicka-Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber and Kruckenberg 
1972). It also interferes with noradrenaline (norepinephrine) activity in central adrenergic mechanisms 
in animals (Brzezinski 1978; Osumi et al. 1975). Inhibition of acetylcholinesterase activity results in 
accumulation of acetylcholine at muscarinic and nicotinic receptors leading to peripheral and central 
nervous system effects. These effects usually appear within a few minutes to a few hours after 
exposure, depending on the extent of exposure. In a human case report, a 16-year-old white male 
who mistakenly ingested a formulation (identified as Dermaton®) was hospitalized 90 minutes 
afterward with symptoms of abdominal cramps, nausea, vomiting, generalized weakness, cold dry 
skin, hypothermia, listlessness, constricted pupils, hypertension, respiratory distress, fine generalized 
muscular twitching, and apprehension. Plasma and erythrocyte activity levels were significantly 
inhibited. All vital signs returned to normal after gastric lavage and treatment with atropine and 
pralidoxime (Cupp et al. 1975). 
The available information indicates that chlorfenvinphos has similar neurological effects in animals. 
The information indicates that the substance causes disruptions in the central and peripheral nervous 
system in rats and dogs following acute-, intermediate-, or chronic-duration exposures via the oral 
route at doses as low as 0.8 mg/kg/day (Ambrose et al. 1970; Barna and Simon 1973; Maxwell and 
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LeQuesne 1982; Osumi et al. 1975; Puzynska 1984; Takahashi et al. 1994). These disruptions are 
mediated by the inhibition of cholinesterase activity in the peripheral and central nervous tissue and 
are manifested as abnormal muscle reflex, muscle fasciculations, Straub tail reflex, twitches, 
convulsions, chromodacryorrhea, exophthalmos, gasping, lacrimation, prostration, salivation, sleep 
disturbances, diarrhea, emesis, and urination (Ambrose et al. 1970; Maxwell and LeQuesne 1982; 
Osumi et al. 1975; Puzynska 1984; Takahashi et al. 1991). Cholinesterase activity in the brain of male 
Wistar rats was unaffected 3 hours after oral administration of 1 mg/kg of chlorfenvinphos. However, 
at doses of $2 mg/kg, oral chlorfenvinphos produced a marked decrease in the brain cholinesterase 
activity to 18–38% of the control (P<0.001) value. The maximum inhibition occurred 3 hours after the 
administration, after which the cholinesterase activity increased gradually. Erythrocyte cholinesterase 
activity also decreased after 4 mg/kg of chlorfenvinphos; the lowest level (20%, P<0.001) was attained 
3 hours after treatment (Osumi et al. 1975). This study was not used to calculate an acute oral MRL 
because it was deemed less appropriate due to the gavage (oral) route of administration. An oral 
feeding study is preferred for this purpose by the ATSDR MRL Workgroup. In a chronic-duration 
study, chlorfenvinphos significantly inhibited both plasma and erythrocyte cholinesterase activities in a 
dose-dependent manner in weanling albino (Wistar) rats fed daily chlorfenvinphos doses of 0.7, 2.1, 7, 
or 21 mg/kg/day (males) or 0.8, 2.4, 8, or 24 mg/kg/day (females) mg/kg/day in the diet for 104 weeks. 
Plasma and erythrocyte cholinesterase activities were inhibited by 48% in females and 45% in males 
in the first week of treatment and by 20% in females and 33% in males in the fourth week of treatment, 
respectively, at the lowest dose tested (0.7 mg/kg/day for males and 0.8 mg/kg/day for females). No 
gross or microscopic histopathology was evident in the brain tissue examined (Ambrose et al. 1970). 
The LOAEL of 0.7 mg/kg/day, based on adverse neurological effects in rats in this study, was used to 
derive a chronic oral MRL of 0.0007 mg/kg/day for chlorfenvinphos.  In another study, all 36 Sprague-
Dawley rats exposed to chlorfenvinphos doses of 10.5 mg/kg/day in the diet for 3–6 months exhibited 
repetitive muscle activity when given two electrical stimuli simultaneously.  This is indicative of hyper 
stimulation due to depletion or inactivation of neuromuscular junction cholinesterase. The abnormality 
became more marked with time, even on constant dosing (Maxwell and LeQuesne 1982). The 
indications from this study may be useful in explaining electrophysiological abnormalities described in 
some workers chronically exposed to some organophosphorus compounds. 
Besides its cholinergic action, there is limited evidence that chlorfenvinphos acts via central 
noradrenergic mechanisms in rats by accelerating the noradrenaline (norepinephrine) turnover in the 
brain in vivo by the release of noradrenaline (norepinephrine) from brain tissue stores (Brzezinski 
1978). 
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On the basis of the existing evidence, human exposure to chlorfenvinphos is likely to result in 
neurological effects stemming from interference with both the central cholinergic and adrenergic 
mechanisms. 
Reproductive Effects.  No studies were located regarding reproductive effects in humans following 
acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to chlorfenvinphos. 
Reports from single-generation, intermediate- or chronic-duration rat and dog studies are largely 
negative for reproductive effects (Ambrose et al. 1970). However, these studies did not evaluate 
reproductive function. A 3-generation reproductive study in albino (Wistar) rats reported significant 
(50%) reduction in fertility in the F/2 generation at a LOAEL of 3 mg/kg/day (Ambrose et al. 1970). 
Although human data are lacking, the indications provided by the animal data suggest that adverse 
reproductive effects may result from prolonged human exposure to chlorfenvinphos at levels found at 
hazardous wastes sites. 
Developmental Effects.  No studies were located regarding developmental effects in humans 
following acute-, intermediate-, or chronic-duration inhalation exposure to chlorfenvinphos; or 
regarding acute-duration exposure of animals to chlorfenvinphos. A statistical model for hazard 
identification concluded that chlorfenvinphos is likely to interfere with development in rabbits and 
hamsters but not in rats. The model was essentially a database of 175 probable, suspected, 
unknown, and probably negative teratogenic or embryotoxic drugs and chemical compounds. For 
each of the compounds, including chlorfenvinphos, the results of any developmental toxicity testing in 
up to 14 animal species and any reports of mutagenicity or carcinogenicity were recorded. The 
compounds were categorized with respect to their human developmental toxicant effect: -1.0 testing 
negative, 0.0 not tested (unknown), 0.5 tested with equivocal results (suspicious), and 1.0 testing 
positive. Although the model did not evaluate the adverse reproductive effects potential of 
chlorfenvinphos in primates, mice, and dogs, it correctly classified the study compounds 63–91% of 
the time. The model had a sensitivity of 62–75%, and a positive predictive value of 75–100%. 
However, the model had a negative predictive value of 64–91%, indicating the model is not optimal for 
hazard identification (Jelovsek et al. 1989). In acute exposures, chlorfenvinphos inhibited respiratory 
efficiency of juvenile rats in a dose-dependent manner at a LOAEL of 29 mg/kg/day. At 
300 mg/kg/day, chlorfenvinphos completely arrested respiration in these rats (Skonieczna et al. 1981). 
In a 3-generation rat study, chlorfenvinphos induced significant but slightly reversible body weight 
gains in female rats at a LOAEL of $8 mg/kg/day as well as increased pup mortality and reduced 
lactational index at a LOAEL of 2.7 mg/kg/day. However, no teratogenic effects were reported in 
offspring rats (Ambrose et al. 1970). In single-generation intermediate- and chronic-duration studies 
with juvenile rats in which the rats were given dietary chlorfenvinphos doses of 90 mg/kg/day (males) 
or 100 mg/kg/day (females) for 12 weeks, or 21 mg/kg/day (males) or 24 mg/kg/day (females) in the 
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diet for 104 weeks, no significant effects on development were reported (Ambrose et al. 1970). 
Although human data are lacking, the indications provided by the animal data suggest that adverse 
developmental effects may result from prolonged human exposure to chlorfenvinphos at levels found 
at hazardous wastes sites. 
Genotoxic Effects.  No studies were located regarding genotoxic effects of chlorfenvinphos in 
humans or animals following any route of exposure.  Chlorfenvinphos was negative for mutagenicity in 
both base-pair change-type strains microorganisms (WP2 hcr of Escherichia coli; TA1535, TA1537, 
TA1538, TA98 of Salmonella typhimurium). In a mutagenicity study, the dose-response curve at 
doses of 0, 50, 500, and 5,000 µg/plate, for the mutagenic activity of chlorfenvinphos for the S. 
typhimurium strain TA100 was reduced by the S9 mix (metabolic activation). At present, no mutagenic 
pesticide whose activity decreases in the presence of the S9 mix is carcinogenic except captan (F-28) 
(Moriya et al. 1983). The mutagenic potency of chlorfenvinphos for strain TA100 has been reported as 
0.038 revertants/nmol, indicative of a positive response (Dean 1972; Moriya et al. 1983; Vishwanath 
and Kaiser 1986). A mixture of 15 pesticides (containing 0.3% chlorfenvinphos) tested negative for 
mutagenicity in the Salmonella microsome assay, with or without metabolic activation with 
PCB-induced rat liver S9, at concentrations up to 500 µg/plate in the Salmonella-microsome assay.
The mixture also failed to induce SCEs in human lymphocytes in vitro as well as in vivo mutagenicity in 
the micronucleus bone marrow assay in male Wistar rats at concentrations proportional to the ratio 
determined in foods ranging from 0.1 to 20 µg/mL (Dolara et al. 1993). In other large-scale screening 
programs which revealed microbial mutagenic activity in four new compounds (all fungicides), 
chlorfenvinphos (without metabolic activation) exhibited no mutation induction capacity in a rec-assay 
procedure (prescreening of DNA-damaging chemicals) utilizing strains of Bacillus subtilis, H17 Rec+ 
and M45 Rec-. Also, no mutation potential was evident in a reversion-assay (determination of 
mutation specificities) in which two tryptophan-requiring strains (auxotrophic) of E. coli (B/r try WP2 
and WP2 try hcr) and four strains of S. typhimurium (TA1535, TA1536, TA1537, TA1538) were used. 
The E. coli auxotrophic strains and Salmonella TA1535 are reversible by base-pair change-type 
mutagens and the three Salmonella strains (TA1536, TA1537, and TA1538) are reversible by 
frameshift mutagens (Shirasu 1973; Shirasu et al. 1976). 
There are no unequivocal data to indicate that chlorfenvinphos reacts directly with DNA in vivo or in 
vitro to produce mutations in either germ or somatic cells.  In a study to determine the ability of vinyl 
phosphate esters, like chlorfenvinphos, to form methylated bases in DNA of calf thymus failed to 
detect 6-methyl guanine, a known mutagen. In both the reaction with dsDNA and ssDNA, 7-methyl 
guanine was the main methylation product. However, all methyl derivatives of adenine constituted 
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about 40% and 50% of all methylation products in the case of dsDNA and ssDNA, respectively. 
3-Methylcytosine was the only methyl derivative of a pyrimidine identified (Wiaderkiewicz et al. 1986). 
In another study, tetrachlorvinphos (Gardona®) was evaluated for its potential to induce chromosomal 
aberrations and SCEs in vitro in a primary culture of Swiss mice spleen cells at concentrations of 0.25, 
0.50, 1.0, or 2.0 µg/mL. After 4 hours of treatment, tetrachlorvinphos induced a high percentage of 
metaphases with chromosomal aberrations in the mouse spleen cells in a dose-dependent manner. 
According to the authors, the results indicate that tetrachlorvinphos in the tested concentrations is 
mutagenic in mouse spleen cell cultures (Amer and Aly 1992). In this study, a structural analog of 
chlorfenvinphos (tetrachlorvinphos) was used; therefore, the data are difficult to relate to 
chlorfenvinphos without extensive structure-activity relationship analysis.  Data from these studies are 
shown on Tables 2-3 and 2-4. 
Cancer  There are no epidemiological or laboratory animal data to evaluate the carcinogenicity of 
chlorfenvinphos in humans by any route of exposure.  However, a study to determine the ability of 
vinyl phosphate esters, like chlorfenvinphos, to form methylated bases in DNA of calf thymus failed to 
detect 6-methyl guanine, a known mutagen. In both the reaction with dsDNA and ssDNA, 7-methyl 
guanine was the main methylation product. However, all methyl derivatives of adenine constituted 
about 40% and 50% of all methylation products in the case of dsDNA and ssDNA, respectively. 
3-Methylcytosine was the only methyl derivative of pyrimidine identified (Wiaderkiewicz et al. 1986). It 
is noteworthy that the production of electrophilic metabolic intermediates or epoxides in the 
metabolism of chlorfenvinphos, which could react with nucleophilic cellular components (DNA, RNA, 
and proteins) leading to carcinogenesis, was considered unlikely by a theoretical analysis (Akintonwa 
1985). 
In a mutagenicity study, the dose-response curve, at doses of 0, 50, 500, and 5,000 µg/plate, for the 
mutagenic activity of chlorfenvinphos for the S. typhimurium strain TA100 was reduced by the S9 mix 
(metabolic activation). At present, no mutagenic pesticide whose activity decreases in the presence of 
the S9 mix is carcinogenic except captan (F-28) (Moriya et al. 1983). A theoretical analysis that 
predicted the mammalian biotransformation products based on the recognition of the structure of 
chlorfenvinphos, understanding of Types I and II metabolism of foreign compounds, and mechanistic 
biochemistry, also acknowledged that cytochrome P-450 monooxygenase (an inducible enzyme) is the 
relevant enzyme which mediates the biotransformation of chlorfenvinphos. The author of this study 
postulated that the 2,4-dichlorobenzoyl glycine (2,4-dichlorohippuric acid) was produced in the rat by 
this mechanism. The production of electrophilic metabolic intermediates or epoxides in the 
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with nucleophilic cellular components (DNA, RNA, and proteins) leading to carcinogenesis, was 
considered unlikely by this theoretical approach (Akintonwa 1984). 
In contrast, tetrachlorvinphos (Gardona®), a structural analog to chlorfenvinphos, was evaluated for 
potential to induce chromosomal aberrations and SCEs in vitro in a primary culture of Swiss mice 
spleen cells at concentrations of 0.25, 0.50, 1.0, or 2.0 µg/mL. After 4 hours of treatment, tetra­
chlorvinphos induced a high percentage of metaphases with chromosomal aberrations in the mouse 
spleen cells in a dose-dependent manner. The corresponding number of metaphases for tetra­
chlorvinphos doses of 0.25, 0.50, 1.0, and 2.0 µg/m were 150, 590, 590, 600, and 600. According to 
the authors, the results of this evaluation indicate that tetrachlorvinphos (in the tested concentrations) 
ismutagenic in mouse spleen cell cultures (Amer and Aly 1992). However, in both of these studies, 
structural analogs of chlorfenvinphos (methylbromophenvinphos and tetrachlorvinphos, respectively) 
were used; therefore, the data are difficult to relate to chlorfenvinphos without extensive structure-
activity relationship analysis. 
Although neither human epidemiological evidence or evidence from rodent cancer bioassays is 
available, the current theoretical evidence indicates that human exposure to chlorfenvinphos is not 
likely to present cancer risk. 
2.6 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They 
have been classified as markers of exposure, markers of effect, and markers of susceptibility 
(NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of 
biomarkers as tools of exposure in the general population is very limited.  A biomarker of exposure is a 
xenobiotic substance or its metabolite(s), or the product of an interaction between a xenobiotic agent 
and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NRC 
1989). The preferred biomarkers of exposure are generally the substance itself or substance-specific 
metabolites in readily obtainable body fluid(s) or excreta. However, several factors can confound the 
use and interpretation of biomarkers of exposure. The body burden of a substance may be the result 
of exposures from more than one source. The substance being measured may be a metabolite of 
another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several 
different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) 
and environmental conditions (e.g., duration and route of exposure), the substance and all of its 
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metabolites may have left the body by the time samples can be taken. It may be difficult to identify 
individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 
chlorfenvinphos are discussed in Section 2.6.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within 
an organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals 
of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital 
epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or 
decreased lung capacity. Note that these markers are not often substance specific. They also may 
not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers 
of effects caused by chlorfenvinphos are discussed in Section 2.6.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic 
genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a 
decrease in the biologically effective dose, or a target tissue response.  If biomarkers of susceptibility 
exist, they are discussed in Section 2.8, Populations That Are Unusually Susceptible. 
2.6.1 Biomarkers Used to Identify or Quantify Exposure to Chlorfenvinphos 
Chlorfenvinphos is rapidly absorbed from the gastrointestinal tract and widely distributed throughout 
the body in humans (Pach et al. 1987; Wagner et al. 1990). Traces of unchanged chlorfenvinphos 
have been detected in animal urine following exposure (Hunter 1972; Szczepaniak and Sienkiewitcz 
1980). Chlorfenvinphos undergoes biotransformation to a variety of polar metabolites, including 
2-chloro-1-(2,4-dichlorophenyl) vinylethylhydrogen phosphate; 1-(2,4-dichlorophenyl) ethanol; 
1-(2,4-dichlorophenyl) ethanediol; 2,4-dichloromandelic acid; and 2,4-dichlorobenzoyl glycine (Hutson 
and Wright 1980), which have been detected in animals. Analysis of urine samples for the presence 
of these metabolites represents a potentially preferable means of assessing exposure since this 
method is non-invasive. However, as an organophosphate, chlorfenvinphos is rapidly metabolized 
and excreted from the body; therefore, urinary metabolite analysis is useful only in the evaluation of 
recent exposures. 
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The major action resulting from human exposure to chlorfenvinphos is the inhibition of cholinesterase 
activity (see Section 2.4). Two pools of cholinesterases are present in human blood: ­
acetylcholinesterase in erythrocytes and pseudocholinesterase in plasma.  Acetylcholinesterase, 
present in human erythrocytes, is identical to the enzyme present in neuromuscular tissue (the target 
of chlorfenvinphos action), while plasma pseudocholinesterase has no known physiological function. 
Inhibition of both forms of cholinesterase activities has been associated with exposure to 
chlorfenvinphos in humans and animals (Cupp et al. 1975; Gralewicz et al. 1989a, 1989b, 1990; 
Hunter 1969; Maxwell and LeQuesne 1982; Osicka-Koprowska et al. 1984; Pach et al. 1987; 
Takahashi et al. 1991; Vestweber and Kruckenberg 1972). Inhibition of erythrocyte, plasma, or whole 
blood cholinesterase activities may be used as a marker of exposure to chlorfenvinphos.  However, 
inhibition of cholinesterase activity is a common action of anticholinesterase compounds, which 
include organophosphates, like chlorfenvinphos, and carbamate compounds. In addition, a wide 
variation in normal cholinesterase values exists in the general population, and there are no studies 
which report a quantitative association between cholinesterase activity levels and exposure to 
chlorfenvinphos in humans. Thus, the inhibition of cholinesterase activity is not a specific biomarker of 
effect for chlorfenvinphos exposure; it is indicative only of effect and is not useful for dosimetric 
analysis. It should be noted that changes in plasma cholinesterase (pseudocholinesterase) activity are 
considered a more sensitive biomarker of exposure for organophosphate exposure than changes in 
erythrocyte cholinesterase activity (Endo et al. 1988; Hayes et al. 1980). It has been suggested that in 
the absence of baseline values for cholinesterase activity, sequential post-exposure cholinesterase 
analyses be used to confirm a diagnosis of organophosphate (like chlorfenvinphos) poisoning (Coye et 
al. 1987). 
This method of using the inhibition of cholinesterase activity as an indicator for exposure to 
organophosphate exposure lacks even greater specificity when used to assess exposure to 
compounds like chlorfenvinphos which are weak cholinesterase inhibitors. As a vinyl phosphate, 
chlorfenvinphos is metabolized to desethyl chlorfenvinphos which could be detected in urine as a 
specific biomarker of exposure to chlorfenvinphos or other vinyl phosphates. The method of detection 
involves conversion of urinary desethyl chlorfenvinphos to the more easily measurable methyl desethyl 
chlorfenvinphos with diazomethane. The analyses of 24-hour samples of urine from 14 male 
volunteers were made at 14-day intervals on four occasions (days 10, 24, 38, and 52) during 
exposure, and on one occasion, 15–16 days after cessation of exposure, using this novel detection 
method. The average daily excretion of beta-methyl desethyl chlorfenvinphos during exposure was 
120 µg, which was 4.7% of the dose. In post-exposure urine, the concentrations of beta-methyl 
desethyl chlorfenvinphos were 0 in most cases, and no greater than 5–10 µg/day in the remainder. 
The excretion rate of alpha-methyl desethyl chlorfenvinphos was 15 ±5 µg/day during exposure, but 
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fell to 0 or <5 µg/day post-exposure. Thus, the higher level of excretion of desethyl chlorfenvinphos in 
the urine found in an acute dosing experiment was not maintained when the dose was diminished 
four-fold and administered daily. However, since desethyl chlorfenvinphos accounts for only about 5% 
of the dose at this low exposure level, its concentration in urine would lack sensitivity when used as an 
index of exposure to chlorfenvinphos (Hunter et al. 1972). Although this method of assessing 
chlorfenvinphos exposure may not be useful in low exposure conditions, the method could be used to 
evaluate exposure to high doses of chlorfenvinphos such as occurs in human acute poisoning cases. 
It has been suggested that the concentration of chlorfenvinphos (or its unique metabolites) in the blood 
may be a better index of exposure than inhibition of cholinesterase activity (Hunter 1968, 1969). 
2.6.2 Biomarkers Used to Characterize Effects Caused by Chlorfenvinphos 
Inhibition of erythrocyte, plasma, or whole blood cholinesterase activities in humans and animals that 
results from chlorfenvinphos exposure (Barna and Simon 1973; Brzezinski 1978; Cupp et al. 1975; 
Pach et al. 1987; Kolmodin-Hedman and Eriksson 1987; Osicka-Koprowska et al. 1984; Osumi et al. 
1975; Takahashi et al. 1991) may be used as a marker of effect for chlorfenvinphos exposure. 
However, inhibition of cholinesterase activity is a common action of anticholinesterase compounds, 
which include organophosphates, like chlorfenvinphos, and carbamate compounds. In addition, a 
wide variation in normal cholinesterase values exists in the general population, and there are no 
studies which report a quantitative association between cholinesterase activity levels and exposure to 
chlorfenvinphos in humans. Thus, inhibition of cholinesterase activity is not a specific biomarker of 
effect for chlorfenvinphos exposure; it is indicative only of effect and not useful for chlorfenvinphos­
specific dosimetric analysis. 
It should be noted that plasma cholinesterase (pseudocholinesterase) activity is considered a more 
sensitive biomarker of effect for organophosphate exposure than erythrocyte cholinesterase activity 
(Endo et al. 1988; Hayes et al. 1980). It has been suggested that in the absence of baseline values 
for cholinesterase activity, sequential post-exposure cholinesterase analyses be used to confirm a 
diagnosis of organophosphate poisoning (Coye et al. 1987). 
In combination with analysis of reductions in the level of cholinesterase activity, the manifestations of 
severe organophosphate (chlorfenvinphos) poisoning, clinically characterized by a collection of 
cholinergic signs and symptoms, which may include dizziness, fatigue, tachycardia or bradycardia, 
miosis, diarrhea, and vomiting (Chambers and Levi 1992; Cupp et al. 1975; Klaassen et al. 1986; 
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Takahashi et al. 1991; Williams and Burson 1985), are useful biomarkers of effect for identifying 
poisoned victims of organophosphates (chlorfenvinphos). Also, these manifestations are not specific 
to chlorfenvinphos but to anticholinesterase compounds (such as organophosphates and carbamate 
compounds) in general. A positive response to atropine treatment is considered a confirmation of 
organophosphate poisoning. 
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (1990) and for information on 
biomarkers for neurological effects see OTA (1990). 
2.7 INTERACTIONS WITH OTHER CHEMICALS 
The toxicity of chlorfenvinphos may be affected by other substances.  Some chemicals may increase 
the toxicity of chlorfenvinphos in an additive manner. Chemical substances such as other 
anticholinesterase organophosphates, carbamates, or some pyrethroid insecticides that cause 
neurotoxicity are expected to act in an additive manner with chlorfenvinphos with respect to its 
potential to induce cholinergic toxicity. 
As a direct-acting cholinesterase activity inhibitor (P=O type in contradistinction from P=S types), other 
chemicals may interfere with the toxicity of chlorfenvinphos indirectly by accelerating its metabolism to 
less toxic metabolites through their actions on drug-metabolizing enzymes, specifically, glutathione­
S-transferase and P-450 or mixed function monooxygenases (Akintonwa 1984, 1985; Akintonwa and 
Itam 1988; Donninger 1971; Hansen 1983; Hutson and Logan 1986; Hutson and Millburn 1991; 
Hutson and Wright 1980). The duration and intensity of action of chlorfenvinphos is largely determined 
by the speed at which it is metabolized via oxidative O-dealkylation in the body by liver microsomal 
cytochrome P-450 or mixed function monooxygenases (MFO).  More than 200 drugs, insecticides, 
carcinogens, and other chemicals are known to induce the activity of liver microsomal drug-
metabolizing enzymes. The characteristic biological actions of these chemicals are highly varied. 
Although there is no relationship between their actions or structures and their ability to induce 
enzymes, most of the inducers are lipid-soluble at physiological pH. These inducers of the MFO 
system include the following classes of drugs: hypnotic and sedatives (barbiturates, ethanol, 
tetrahydrofuran, metyrapone); anesthetic gases (methoxyflurane, halothane); central nervous system 
stimulants (amphetamine); anticonvulsants (diphenylhydantoin); tranquilizers (meprobamate); 
antipsychotics (triflupromazine); hypoglycemic agents (carbutamide); anti-inflammatory agents 
(phenylbutazone); muscle relaxants (orphenadrine); analgesics (aspirin, morphine); antihistaminics 
(diphenhydramine); alkaloids (nicotine); polychlorinated aromatic hydrocarbons; insecticides 
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(chlordane, DDT, BHC, aldrin, dieldrin, heptachlorepoxide); pyrethrins; steroid hormones (testosterone, 
progesterone, cortisone); and polycyclic aromatic hydrocarbons (3-methylcholanthrene, 
3,4-benzpyrene, α-naphthoflavone) (Akintonwa 1984; Hansen 1983; Hutson and Logan 1986; Hutson 
and Millburn 1991; Hutson and Wright 1980; Ikeda et al. 1991; Klaassen et al. 1986; Williams and 
Burson 1985). Thus, exposure to any of these enzyme inducers prior to, or concurrent with, exposure 
to chlorfenvinphos may result in accelerated biotransformation of chlorfenvinphos to its less toxic 
metabolites. Conversely, since chlorfenvinphos is active per se, concurrent exposure to 
chlorfenvinphos and MFO enzyme-inhibiting substances (e.g., carbon monoxide; ethylisocyanide; SKF 
525A, halogenated alkanes, such as CCl4; alkenes, such as vinyl chloride; and allylic and acetylenic 
derivatives) would increase the mammalian half-life and, thus, the toxicity of chlorfenvinphos 
(Akintonwa 1984; Akintonwa and Itam 1988; Donninger 1971; Hansen 1983; Hutson and Logan 1986; 
Hutson and Millburn 1991; Hutson and Wright 1980; Williams and Burson 1985). 
Chlorfenvinphos exposure may interfere with the short-acting muscle relaxant succinylcholine used 
concurrently with anesthetics. The action of succinylcholine is terminated by means of its hydrolysis 
by plasma cholinesterase (Klaassen et al. 1986). Since plasma cholinesterase activity is strongly 
inhibited by chlorfenvinphos in humans (Cupp et al. 1975; Kolmodin-Hedman and Eriksson 1987; 
Pach et al. 1987; Takahashi et al. 1991; Vestweber and Kruckenberg 1972) and animals (Gralewicz et 
al. 1989a, 1989b, 1990; Kolmodin-Hedman and Eriksson 1987; Maxwell and LeQuesne 1982; Osicka-
Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber and Kruckenberg 1972), it 
is expected that concurrent exposure to chlorfenvinphos may result in the prolongation of the action of 
succinylcholine leading to prolonged muscular paralysis. 
2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to chlorfenvinphos than will most 
persons exposed to the same level of chlorfenvinphos in the environment. Reasons may include 
genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., 
cigarette smoke). These parameters may result in reduced detoxification or excretion of 
chlorfenvinphos, or compromised function of target organs affected by chlorfenvinphos. Populations 
who are at greater risk due to their unusually high exposure to chlorfenvinphos are discussed in 
Section 5.6, Populations With Potentially High Exposure. 
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The magnitude of chlorfenvinphos toxicity, like the toxicity of any xenobiotic, is affected by the rate of 
its metabolic biotransformation to less toxic substances (Klaassen et al. 1986). Therefore, low 
xenobiotic metabolizing activity would result in greater toxicity. The newborn of several animal 
species, including humans, have an almost complete lack of ability to metabolize xenobiotics and may 
be more sensitive to chlorfenvinphos toxicity. Studies on experimental animals showed that starvation 
depressed P-450 activity due to actual loss of the enzyme protein (Boyd and Carsky 1969; Puzynska 
1984). Thus, it is expected that dietary deficiency in protein would increase chlorfenvinphos toxicity by 
diminishing its metabolism in the liver. Hereditary factors may also contribute to population sensitivity 
to chlorfenvinphos. Atypical plasma cholinesterase with low activity is present in a small percentage of 
the human population. This is the result of an hereditary factor with 0.04% occurrence in the 
population. Since plasma cholinesterase activity is strongly inhibited by chlorfenvinphos (Cupp et al. 
1975; Gralewicz et al. 1989a, 1989b, 1990; Kolmodin-Hedman and Eriksson 1987; Maxwell and 
LeQuesne 1982; Osicka-Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber 
and Kruckenberg 1972), it is expected that individuals who have atypical ChE (or low plasma 
cholinesterase activity) will be unusually sensitive to the muscle relaxant succinylcholine (Klaassen et 
al. 1986) and may suffer prolonged muscle paralysis if administered succinylcholine while exposed to 
chlorfenvinphos. Congenital low plasma cholinesterase activity may also increase subpopulation 
sensitivity to chlorfenvinphos exposure. This is because, after exposure, plasma cholinesterase acts 
as a depot for chlorfenvinphos due to its strong affinity for the substance (Davies and Holub 1980; 
Edson and Noakes 1960; Klemmer et al. 1978; Williams et al. 1959), thus decreasing the availability of 
the chlorfenvinphos dose to neuromuscular tissue, the target of chlorfenvinphos toxicity in the 
population with normal plasma cholinesterase levels.  In individuals with congenital low plasma 
cholinesterase activity, less chlorfenvinphos is bound in the blood and more unbound chlorfenvinphos 
is in circulation to reach neuromuscular tissue, the target of chlorfenvinphos toxicity. 
Individuals who have abnormally low tissue cholinesterase due to prior exposure to cholinesterase 
activity inhibitors are also exceptionally susceptible to the cholinesterase activity-inhibiting toxicity of 
chlorfenvinphos. These individuals may include those who are occupationally exposed to 
anticholinesterases, such as other cholinesterase activity inhibiting organophosphate or carbamate 
pesticides. In this regard, patients on medication that inhibit cholinesterase activity may also be 
unusually susceptible to the cholinesterase activity inhibiting toxicity of chlorfenvinphos. 
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2.9 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects 
of exposure to chlorfenvinphos. However, because some of the treatments discussed may be 
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
chlorfenvinphos. When specific exposures have occurred, poison control centers and medical 
toxicologists should be consulted for medical advice. The following text provides specific information 
about treatment following exposures to chlorfenvinphos. 
2.9.1 Reducing Peak Absorption Following Exposure 
Organophosphate insecticides like chlorfenvinphos are rapidly absorbed after inhalation, ingestion, or 
dermal contact (Hutson and Wright 1980; Ikeda et al. 1991; Wagner et al. 1990). In oral exposures, 
emesis is not indicated because of the danger of aspiration of stomach contents by an obtunded 
patient. Gastric lavage, with a solution of 5% sodium bicarbonate or 2% potassium permanganate, 
may be indicated within the first 60 minutes after ingestion to get rid of unabsorbed chlorfenvinphos in 
the stomach (Cupp et al. 1975; Pach et al. 1987; Shankar 1967, 1978). Activated charcoal can also 
be used, but cathartics are not necessary due to the diarrhea induced by muscarinic activity. 
However, if diarrhea is not present in the patient, cathartics, mixed with activated charcoal, can be 
used. 
Decontamination is the first step in reducing dermal or conjunctival absorption. This decontamination 
should begin immediately after the exposure is recognized. Contaminated clothing should be 
removed, and skin, hair, and nails should be washed with soap and plenty of water. Health care 
workers and emergency responders should be protected from secondary contamination, and clothes 
and other contaminated material should be treated as contaminated waste. Eyes should be irrigated 
with copious amounts of room-temperature water or saline, if available, for at least 15 minutes. If 
irritation, lacrimation, or especially pain, swelling, and photophobia persist after 15 minutes of irrigation, 
expert ophthalmologic care should be sought (Ellenhorn and Barceloux 1988). 
If exposure is via inhalation, the exposed individual should be moved to fresh air and efforts should be 
directed toward the maintenance of an open airway, airway suctioning, endotracheal intubation. 
Artificial ventilation with supplemental oxygen may be helpful (Ellenhorn and Barceloux 1988). 
97 CHLORFENVINPHOS 
2. HEALTH EFFECTS 
2.9.2 Reducing Body Burden 
Chlorfenvinphos is rapidly metabolized, with an estimated mammalian biological half-life of 
12–15.13 hours (Akintonwa 1984; Akintonwa and Itam 1988; Donninger 1971; Hutson and Millburn 
1991; Hutson and Wright 1980). Consequently, efforts at reducing body burdens of poisoned persons 
may not be critical to the outcome. Although hemoperfusion has been successfully used in one case 
of chlorfenvinphos poisoning (Pach et al. 1987), dialysis and hemoperfusion are not recommended in 
organophosphate poisonings because of the extensive tissue distribution of the absorbed doses 
(Mücke et al. 1970; Poklis et al. 1980). The use of P-450-inducing substances such as some 
antipsychotics (triflupromazine) and analgesics (aspirin, morphine) would tend to accelerate the 
metabolism of chlorfenvinphos, thereby decreasing its toxicity (Akintonwa 1984; Akintonwa and Itam 
1988; Donninger 1971; Hutson and Millburn 1991; Hutson and Wright 1980; Klaassen et al. 1986; 
Williams and Burson 1985). 
2.9.3 Interfering with the Mechanism of Action for Toxic Effects 
As an anticholinesterase organophosphate, the principal toxic effects of chlorfenvinphos in humans 
and laboratory animals derive from inhibition of cholinesterase activity (Cupp et al. 1975; Gralewicz et 
al. 1989a, 1989b, 1990; Hunter 1969; Kolmodin-Hedman and Eriksson 1987; Maxwell and LeQuesne 
1982; Osicka-Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber and 
Kruckenberg 1972). Severe inhibition of the activities of these enzymes results in accumulation of ­
acetylcholine at its sites of action, and excessive or interminable stimulation of both sympathetic and 
parasympathetic cholinergic receptors leading to muscarinic and nicotinic effects (Klaassen et al. 
1986; Williams and Burson 1985). 
Timely treatment of chlorfenvinphos poisoning cases with atropine and cholinesterase regeneration 
with pralidoxime and other oximes, significantly reduces the cholinergic effects (Cupp et al. 1975; Pach 
et al. 1987). 
Pralidoxime acts by hydrolyzing phosphorylated acetylcholinesterase and is effective in counteracting 
the paralytic effects (muscular weakness and fasciculations) of anticholinesterase agents, such as 
chlorfenvinphos, if it is administered prior to the “aging” (See Mechanisms of Toxicity) of the 
phosphorylated enzyme (Williams and Burson 1985). Pralidoxime is most effective if started within the 
first 24 hours, preferably within 6–8 hours of exposure, prior to the irreversible phosphorylation of the 
enzyme (Shankar 1967, 1978; Schenker 1992). 
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Atropine is an anti-muscarinic agent which, in large doses, alleviates bronchoconstriction and reduces 
secretion in the oral cavity and the airway. Atropine also counters some of the central nervous system 
effects (Cupp et al. 1975; Pach et al. 1987). It is recommended that atropine be given immediately by 
intravenous injection at a dose of 2 mg and every 10–20 minutes thereafter at an intramuscular dose 
of 0.67 mg until evidence of "atropinization" or muscarinic blockade, such as flushing, dry mouth, 
dilated pupils, and tachycardia is seen (Shankar 1978). Atropine therapy is required for less than 
24 hours because of the shorter duration of effect (Schenker et al. 1992). The most clinically important 
indication for continued atropine treatment is persistent wheezing (pulmonary rales) or bronchorrhea 
(Woo 1990). Pralidoxime acts to regenerate inhibited cholinesterase enzyme activity at all affected 
sites (Shankar 1967, 1978; Schenker 1992; Taitelman 1992). 
2.10 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of chlorfenvinphos is available. Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is 
required to assure the initiation of a program of research designed to determine the health effects (and 
techniques for developing methods to determine such health effects) of chlorfenvinphos. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to 
mean that all data needs discussed in this section must be filled. In the future, the identified data 
needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
2.10.1 Existing Information on Health Effects of Chlorfenvinphos 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
chlorfenvinphos are summarized in Figure 2-5. The purpose of this figure is to illustrate the existing 
information concerning the health effects of chlorfenvinphos. Each dot in the figure indicates that one 
or more studies provide information associated with that particular effect. The dot does not 
necessarily imply anything about the quality of the study or studies, or should missing information in 
this figure be interpreted as a "data 
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need." A data need, as defined in ATSDR's Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to 
conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more 
broadly as any substance-specific information missing from the scientific literature. 
The available information indicates that chlorfenvinphos is a toxic substance to most species of 
experimental animals, deriving its toxicity principally from the inhibition of cholinesterase activity.  All 
three reports concerning the health effects of chlorfenvinphos in humans described individuals or 
group of individuals exposed either occupationally or in the home by accident. The route in the 
occupational exposure reports is believed to be dermal, although an occupational exposure was 
reported as inhalation. The route for the accidental exposure case was oral. Thus, Figure 2-5 reflects 
that information exists for oral and inhalation exposures in humans.  However, all of the human reports 
on inhalation exposures are limited because of probable concurrent or sequential exposures to other 
substances of similar qualitative toxicity present in the environment (workplace or home), such as 
other organophosphate pesticides present as components of organophosphate-containing household 
products. In all cases, the doses at which these effects occurred in the human studies are not known 
and the purity of the material to which these subjects were exposed is questionable because of the 
accidental nature of the exposures, thus rendering evaluation of substance-relatedness to these 
reported toxicities uncertain. The availablehuman data, therefore, fail to fully characterize the human 
health effects from acute-, intermediate-, or chronic-duration inhalation exposures to chlorfenvinphos. 
Information regarding the health effects of chlorfenvinphos following ingestion in laboratory animals is 
also limited due to a paucity of definitive studies. Only limited information is available on the health 
effects resulting from dermal exposures. In all health effects categories, acute-, intermediate-, and 
chronic-duration exposure data for inhalation exposure are limited for both humans and laboratory 
animals. Consequently, it was not possible to develop acute-, intermediate-, or chronic-duration 
inhalation MRLs for chlorfenvinphos. Furthermore, no information on the carcinogenic effects of 
chlorfenvinphos exposure is available for humans or laboratory animals by any route of exposure. 
An acute oral MRL of 0.002 mg/kg/day has been derived for chlorfenvinphos from a LOAEL of 
2.4 mg/kg/day, based on adverse neurological effects in rats (Barna and Simon 1973). An 
intermediate oral MRL of 0.002 mg/kg/day for chlorfenvinphos has been developed from a LOAEL of 
2 mg/kg/day, based on adverse immunolymphoreticular effects in mice (Kowalczyk-Bronisz et al. 
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1992). A chronic oral MRL of 0.0007 mg/kg/day for chlorfenvinphos has been developed from a 
LOAEL of 0.7 mg/kg/day, based on adverse neurological effects in rats (Ambrose et al. 1970). 
2.10.2 Identification of Data Needs 
Acute-Duration Exposure.  No data are available on the acute-duration effects of human inhalation 
exposure to chlorfenvinphos. The available animal inhalation studies reported only serious effects 
(mortality, apnea, salivation, urination, exophthalmos, twitches, and tremors) (Takahashi et al. 1994; 
Tsuda et al. 1986) following exposure to chlorfenvinphos. Therefore, the data from these studies are 
not appropriate for use in the derivation of an acute-duration inhalation MRL. 
The information available on acute oral human exposures consists primarily of studies that reported 
interference with central cholinergic and adrenergic mechanisms (disturbances in cholinesterase and 
noradrenaline (norepinephrine) levels) and secondary effects resulting from these disturbances 
manifested as neurological symptoms and death in some cases. The adverse effects reported in 
humans included death (Felthous 1978) and neurological effects (Cupp et al. 1975; Kolmodin-Hedman 
and Eriksson 1987; Pach et al. 1987). In animals effects noted from acute oral exposure to 
chlorfenvinphos included death in rats (Ambrose et al. 1970; Hutson and Logan 1986; Hutson and 
Wright 1980; Ikeda et al. 1991, 1992; Puzynska 1984; Takahashi et al. 1991), mice (Hutson and 
Logan 1986; Kowalczyk-Bronisz et al. 1992; Wysocka-Paruszewska et al. 1980), dogs (Hutson and 
Logan 1986; Ambrose et al. 1970), and rabbits (Ambrose et al. 1970; Hutson and Logan 1986); 
systemic effects in rats, i.e., hepatic (Ikeda et al. 1991; Puzynska 1984), endocrine (Osicka-Koprowska 
et al. 1984), and metabolic (Barna and Simon 1973); and neurological effects in rats (Barna and 
Simon 1973; Brzezinski 1978; Ikeda et al. 1992; Osicka-Koprowska et al. 1984; Osumi et al. 1975; 
Puzynska 1984; Takahashi et al. 1991). Thus, the acute effects of oral chlorfenvinphos are relatively 
well-characterized, stemming principally from the inhibition of cholinesterase activity. 
No effects were noted in humans dermally exposed to chlorfenvinphos for acute durations (Hunter 
1968). In animals, death (Ambrose et al. 1970) and neurological effects (Vestweber and Kruckenberg 
1972) have resulted from dermal exposure to chlorfenvinphos. 
Additional studies via the inhalation and dermal routes of exposure would be helpful for establishing a 
dose-response relationship and for identifying thresholds for adverse effects for these routes of 
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exposure to chlorfenvinphos. This information is necessary for determining levels of significant 
exposure to chlorfenvinphos that are associated with adverse health effects for the protection of 
potentially exposed populations living near hazardous waste sites that contain chlorfenvinphos. 
Intermediate-Duration Exposure.  No information is available on the effects of human intermediate-
duration exposure, by any route (inhalation, oral, dermal). No animal studies were available on 
intermediate-duration inhalation or dermal exposure to chlorfenvinphos. 
Available information on the adverse effects resulting from intermediate-duration oral exposure of 
animals to chlorfenvinphos include death in rats and dogs (Ambrose et al. 1970); systemic effects in 
rats, i.e., renal (Ambrose et al. 1970) and metabolic (Barna and Simon 1973); 
immunological/lymphoreticular effects in rats (Ambrose et al. 1970: Kowalczyk-Bronisz et al. 1992; 
Roszkowski 1978); neurological effects in rats (Ambrose et al. 1970; Barna and Simon 1973; Maxwell 
and LeQuesne 1982) and dogs (Ambrose et al. 1970); reproductive effects in rats (Ambrose et al. 
1970); developmental effects in rats (Ambrose et al. 1970). Additional available studies found no 
effects on mortality in rats and dogs (Ambrose et al. 1970); no significant systemic effects, i.e., 
respiratory, cardiovascular, gastrointestinal, musculoskeletal, hepatic, renal, endocrine, and body 
weight in dogs or respiratory, cardiovascular, gastrointestinal, hepatic, renal, endocrine, dermal effects 
in rats (Ambrose et al. 1970) endocrine system effects in mice (Kowalczyk-Bronisz et al. 1992), or 
body weight changes in rabbits (Roszkowski 1978) and rats (Barna and Simon 1973; Maxwell and 
LeQuesne 1982); no immunological/lymphoreticular effects in rats and dogs (Ambrose et al. 1970); 
and no reproductive effects in rats (Ambrose et al. 1970). Data from these studies sufficiently 
demonstrate that chlorfenvinphos interferes with the immunological/ lymphoreticular system.  An 
intermediate oral MRL of 0.002 mg/kg/day for chlorfenvinphos has been developed from a LOAEL of 
2 mg/kg/day, based on adverse immunolymphoreticular effects in mice (Kowalczyk-Bronisz et al. 
1992). 
Due to the lack of adequate human or animal data for effects from intermediate-duration inhalation 
exposure to chlorfenvinphos, no intermediate-duration inhalation MRL was derived for 
chlorfenvinphos. Additional studies via the inhalation and dermal routes of exposure would be helpful 
for establishing a dose-response relationships and for identifying thresholds for adverse effects for 
chlorfenvinphos exposure. This information is necessary for determining levels of significant exposure 
to chlorfenvinphos that are associated with adverse health effects for the protection of potentially 
exposed populations living near hazardous waste sites that contain chlorfenvinphos. 
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Chronic-Duration Exposure and Cancer.  No controlled epidemiological studies regarding the 
systemic toxicities of chlorfenvinphos resulting from chronic-duration inhalation exposure are available. 
However, two retrospective epidemiological studies regarding the systemic toxicities of 
chlorfenvinphos resulting from chronic-duration inhalation exposures are available.  Although the 
existing human studies reported immunological (Wysocki et al. 1987) and neurological effects 
(Kolmodin-Hedman and Eriksson 1987), the subjects in the Wysocki et al. (1987) report were also 
concurrently exposed to greater concentrations of other potentially immunotoxic substances such as 
formothion, sumithion, and malathion while the subjects in the Kolmodin-Hedman and Eriksson (1987) 
study were exposed to unknown concentrations of a mixture of potentially neurotoxic pesticides which 
included dimethoate, formothion, and isofenphos. Therefore, data from these studies were not useful 
for developing a chronic inhalation MRL for chlorfenvinphos. 
There is no information on the effects of chronic human oral exposure to chlorfenvinphos. In animals 
the existing information on adverse effects from chronic oral exposure to chlorfenvinphos is limited to 
systemic effects, i.e., hepatic and body weight effects in rats (Ambrose et al. 1970); and neurological 
effects in rats and dogs (Ambrose et al. 1970). Additional available studies found no effects on 
mortality in rats and dogs (Ambrose et al. 1970); no significant systemic effects, i.e., cardiovascular, 
hematological, hepatic, renal, endocrine, or body weight in dogs, or respiratory, cardiovascular, 
gastrointestinal, hematological, musculoskeletal, renal, endocrine, or dermal effects in rats (Ambrose 
et al. 1970); no immunological/ lymphoreticular effects in rats and dogs (Ambrose et al. 1970); and no 
reproductive effects in rats (Ambrose et al. 1970). Data from these studies sufficiently demonstrate 
that chlorfenvinphos is an anticholinesterase organophosphate. A chronic oral MRL of 
0.0007 mg/kg/day for chlorfenvinphos has been developed from a LOAEL of 0.7 mg/kg/day, based on 
adverse neurological effects in rats (Ambrose et al. 1970). 
No information on the effects of chronic-duration dermal exposure to chlorfenvinphos is currently 
available. 
No epidemiological studies or chronic rodent cancer bioassays are available for assessing the 
carcinogenic potential of chlorfenvinphos. However, a study to determine the ability of vinyl phosphate 
esters (like chlorfenvinphos) to form methylated bases in DNA of calf thymus failed to detect 6-methyl 
guanine, a known mutagen. In both the reaction with dsDNA and ssDNA, 7-methyl guanine was the 
main methylation product. However, all methyl derivatives of adenine constituted about 40% and 50% 
of all methylation products in the case of dsDNA and ssDNA, respectively. 3-Methylcytosine was the 
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only methyl derivative of pyrimidine identified. An analog of chlorfenvinphos, methylbromo­
phenvinphos, was used in this study (Wiaderkiewicz et al. 1986); therefore, the data are difficult to 
relate to chlorfenvinphos without extensive structure-activity relationship analysis.  In a mutagenicity 
study, the dose-response curve, at doses of 0, 50, 500, 5,000 µg/plate for the mutagenic activity of 
chlorfenvinphos for the S. typhimurium strain TA100 was reduced by the S9 mix (metabolic activation). 
At present, no mutagenic pesticide for which activity decreases in the presence of the S9 mix is 
carcinogenic except captan (F-28) (Moriya et al. 1983). 
Additional studies via the inhalation and dermal routes of exposure would be helpful for establishing a 
dose-response relationships and for identifying thresholds for adverse effects for prolonged exposure 
to chlorfenvinphos. This information is necessary for determining levels of significant exposure to 
chlorfenvinphos that are associated with adverse health effects for the protection of potentially 
exposed populations living near hazardous waste sites that contain chlorfenvinphos. Inhalation, oral, 
and dermal bioassays would be helpful to determine whether populations with long-term inhalation, 
oral, or dermal exposure (especially those living near hazardous waste sites or establishments where 
wastes containing chlorfenvinphos are released into the air or water) are at risk of developing cancers. 
Genotoxicity.  No studies were located regarding genotoxic effects of chlorfenvinphos in humans 
following inhalation, oral, or dermal exposure. Chlorfenvinphos was negative for mutagenicity in both 
base-pair change-type strains microorganisms (WP2 hcr of E. coli; TA1535, TA1537, TA1538, TA98 of 
S. typhimurium). In a mutagenicity study, the dose-response curve, at doses of 0, 50, 500, and 
5,000 µg/plate, for the mutagenic activity of chlorfenvinphos for the S. typhimurium strain TA100 was 
reduced by the S9 mix (metabolic activation). At present, no mutagenic pesticide whose activity 
decreases in the presence of the S9 mix is carcinogenic except captan (F-28) (Moriya et al. 1983). 
The mutagenic potency of chlorfenvinphos for strain TA100 has been reported as 
0.038 revertants/nmol, indicative of a positive response (Dean 1972; Moriya et al. 1983; Vishwanath 
and Kaiser 1986). A mixture of 15 pesticides (containing 0.3% chlorfenvinphos) tested negative for 
mutagenicity in the Salmonella microsome assay, with or without metabolic activation with 
PCB-induced rat liver S9, at concentrations up to 500 µg/plate in the Salmonella-microsome assay.
The mixture also failed to induce SCEs in human lymphocytes in vitro as well as in vivo mutagenicity in 
the micronucleus bone marrow assay in male Wistar rats at concentrations proportional to the ratio 
determined in foods (range = 0.1–20 µg/mL) (Dolara et al. 1993). In other large-scale screening 
programs, which revealed microbial mutagenic activity in four new compounds (all fungicides), 
chlorfenvinphos (without metabolic activation) exhibited no mutation induction capacity in a rec-assay 
procedure (prescreening of DNA-damaging chemicals) utilizing strains of B. subtilis, H17 Rec+ and 
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M45 Rec-. Also, no mutation potential was evident in a reversion-assay (determination of mutation 
specificities) in which two tryptophane-requiring strains (auxotrophic) of E. coli (B/r try WP2 and WP2 
try hcr) and four strains of S. typhimurium (TA1535, TA1536, TA1537, TA1538) were used. The E. 
coli auxotrophic strains and Salmonella TA1535 are reversible by base-pair change-type mutagens 
and the three Salmonella strains (TA1536, TA1537, and TA1538) are reversible by frameshift 
mutagens (Shirasu 1973; Shirasu et al. 1976). 
There are no unequivocal data to indicate that chlorfenvinphos reacts directly with DNA in vivo or in 
vitro to produce mutations in either germ or somatic cells.  In a study to determine the ability of vinyl 
phosphate esters (like chlorfenvinphos) to form methylated bases in DNA of calf thymus, DNA failed to 
detect 6-methyl guanine, a known mutagen. In the reaction both with dsDNA and ssDNA, 7-methyl 
guanine was the main methylation product. However, all methyl derivatives of adenine constituted 
about 40% and 50% of all methylation products in the case of dsDNA and ssDNA, respectively. 
3-Methylcytosine was the only methyl derivative of pyrimidine identified (Wiaderkiewicz et al. 1986). In 
another study, tetrachlorvinphos (Gardona®) was evaluated for potential to induce chromosomal 
aberrations and SCEs in vitro in a primary culture of Swiss mice spleen cells at concentrations of 0.25, 
0.50, 1.0, or 2.0 µg/mL. Tetrachlorvinphos induced a high percentage of metaphases with 
chromosomal aberrations in the mouse spleen cells after 4 hours of treatment in a dose-dependent 
manner. According to the authors, the results indicate that tetrachlorvinphos in the tested 
concentrations are mutagenic in mouse spleen cell cultures (Amer and Aly 1992). In both of these 
studies, structural analogs of chlorfenvinphos (methylbromophenvinphos and tetrachlorvinphos, 
respectively) were used; therefore, the data are difficult to relate to chlorfenvinphos without extensive 
structure-activity relationship analysis. These limited data suggest that chlorfenvinphos might not be 
genotoxic. Thus, the existing information on the mutagenic potential of chlorfenvinphos is equivocal. 
Additional genotoxicity assays in microorganisms and mammalian cells (in vivo and in vitro) will be 
helpful in determining if the substance is clastogenic or can cause mutation in somatic or germ cells. 
This information is necessary to determine whether potentially exposed populations, especially those 
living near hazardous waste sites, are at risk of developing genetic diseases. 
Reproductive Toxicity.  No studies were located regarding reproductive effects in humans following 
acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to chlorfenvinphos. 
Animal studies regarding reproductive effects after acute-, intermediate-, or chronic- inhalation or 
dermal exposure to chlorfenvinphos, or acute-duration oral exposure to chlorfenvinphos are also 
lacking. A 3-generation reproductive study in albino (Wistar) rats orally exposed to chlorfenvinphos 
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reported significant (14%) reduction in fertility and decrease in maternal body weight gains at a 
LOAEL of 2.7 mg/kg/day (Ambrose et al. 1970). Single-generation studies, in which rats and dogs 
were exposed to chlorfenvinphos for intermediate- or chronic-durations found no histopathology or 
changes in relative weights of the testes and ovaries of the tested animals (Ambrose et al. 1970). 
However, these studies did not evaluate reproductive function. Consequently, additional 
reproductive toxicity studies in animals exposed to chlorfenvinphos via inhalation, oral, or dermal 
route would be helpful in evaluating the potential for chlorfenvinphos to cause adverse reproductive 
effects in humans. This information is necessary to determine whether potentially exposed 
populations, especially those living near hazardous waste sites, are at risk of developing reproductive 
diseases. 
Developmental Toxicity.  No studies were located regarding developmental effects in humans 
following acute-, intermediate-, or chronic-duration inhalation, oral, or dermal exposure to 
chlorfenvinphos. Animal studies regarding developmental effects after acute-, intermediate- or 
chronic-duration inhalation and dermal exposure to chlorfenvinphos are also lacking. The limited 
information on the developmental toxicity of oral chlorfenvinphos exposure indicates that the 
substance may interfere with the normal development of rats by inhibiting cellular respiration 
(Skonieczna et al. 1981) and interfering with maternal body weight gains, and reducing lactational 
index and offspring survivability in the developing rodents (Ambrose et al. 1970).  A statistical model 
for hazard identification developed for use in predicting the developmental toxicity of 175 chemicals, 
including chlorfenvinphos, produced equivocal results concerning the developmental toxicity of 
chlorfenvinphos to the rat, rabbit, and hamster. The model was essentially a database of 
175 probable, suspected, unknown, and probably negative teratogenic or embryotoxic drugs and 
chemical compounds. For each of the compounds, including chlorfenvinphos, the results of any 
developmental toxicity testing in up to 14 animal species and any reports of mutagenicity or 
carcinogenicity were recorded. The compounds were categorized with respect to their human 
developmental toxicant effect: -1.0 testing negative, 0.0 not tested (unknown), 0.5 tested with 
equivocal results (suspicious), and 1.0 testing positive. However, the model had a sensitivity of 
62–75%, a positive predictive value of 75–100%, and a negative predictive value of 64–91%, 
indicating that it is not optimal for hazard identification (Jelovsek et al. 1989). Additional information 
on the developmental effects in animals exposed to chlorfenvinphos via the inhalation, oral, or dermal 
route would be helpful in evaluating the potential for chlorfenvinphos to cause developmental toxicity 
in humans. This information is necessary to determine whether offspring of potentially exposed 
populations, especially those living near hazardous waste sites, are at risk of developmental adverse 
effects. 
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Immunotoxicity.  No studies were located regarding immunological and lymphoreticular effects in 
humans following acute- or intermediate-duration inhalation exposure to chlorfenvinphos, or 
regarding immunological and lymphoreticular effects in humans following acute-, intermediate-, or 
chronic-duration oral exposure to chlorfenvinphos. No studies were available regarding 
immunological and lymphoreticular effects in animals following acute-, intermediate-, or chronic-
duration inhalation or dermal exposure to chlorfenvinphos. 
Only one study was located that reported immunological effects in humans. In this report, 
occupational exposure to inhaled chlorfenvinphos for an average of 15 years was associated with 
damage to humoral mechanisms in humans. This study is not suitable for assessing the 
immunological and lymphoreticular effects of human exposure to chlorfenvinphos because the 
subjects of this study were also concurrently exposed to greater concentrations of other potentially 
immunotoxic substances such as formothion, sumithion, and malathion (Wysocki et al. 1987). In 
animal studies, intermediate-duration dietary exposure of rats resulted in a significant and irreversible 
reduction in relative spleen weight of female rats given $3 mg/kg/day chlorfenvinphos for 12 weeks. 
However, no gross or microscopic histopathology was evident in the spleen and bone marrow tissues 
of the rats upon examination (Ambrose et al. 1970). A chronic study in dogs and rats did not note 
any histopathological changes in the spleen or bone marrow or changes in absolute or relative spleen 
weights in Wistar rats or Beagle dogs of both sexes given dietary chlorfenvinphos doses of 
21 mg/kg/day (males) or 24 mg/kg/day (females), or 10 mg/kg/day (males) or 50 mg/kg/day 
(females), respectively, for 104 week (Ambrose et al. 1970). In other animal studies, C57BL/6 mice 
and (C57BL/6 x DBA/2)F1 (BDF1/Iiw) hybrid mice (6–8 weeks old) orally exposed to chlorfenvinphos 
for 90 days exhibited a reversible reduction in the number of E rosettes-forming cells as well as a 
dose-related decrease in number of hemolysin producing cells; reduction in the number of plaque-
forming cells; increases in Interlukin-1 activity and DTH reaction; stimulation of spleen colonies; and 
disturbance in humoral immune factors (immunoglobulins) at a LOAEL of 1.5 mg/kg (Kowalczyk-
Bronisz et al. 1992). 
Rabbits orally exposed to chlorfenvinphos for 90 days also exhibited significantly elevated serum 
hemagglutinin level (16%) and hemolysin activity (66%, P<0.05) as well as increased number of 
nucleated lymphoid cells producing hemolytic antibody to sheep erythrocytes. Spleen 
cytomorphology changes, manifested mainly as transformation of primary follicles into secondary 
ones with well developed germinal centers, were also observed (Roszkowski 1978). While the 
existing human inhalation study and the animal oral studies provide some indication that 
chlorfenvinphos exposure is associated with immunological changes, these changes were not 
consistent with depressive effect on immune reactions. Thus, the changes reported in these studies 
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may simply be immunological mobilizations of the organisms to xenobiotics in contradistinction from 
immune system damage. Consequently, additional TIER II animal immunotoxicity testing (cell­
mediated immunity, cell surface marker profile immunopathology, humoral immunity, cytolytic 
macrophage function, and bone marrow tests) via the inhalation, oral, or dermal route for 
chlorfenvinphos would be helpful to more fully assess the potential of chlorfenvinphos to cause 
immunotoxicity in humans. This information is necessary to determine whether potentially exposed 
populations, especially those living near hazardous waste sites, are at risk of developing 
immunological diseases. 
Neurotoxicity.  No studies were located regarding neurological effects in humans after acute- or 
intermediate-duration inhalation exposure to chlorfenvinphos; or following acute-, intermediate-, or 
chronic-duration oral exposure; or after intermediate- or chronic-duration dermal exposure.  In 
humans, chlorfenvinphos inhibits cholinesterase activity in the central and peripheral nervous system 
when administered by the oral (Cupp et al. 1975; Pach et al. 1987) or inhalation route in acute-
duration exposures (Kolmodin-Hedman and Eriksson 1987). Inhibition of cholinesterase activity 
results in accumulation of acetylcholine at muscarinic and nicotinic receptors leading to peripheral 
and central nervous system effects. These effects usually appear within a few minutes to a few hours 
after exposure depending on the extent of exposure. In a human case report, a 16-year-old white 
male who mistakenly ingested a formulation (identified as Dermaton®) was hospitalized 90 minutes 
afterward with symptoms of abdominal cramps, nausea, vomiting, generalized weakness, cold dry 
skin, hypothermia, listlessness, constricted pupils, hypertension, respiratory distress, fine generalized 
muscular twitching, and apprehension. Plasma and erythrocyte activity levels were significantly 
inhibited. All vital signs returned to normal after gastric lavage and treatment with atropine and 
pralidoxime (Cupp et al. 1975). 
No studies were located regarding neurological effects in animals after acute- or intermediate-
duration inhalation or dermal exposure to chlorfenvinphos. The available information indicates that 
chlorfenvinphos has similar neurological effects in animals. In animals, chlorfenvinphos inhibits 
cholinesterase activity in the blood and neuromuscular tissue by the oral route in acute-duration 
exposures in rats at doses as low as 2 mg/kg (Barna and Simon 1973; Osicka-Koprowska et al. 
1984; Osumi et al. 1975; Puzynska 1984; Takahashi et al. 1991); in rats following 
intermediate-duration exposures via the oral route at doses as low as 9 mg/kg/day (Ambrose et al. 
1970; Maxwell and LeQuesne 1982); and in dogs following chronic-duration exposure via the oral 
route at doses as low as 0.7 mg/kg/day (Ambrose et al. 1970). These disruptions in cholinesterase 
activity resulted in cholinergic responses manifested as abnormal muscle reflex, muscle 
fasciculations, Straub tail reflex, twitches, convulsions, chromodacryorrhea, exophthalmos, gasping, 
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lacrimation, prostration, salivation, sleep disturbances, diarrhea, emesis, and urination (Ambrose et 
al. 1970; Maxwell and LeQuesne 1982; Osumi et al. 1975; Puzynska 1984; Takahashi et al. 1991). 
In one of these studies, all 36 Sprague-Dawley rats exposed to chlorfenvinphos doses of 
10.5 mg/kg/day in the diet for 3–6 months exhibited repetitive muscle activity when given two 
simultaneous stimuli. This abnormality became more pronounced with time, even on constant dosing 
(Maxwell and LeQuesne 1982). The findings from this study may be useful in explaining 
electrophysiological abnormalities described in some workers chronically exposed to some 
organophosphorus compounds. 
Intraperitoneal administration of daily doses of 100, 150, 200, or 300 mg/kg/day chlorfenvinphos to 
White Leghorn hens for 10 days or until death resulted in cholinergic signs. Typical cholinergic signs, 
including inability to stand, salivation, and retching (as well as some deaths) were observed 
immediately after the administration of any dose level of chlorfenvinphos, with or without atropine 
coadministration. No signs of delayed neurotoxicity or evidence of neurological lesions suggestive of 
demyelination or neural damage were observed in the brain and sciatic nerve tissues examined 
(Ambrose 1970). Although all doses of chlorfenvinphos elicited cholinergic responses (leg weakness, 
salivation, and retching) from hens given 100, 150, 200, or 300 mg/kg by intraperitoneal injection, no 
signs of delayed neurotoxicity was evident after 20 days of observation (Ambrose et al. 1970). 
Besides its cholinergic action, chlorfenvinphos also acts via central noradrenergic mechanisms in rats 
by accelerating the noradrenaline (norepinephrine) turnover in the brain in vivo by the release of 
noradrenaline (norepinephrine) from brain tissue stores (Brzezinski 1978). 
Although the available toxicity information in humans and animals is sufficient to establish that short-
and long-term exposure to chlorfenvinphos results in adverse neurological effects, additional animal 
studies by the inhalation, oral, and dermal routes will be helpful in the more accurate assessment of 
the exposure levels at hazardous waste sites at which these effects are likely to occur. 
Epidemiological and Human Dosimetry Studies.  Although the available epidemiological studies 
sufficiently identify inhibition of cholinesterase activity as the characteristic and most critical effect of 
human exposure to chlorfenvinphos, these studies inadequately identify the dose at which this effect 
occurs (Cupp et al. 1975; Kolmodin-Hedman and Eriksson 1987; Pach et al. 1987; Wysocki et al. 
1987). Well-conducted acute-, intermediate-, and chronic-duration (for effects other than inhibition of 
cholinesterase activity) human dosimetry studies are not available.  Therefore, well conducted 
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retrospective epidemiological studies would be helpful in determining and quantifying the effects 
(including neurologic, immunologic, and reproductive effects) of inhalation, oral, or dermal 
chlorfenvinphos exposure on human health; such studies would also provide useful data regarding the 
carcinogenic potential of chlorfenvinphos in humans, especially people living around hazardous waste 
sites or establishments where wastes containing chlorfenvinphos are released into the air or water, and 
people who are occupationally exposed to chlorfenvinphos for long periods of time. 
Biomarkers of Exposure and Effect.
Exposure.  The major action resulting from human exposure to chlorfenvinphos is the inhibition of 
acetylcholinesterase activity (see Section 2.4). Two pools of cholinesterases are present in human 
blood: acetylcholinesterase in erythrocytes and neuromuscular tissue and butyrylcholinesterase 
(pseudocholinesterase) in plasma. Acetylcholinesterase, present in human erythrocytes, is identical to 
the enzyme present in neuromuscular tissue (the target of chlorfenvinphos action). While plasma 
cholinesterase (pseudocholinesterase or butyrylcholinesterase) has no known physiological function, it 
has been suggested that it scavenges acetylcholine that gets into the plasma. Inhibition of the activity 
of both forms of cholinesterase has been associated with exposure to chlorfenvinphos in humans and 
animals (Cupp et al. 1975; Gralewicz et al. 1989a, 1989b, 1990; Hunter 1969; Kolmodin-Hedman and 
Eriksson 1987; Maxwell and LeQuesne 1982; Osicka-Koprowska et al. 1984; Pach et al. 1987; 
Takahashi et al. 1991; Vestweber and Kruckenberg 1972). Inhibition of erythrocyte, plasma, or whole 
blood cholinesterase may be used as a marker of exposure to chlorfenvinphos. However, inhibition of 
cholinesterase activity is a common action of anticholinesterase compounds, which include 
organophosphates like chlorfenvinphos, and carbamate compounds. In addition, a wide variation in 
normal cholinesterase values exists in the general population, and there are no studies which report a 
quantitative association between cholinesterase activity levels and exposure to chlorfenvinphos in 
humans. 
Chlorfenvinphos undergoes biotransformation to a variety of polar metabolites, including 2-chloro­
1-(2,4-dichlorophenyl) vinylethylhydrogen phosphate; 1-(2,4-dichlorophenyl) ethanol; 1-(2,4-dichloro­
phenyl) ethanediol; 2,4-dichloromandelic acid; and 2,4-dichlorobenzoyl glycine (Hutson and Wright 
1980), which have been detected in animals. Analysis of blood samples for the presence of these 
metabolites represents a potential means of assessing exposure. Analysis of urine samples for 
metabolic products provides a non-invasive method for detecting exposure. As an organophosphate, 
chlorfenvinphos is rapidly metabolized and excreted from the body; therefore, urinary metabolite 
analysis is useful only in the evaluation of recent exposures (Hutson and Wright 1980). There are no 
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studies which report a quantitative association between metabolite levels and exposure to 
chlorfenvinphos in humans. Therefore, these biomarkers are only indicative of exposure and are also 
not useful for dosimetric analysis. The inhibition of cholinesterase activity method as a measure of 
organophosphate exposure lacks even greater specificity when used to assess exposure to compounds 
which are weak inhibitors of cholinesterase activity, like chlorfenvinphos (Hunter et al. 1972).  As a vinyl 
phosphate, chlorfenvinphos is metabolized to desethyl chlorfenvinphos, which could be detected in 
urine as a specific biomarker of exposure to chlorfenvinphos, or other vinyl phosphates (Akintonwa 
1984, 1985; Akintonwa and Itam 1988; Donninger 1971; Hansen 1983; Hutson and Logan 1986; 
Hutson and Millburn 1991; Hutson and Wright 1980). The method of detection involves conversion of 
urinary desethyl chlorfenvinphos to the more easily measurable methyl desethyl chlorfenvinphos with 
diazomethane. This method is a more specific biomarker for chlorfenvinphos exposure and has been 
successfully used as such in a case of 14 male volunteers exposed to chlorfenvinphos for 53 days. 
However, since desethyl chlorfenvinphos accounts for only about 5% of the dose at this low exposure 
level, its concentration in urine would lack sensitivity when used as an index of exposure to 
chlorfenvinphos (Hunter et al. 1972). Although this method of assessing chlorfenvinphos exposure may 
not be useful in low exposure conditions, the method could be used to evaluate exposure to high doses 
that occur in human acute poisoning cases. Further research in the adaptation of this method for low-
dose exposure would be useful. 
Effect.  Inhibition of the activities of erythrocyte, plasma, or whole blood cholinesterase in humans and 
animals that results from chlorfenvinphos exposure (Cupp et al. 1975; Gralewicz et al. 1989a, 1989b, 
1990; Hunter 1969; Kolmodin-Hedman and Eriksson 1987; Maxwell and LeQuesne 1982; Osicka-
Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber and Kruckenberg 1972) 
may be used as a marker of effect for chlorfenvinphos exposure. However, the inhibition of 
cholinesterase activity is a common action of anticholinesterase compounds, which include 
organophosphates like chlorfenvinphos, and carbamate compounds. In addition, a wide variation in 
normal cholinesterase values exists in the general population, and there are no studies which report a 
quantitative association between cholinesterase activity levels and exposure to chlorfenvinphos in 
humans. Thus, the inhibition of cholinesterase activity is not a specific biomarker of effect for 
chlorfenvinphos exposure; it is indicative only of effect and is not useful for chlorfenvinphos-specific 
dosimetric analysis. In combination with analysis of reductions in the level of cholinesterase activity, the 
manifestations of severe organophosphate (chlorfenvinphos) poisoning, clinically characterized by a 
collection of cholinergic signs and symptoms (which may include dizziness, fatigue, tachycardia or 
bradycardia, miosis, and vomiting) (Chambers and Levi 1992; Cupp et al. 1975; Klaassen et al. 1986; 
Pach et al. 1987; Takahashi et al. 1991; Williams and Burson 1985), are useful biomarkers of effect for 
identifying victims of organophosphates (chlorfenvinphos) poisoning.  These manifestations, however, 
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are also not specific to chlorfenvinphos, but to anticholinesterase compounds, such as 
organophosphates and carbamate compounds, in general. A study conducted in rats reported that 
1–6 hours after administration, chlorfenvinphos (13 mg/kg) decreased the noradrenaline 
(norepinephrine) level in rat brain by 20% as compared to controls (Brzezinski 1978).  A similar study in 
Wistar rats found a 16% transient reduction in brain noradrenaline (norepinephrine) 3 hours after oral 
dosing with 4 mg/kg chlorfenvinphos (Osumi et al. 1975). Further research on the adrenergic effects of 
chlorfenvinphos exposure might provide a more specific biomarker for chlorfenvinphos when used in 
combination with inhibition of cholinesterase activity and clinical signs of interference with the central 
cholinergic mechanism. 
Absorption, Distribution, Metabolism, and Excretion.  No studies were located regarding the 
absorption of chlorfenvinphos after inhalation exposure; or regarding the distribution or metabolism of 
chlorfenvinphos after inhalation or dermal exposure; or regarding excretion of chlorfenvinphos after 
inhalation or dermal exposure in humans. In humans, dermally applied chlorfenvinphos was absorbed 
in a concentration-dependent manner with rates of 0.06–1.43 mg/cm2/hour. Concentrations of intact 
chlorfenvinphos of <0.7–22 µg/L were found in the blood of volunteers 8 hours later (Hunter 1969). The 
rates of chlorfenvinphos de-ethylation by liver microsomal fractions are 0.36 nmol/minute per mg protein 
(range 0.11–0.82) without induction and 1.03 nmol/minute per nmol of cytochrome P-450 (range 
0.42–1.78) with induction (Hutson and Logan 1986). Chlorfenvinphos levels of 13.66, 1.69, 2.02, and 
1.89 µg/kg were detected in 4 of the 11 samples of cervical mucus in environmentally exposed persons. 
Chlorfenvinphos levels of 0.42 µg/kg were detected in 1 of the 10 sperm fluid samples and 1 of the 
10 human milk samples, respectively (Wagner et al. 1990). A serum concentration of 300 ng/mL 
chlorfenvinphos was reported for a 29-year-old patient who had attempted suicide by ingesting about 
50 mL of the preparation Enolofos®, which contains 50% chlorfenvinphos. The authors of this report 
surmised that orally absorbed chlorfenvinphos is widely and rapidly distributed (Pach et al. 1987). 
No studies were located regarding the absorption of chlorfenvinphos after inhalation or dermal 
exposure; or regarding the distribution or metabolism of chlorfenvinphos after inhalation, oral, or dermal 
exposure; or regarding excretion of chlorfenvinphos after inhalation or dermal exposure in animals.  The 
available animal studies indicate that orally administered chlorfenvinphos is minimally absorbed and 
metabolized in rats (Hutson and Wright 1980). The metabolism of oral doses of the substance is 
mediated by hepatic microsomal monooxygenase (cytochrome P-450) via oxidative dealkylation 
(Donninger 1971; Hutson and Millburn 1991; Ikeda et al. 1991). Thirteen metabolites of 
chlorfenvinphos have been identified in animal studies or predicted from theoretical biotransformation 
as justified by the known structure of chlorfenvinphos and understanding of biochemical reactions of 
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monooxygenation, reduction, hydrolysis, glucuronidation, glutathione-S-transferase conjugation, and 
amino acid conjugation. The 13 metabolites identified or predicted are: 2-chloro-1-(2’,4’-dichlorophenyl) 
vinyldiethyl phosphate; acetaldehyde; 2-chloro-1-(2’,4’-dichlorophenyl) vinylethylhydrogen phosphate; 
2,4-dichlorophenacylchloride; 2-chloro-1-(2’,4’-dichlorophenyl) ethanol; 2,4-dichloromandelic acid; 
2,4-dichloromandelic acid ester glucuronide; 2,4-dichloroacetophenone; 1-(2’,4’-dichlorophenyl) ethanol; 
1-(2’,4’-dichlorophenyl) ethanediol; 1-(2’,4’-dichlorophenyl) ethanediol-2-glucuronide; 1-hydroxy­
1-(2’,4’-dichlorophenyl) acetyl glycine; and 1-(2’,4’-dichlorophenyl) ethanediol (Akintonwa 1984, 1985; 
Akintonwa and Itam 1988; Hunter et al. 1972; Hutson and Millburn 1991; Hutson and Wright 1980). 
Orally absorbed chlorfenvinphos is eliminated mainly in the urine in rats in 0-32 hours (Hutson and 
Wright 1980). Additional studies in animals, designed to measure the rate of inhalation, gastrointestinal, 
and dermal absorption, distribution, and excretion of chlorfenvinphos would be useful in extrapolating 
the toxicokinetics of chlorfenvinphos in humans, especially those living around hazardous waste sites. 
Comparative Toxicokinetics.  Chlorfenvinphos inhibits cholinesterase activity in the central and 
peripheral nervous system, resulting in cholinergic symptoms as reported in several human poisoning 
incidents (Cupp et al. 1975; Hunter 1969; Pach et al. 1987; Kolmodin-Hedman and Eriksson 1987). 
However, the purity of the material to which these subjects were exposed is questionable, and the 
doses at which these effects occurred are unknown because of the accidental nature of the exposures. 
Therefore, it is difficult to determination whether the adverse effects reported in these human studies 
are attributable to exposure to technical chlorfenvinphos. Although information is available that 
indicates that dermally applied chlorfenvinphos was absorbed in a concentration-dependent manner 
(with rates of 0.06–1.43 mg/cm2/hour), inhibiting cholinesterase in a dose-dependent in the human 
subjects (Hunter 1969), information on the toxicokinetics of chlorfenvinphos in humans is limited to 
serum levels following ingestion (Pach et al. 1987). 
Similarly, chlorfenvinphos inhibits cholinesterase activity in the central and peripheral nervous system in 
animals (Gralewicz et al. 1989a, 1989b, 1990; Kolmodin-Hedman and Eriksson 1987; Maxwell and 
LeQuesne 1982; Osicka-Koprowska et al. 1984; Pach et al. 1987; Takahashi et al. 1991; Vestweber 
and Kruckenberg 1972). 
The level of activity of cholinesterases in the livers of mammalian species and the distribution of these 
enzymes have been suggested to be important factors in accounting for species specificity of some 
phosphate triester anticholinesterase agents, including chlorfenvinphos. These factors may account for 
the great variation in the conversion of chlorfenvinphos to less toxic metabolites and, consequently, the 
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toxicity of chlorfenvinphos among different animal species. The relative rates of conversion of 
chlorfenvinphos (by O-dealkylation) to the diester by liver slices from the rat, mouse, rabbit, and dog are 
1, 8, 24, and 80 hours, respectively; evidently correlating with the published acute oral LD50 values for 
the species. A quantitative study of the species distribution of phosphate esterases and glutathione 
S-alkyl transferase found that these enzymes are significantly less in the pig than all the other species 
studied (Donninger 1971; Hansen 1983; Ikeda et al. 1991). The ease of absorption, bioavailability in 
blood, and rates of uptake by the brain and sensitivity of brain cholinesterase to the phosphorylating 
action of the compound may be additional factors in species sensitivity to the toxicity of chlorfenvinphos 
as demonstrated in the dog and rabbit (Hutson and Millburn 1991). 
Additional comparative studies regarding the absorption, distribution, and excretion of chlorfenvinphos 
after inhalation, oral, or dermal exposure in animals would be useful in species or route-route 
extrapolation. This information could be used to determine an appropriate animal model for the 
evaluation of the toxicokinetics of chlorfenvinphos. 
Methods for Reducing Toxic Effects.  Although dialysis and hemoperfusion are currently not 
recommended in organophosphate poisonings because of the extensive tissue distribution of the 
absorbed doses (Mücke et al. 1970; Poklis et al. 1980), hemoperfusion has been successfully used in 
one chlorfenvinphos poisoning treatment (Pach et al. 1987). Further studies are necessary in view of 
the relatively few clinical observations concerning the use of hemoperfusion in the treatment of acute 
poisoning caused by vinyl phosphate compounds like chlorfenvinphos. 
2.10.3 Ongoing Studies 
No information on ongoing studies in humans or laboratory animals for chlorfenvinphos was located. 
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3.1 CHEMICAL IDENTITY 
Chlorfenvinphos is a synthetic organophosphorus insecticide that has been used as a soil or foliar 
insecticide. It was also used to control insect pests on livestock and to control household pests. 
Information regarding the chemical identity of chlorfenvinphos is located in Table 3-1. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
Chlorfenvinphos is a vinyl organophosphate insecticide. The technical material is an amber liquid with 
a mild odor containing about 80–90% chlorfenvinphos (trans and cis isomers with a typical ratio of 
8.5:1). It is sparingly soluble in water, but miscible with most organic solvents. It hydrolyzes slowly in 
water, but is unstable in alkali (Worthing 1983). Information regarding the physical and chemical 






4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
Chlorfenvinphos was introduced into the United States in 1963 (Hayes 1982), by the Shell International 
Chemical Company Ltd., Ciba AG (now Ciba-Geigy AG), and by Allied Chemical Corporation (Worthing 
1983). The Burroughs Wellcome Company produced several chlorfenvinphos-containing formulated 
products including Dermaton® dust, Dermaton® dip, Dermaton® II, and Dermaton® flea and tick collars 
(EPA 1978a, 1978b, 1979, 1982a, 1982b, 1983). Information on current production of chlorfenvinphos 
is conflicting. One source lists current base producers of the compound as American Cyanamid 
Company (under the trade names Birlane® and Supona®) and Ciba Ltd. (under the trade names 
Sapecron® and Steladone®) (Farm Chemicals Handbook 1993). However, no producers of 
chlorfenvinphos were identified in a recent Directory of Chemical Producers for the United States of 
America (SRI 1993). 
Chlorfenvinphos is produced by reaction of triethyl phosphite with 2,2,2',4'-tetrachloroacetophenone 
(Worthing 1983). The technical grade material contains greater than 92% chlorfenvinphos as both the 
Z (trans) and E (cis) isomers in a ratio (Z:E) of 8.5:1 (Spencer 1982; Worthing 1983). 
No information on historic production volumes was found; however, there are currently no registered 
uses for chlorfenvinphos in the United States (REFS 1995). 
No information is available in the Toxics Release Inventory (TRI) database on total environmental 
releases of chlorfenvinphos from production facilities because chlorfenvinphos is not included under 
SARA, Title III (40 CFR 372.65), and, therefore, is not one of the toxic chemicals that facilities are 
required to report to the Toxics Release Inventory database (EPA 1995). 
4.2 IMPORT/EXPORT 
Chlorfenvinphos is not likely to be imported as there are currently no registered uses for this compound 
as a pesticide in the United States (REFS 1995). No definitive information on recent or historic import 
volumes was found. 
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Current production of chlorfenvinphos in the United States could not be verified (SRI 1993), but 
production for domestic consumption is not permitted as all registered uses in the United States were 
canceled in 1991 (REFS 1995). Production of pesticides for export whose registered uses in the United 
States have been cancelled is legal under U.S. law. The Federal Insecticide, Fungicide, and 
Rodenticide Act (FIFRA) generally prohibits the EPA from releasing complete information on pesticide 
production, sales, and distribution. In a recent report by the Foundation for the Advancement of 
Science and Education, the authors report that no government agency maintains current records 
concerning what specific pesticides are exported (FASE 1996). No definitive information on recent or 
historic export volumes was found. 
4.3 USE 
In the United States, chlorfenvinphos was registered for a variety of uses from 1963 until 1991 when all 
products containing chlorfenvinphos as an active ingredient were canceled (REFS 1995). 
Chlorfenvinphos was first registered in 1963 under the trade name Dermaton® as an insecticide/ 
acaricide dip for veterinary use in controlling fleas and ticks on domestic pets and other animals. 
During the mid-1960s and early 1970s, chlorfenvinphos was registered for additional uses as a residual 
fly spray, surface spray, and larvicide. As part of these registrations, chlorfenvinphos was used to 
control adult flies in dairy barns, milk rooms, poultry houses and yards, other animal buildings, feedlots, 
and animal holding pens; and to control larval flies in manure storage pits and piles, and in other refuse 
accumulation areas around dairies and feedlots (REFS 1995). Beginning in the early 1980s, it was 
registered for additional uses under the trade name Dermaton®, in a dust formulation for use in dog 
kennels and in dog collars for the control of fleas and ticks (Farm Chemicals Handbook 1984, 1993; 
Hayes 1982; REFS 1995). 
Available formulations of chlorfenvinphos included a 0.5% dust, 10% pelletized granules, 21% 
emulsifiable concentrate, 24.5% emulsifiable concentrate, 25% wettable powder(WP), and 40% seed 
dressing (with 2% mercury compounds); however, some of these formulations were not registered for 
use in the United States (Hayes 1982; REFS 1995; Spencer 1982). A summary of the registered uses 
of chlorfenvinphos in the United States prior to the cancellation of its registration is given in Table 4-1 
(REFS 1995). 
Chlorfenvinphos was subject to re-registration by the Office of Pesticide Programs of EPA in the 
mid-1980s. At that time, the sole manufacturer, Shell International Chemical Company decided not to 
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products to lapse and be canceled (EPA 1994). A summary of chlorfenvinphos product registrations 
and their effective dates of cancellation are given in Table 4-2. 
Outside the United States, chlorfenvinphos is registered for use under the trade names Birlane®, 
C8949, CGA 26351, Sapecron®, Steladone® and Supona® (Farm Chemicals Handbook 1993). 
Chlorfenvinphos (under the trade name Birlane®) is used as a soil insecticide for controlling root 
maggots, root worms, and cutworms (Farm Chemicals Handbook 1984; Spencer 1982; Worthing 
1983). As a foliar insecticide, it controls Colorado beetles, Leptinotarsa decemlineata on potatoes, and 
scale insects on citrus, where it also exhibits ovicidal activity against mite eggs. It also controls stem 
borers on maize, rice, and sugarcane, and whiteflies (Benusia sp.) on cotton (Farm Chemicals 
Handbook 1984; Worthing 1983). Birlane® 24 controls root flies, phorid and sciarid fly larvae, fruit flies 
on maize and sweet corn, and wheat bulb flies in winter wheat. Birlane® 10% granules are used to 
control root flies and Birlane® Liquid Seed Treatment is used to control wheat bulb flies in winter wheat. 
Supona® is used to control ticks, flies, lice and mites on cattle; blowflies, lice ked, and itchmites on 
sheep; and fleas and ticks on dogs. Steladone® and Sapecron® are used as cattle dips or sprays to 
control ectoparasites on cattle (Farm Chemicals Handbook 1984; REFS 1995; Spencer 1982). 
Chlorfenvinphos is also used in public health applications for control of mosquito larvae (The 
Agrochemicals Handbook 1991). 
No quantitative information on the volume of chlorfenvinphos use in the United States or on historic 
trends in use was found. It is known, however, that chlorfenvinphos was first introduced for use in the 
United States on October 3, 1963, and that the last EPA approved label date for a chlorfenvinphos­
containing product was September 1986. Use is likely to have declined from 1986 until January 22, 
1991, when all uses of the chemical were canceled in the United States (REFS 1995). 
4.4 DISPOSAL 
Chlorfenvinphos is considered to be an extremely hazardous substance (EPA 1988). The 
recommended disposal method for chlorfenvinphos consists of hydrolysis and subsequent transport to 
a landfill (IRPTC 1985). Chlorfenvinphos and chlorfenvinphos-containing wastes should be treated by 
alkali and then mixed with a portion of soil which is rich in organic matter before burial (at least to a 
depth of 0.5 meters) in a pit or in clay soil. For disposal of large quantities of chlorfenvinphos, 
incineration at high temperatures in a unit equipped with an effluent gas scrubbing device is 
recommended (IRPTC 1985). See Chapter 7 for further information on regulations and advisories. 
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5.1 OVERVIEW 
Chlorfenvinphos is currently released to the environment in the United States from runoff and leaching 
from hazardous waste disposal sites. Soil is the environmental medium most likely to be contaminated 
with chlorfenvinphos. The processes that may transport chlorfenvinphos from soil to other media 
include volatilization to the air, leaching to groundwater, runoff to surface water, and absorption by 
plants. Biodegradation appears to be the dominant process responsible for chlorfenvinphos loss from 
soil (Miles et al. 1979, 1983). Biodegradation, hydrolysis, and adsorption to organic matter are likely to 
be responsible for the loss of chlorfenvinphos from water (Beynon et al. 1971, 1973; Rouchaud et al. 
1988). 
If released to air from soil or water via volatilization, chlorfenvinphos is expected to exist primarily in the 
vapor phase, but can also be found associated with particulate matter (Eisenreich et al. 1981). In the 
vapor phase, chlorfenvinphos can react with hydroxyl radicals (estimated half-life value of 7 hours) or 
with ozone (estimated half-life value of 92 hours) (Atkinson and Carter 1984; Lyman et al. 1990; Meylan 
and Howard 1993). 
If released to water, moderate adsorption to particulate matter will transport chlorfenvinphos from the 
water column and partition it to suspended solids and sediment (Swann et al 1983). The hydrolysis 
half-life value for chlorfenvinphos in water is highly dependent on pH and temperature. At a pH of 6 and 
8 and a temperature of 20–30 EC, the half-life values were 170 and 80 days, respectively (Beynon et al. 
1971). 
Chlorfenvinphos does not appear to partition extensively from water into aquatic organisms. Estimated 
whole-body concentration factors for chlorfenvinphos were significant, but relatively low, ranging from 
37 to 460 (Mackay 1982; Veith et al. 1979; Veith et al. 1980 in Bysshe 1990). No experimentally 
measured bioconcentration factor (BCF) values were located in the literature for any aquatic 
invertebrate or fish species. Chlorfenvinphos is absorbed by plants primarily from the soil, but residues 
generally decline fairly rapidly in the tissues through the course of the growing season (Beynon et al. 
1968; Suett 1971, 1975a). 
The estimated half-life value of chlorfenvinphos in sandy soil ranges from 28 days (4 weeks) to 
210 days (30 weeks) (Beynon et al. 1973; Williams 1975a). The rate of degradation is influenced 
greatly by the soil type, amount of organic matter in the soil, soil temperature, soil moisture content, and 
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the history of chlorfenvinphos use. Repeated application of chlorfenvinphos to agricultural soils 
enhanced microbial degradation of the pesticide (Rouchaud et al. 1989a, 1991). 
No information was found on concentrations of chlorfenvinphos in ambient air samples or in drinking 
water in the United States. Chlorfenvinphos was detected in surface and groundwater samples 
(concentrations not specified) at the one hazardous waste site where chlorfenvinphos was detected 
(HazDat 1996). Chlorfenvinphos was also detected in soil samples (concentrations not specified) at the 
one hazardous waste site where chlorfenvinphos was detected (HazDat 1996). It should be noted that 
the amount of chlorfenvinphos found by chemical analysis is not necessarily the amount that is 
bioavailable. 
Currently, both domestic and imported foods (fresh fruits and vegetables) and lanolin-containing 
pharmaceutical products appear to be sources of some exposure for the general population. In the 
past, occupational exposure to chlorfenvinphos may have occurred through dermal contact and 
inhalation of dusts and sprays especially to workers applying the compound as a pesticide. 
Occupational exposure to chlorfenvinphos was reported in California in workers who handled flea 
control products (Ames et al. 1989). 
Workers involved in disposal of chlorfenvinphos or chlorfenvinphos-contaminated wastes are also at a 
higher risk of exposure than the general population. People living in the vicinity of plants where 
chlorfenvinphos was manufactured or formulated, or living near dairy farms, cattle or sheep holding 
areas, or poultry producing facilities where chlorfenvinphos was used; and people living near hazardous 
waste sites containing chlorfenvinphos also are potentially at higher risk of exposure. 
Chlorfenvinphos has been identified in at least 1 of the 1,428 current or former EPA National Priorities 
List (NPL) hazardous wastes sites (HazDat 1996). However, the number of sites evaluated for 
chlorfenvinphos is not known. The frequency of these sites within the United States can be seen in 
Figure 5-1. 
5.2 RELEASES TO THE ENVIRONMENT 
Information on historic production of chlorfenvinphos (including producers, production sites, production 
volumes and years of production) in the United States was not found. Releases of chlorfenvinphos are 
not required to be reported under SARA Section 313; consequently there are no data for this chemical 
in the 1993 Toxics Release Inventory (EPA 1995). 
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There is one NPL hazardous waste site where chlorfenvinphos has been identified (HazDat 1996). 
Hazardous waste disposal sites appear to be the major source for release of this compound into the 
environment since there are currently no registered uses for it in the United States (REFS 1995). 
5.2.1 Air 
Chlorfenvinphos may have been released into the air in the past, during its production and processing. 
Historically, chlorfenvinphos may have volatilized into the air during its use in sprays applied to dairy, 
poultry, and cattle facilities to control flies and fly larvae, or from the skin of animals exposed to 
chlorfenvinphos in cattle dips or sprays. Because of the relatively low volatility of the compound and 
lack of registration for crop use in the United States (REFS 1995), releases to the air from registered 
uses would be expected to be negligible. 
Chlorfenvinphos was not detected in air samples collected at the one NPL hazardous waste site where 
it was detected in some environmental media (HazDat 1996). No other information on releases of 
chlorfenvinphos to air was located; however, there are no current registered uses of this compound in 
the United States (REFS 1995; SRI 1993). 
5.2.2 Water 
In the past, chlorfenvinphos may have been released to surface water during its production and 
processing. Chlorfenvinphos also may have been released to water via runoff after its application to 
dairy, poultry, and cattle facilities to control flies and fly larvae, or when residues from sheep or cattle dip 
tanks were discharged onto soil (Inch et al. 1972). Because chlorfenvinphos was never registered for 
use on crops in the United States (REFS 1995), its releases to water from its registered uses would be 
expected to be minimal. Adsorption to particulate matter will eventually transport chlorfenvinphos from 
water to suspended solids and sediment. 
Chlorfenvinphos has been detected in surface water and groundwater samples collected at the 
one NPL hazardous waste site where it was detected (concentrations unspecified) in some 
environmental media (HazDat 1996). No other information on releases of chlorfenvinphos to water was 
located; however, there are no current registered uses of this compound in the United States (REFS 
1995; SRI 1993). 
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5.2.3 Soil 
Chlorfenvinphos may have been released directly to soil during its production and processing and is 
likely to have been released during its disposal as the recommended disposal practice for small 
quantities was burial in a disposal pit or in clay soil (IRPTC 1985). The chemical may also have been 
released to soil and sediment indirectly from runoff from treated manure storage areas, and areas 
around poultry or cattle holding areas, or when residues from sheep or cattle dip tanks were discharged 
onto soil (Inch et al. 1972). Adsorption to particulate matter will eventually transport chlorfenvinphos 
from water to suspended solids and sediment. Because chlorfenvinphos was not registered for crop 
use in the United States, its releases to soil from its registered uses would be expected to be minimal. 
Chlorfenvinphos has been detected in soil samples collected at the one NPL hazardous waste site 
where it was detected in some environmental media (HazDat 1996).  No other information on releases 
of chlorfenvinphos to soil or sediments was located; however, there are currently no registered uses of 
this chemical in the United States (REFS 1995; SRI 1993). 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
There is a paucity of experimental data regarding the transport and partitioning of chlorfenvinphos in the 
air. Given a vapor pressure ranging from 4.0x10-6 mm Hg (Worthing 1983) to 7.5x10-6 mm Hg (Merck 
1989), chlorfenvinphos should exist in the atmosphere in the vapor phase, but will also partition to 
available airborne particulates (Eisenreich et al. 1981). The solubility of 145 mg/L (Merck 1989) 
ensures that at least partial removal of atmospheric chlorfenvinphos will occur by wet deposition. 
The transport of chlorfenvinphos from water to air can occur due to volatilization. Henry's law constant 
provides a qualitative indication of the importance of volatilization.  Compounds with a Henry's law 
constant (H) of <10-5 atm-m3/mol volatilize slowly from water (Thomas 1990). Chlorfenvinphos with an 
H value of 2.76x10-9 atm-m3/mol (Domine et al. 1992), therefore, will volatilize slowly from water.  Since 
H <10-9 atm-m3/mol, chlorfenvinphos is less volatile than water and its concentration in water may 
increase as water evaporates. Humidity in the air reduces the volatilization rate of water somewhat so 
the lower limit can be set at 10-7; this means that chlorfenvinphos could be considered essentially 
nonvolatile (Thomas 1990). 
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Adsorption to particulate matter will transport chlorfenvinphos from water and partition it to suspended 
solids and sediment in water. The estimated organic carbon-adjusted soil sorption coefficient (Koc) for 
chlorfenvinphos is 280 (Kenaga 1980). This Koc value suggests that chlorfenvinphos in the water 
column adsorbs moderately to suspended solids and sediments based on criteria established by 
Swann et al. (1983), and this process may transport considerable amounts of chlorfenvinphos from 
water to particulate matter. Partitioning of chlorfenvinphos from water to solid suspended matter was 
studied in a field experiment. Chlorfenvinphos was sprayed at a rate of 74 kg/ha on to the surface of a 
pond so the water contained an average concentration of 6.1 ppm (Beynon et al. 1971). The 
concentration decreased to 2.0 ppm after 5 hours, and to 0.12 ppm after 1 month. The sediment 
concentrations increased and persisted for at least 34 days after treatment. Chlorfenvinphos 
disappears from water in two distinct phases, a rapid initial phase and a much slower second phase. It 
is suggested that the first phase represents the initial precipitation of the heavier particles and uptake in 
plankton containing the adsorbed pesticide. Later, chlorfenvinphos is gradually adsorbed to other 
suspended matter, which then precipitates much more slowly, or the second phase may represent the 
slower removal of the residues by biotic processes. 
Based on structure and activity relationships, certain regression equations have been developed to 
estimate the bioconcentration factor (BCF) value for chlorfenvinphos from its water solubility and 
organic carbon partition coefficent (Koc) values. Using these regression equations, the BCF value for 
chlorfenvinphos in aquatic organisms is estimated to be 37 (Kenaga 1980). A log octanol-water 
partition coefficent (Kow) value of 3.806 was reported by Bowman and Sans (1983). Using regression 
equations involving log Kow, the following BCF values were estimated; 306 (Mackay 1982), 343 (Veith et 
al. 1979), and 460 (Veith et al. 1980 in Bysshe 1990). No experimentally measured BCF values were 
located in the literature for any aquatic invertebrate or fish species. However, bioconcentration of 
chlorfenvinphos in aquatic organisms, although relatively low, ranging from 37 to 460, may have some 
environmental significance. No information was found on the biomagnification of chlorfenvinphos 
through aquatic or terrestrial food chains. 
The transport processes that may move chlorfenvinphos from soil to other media are volatilization, 
leaching, runoff, and absorption by plants. Based on the estimated Henry's law constant, volatilization 
is not expected to be an important transport process for moving chlorfenvinphos from soil to other 
media. Like other pesticides, chlorfenvinphos in soil partitions between soil-sorbed and soil-water 
phases (Racke 1992). This latter phase may be responsible for the volatilization of chlorfenvinphos 
from soil; however, due to the low Henry's law constant value, the rate of chlorfenvinphos volatilization 
from the soil-water phase to the atmosphere would be low. In a laboratory study of volatilization from 
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soil, chlorfenvinphos was incorporated into sterilized sand and into a sterilized sandy loam at a 
concentration of 50 ppm. The media contained 25% moisture and were maintained at 20 EC in an 
open beaker. Forty-five days after incorporation, more than 95% of the chlorfenvinphos was still 
present in the beaker (Rouchaud et al. 1988). However, in a field study conducted by Williams (1975a), 
the author suggests that rapid loss (42% in 2 days) of surface-applied chlorfenvinphos (granular) was 
probably due to volatilization and/or photodecomposition. Subsurface application of the granular 
formulation at the same concentration showed only a 6% loss in 2 days post-application. In another 
field study, Suett (1977) reported that the combination of sunlight and warm wet soil for 48 hours 
immediately after application of chlorfenvinphos marginally increased isomerization on both the coarse 
and fine soil tilthes, but did not enhance volatilization. 
The reported Koc value of 280 (Kenaga 1980) suggests that the adsorption of chlorfenvinphos to soil is 
moderately strong; therefore, the rates of leaching and runoff will be relatively minor processes in most 
soils. Very little leaching of chlorfenvinphos and no leaching of its degradation products was observed 
in several field studies. The leaching characteristics of chlorfenvinphos were studied by applying it to 
sloping arable land at 22 kg active ingredient/hectare (a.i./ha) and following its movement down a slope 
(Edwards et al. 1971). Only 0.18% of the chlorfenvinphos applied was leached through the soil, but this 
was nine times more than was observed with dieldrin in a similar experiment.  Only very small amounts 
of chlorfenvinphos moved down the slope and were present in runoff.  In one of the experiments there 
was a pond located at the bottom of the slope and residues could not be detected in the mud or water 
from this pond. Residues of the main soil degradation products were not detected in the pond water at 
23 or 36 weeks post-application. More chlorfenvinphos leached vertically into drainage water than 
laterally over the soil surface. Chlorfenvinphos residues in soil following broadcast applications on the 
surface showed that even after 150 days, only 1–1.5% of the applied chlorfenvinphos leached to a 
depth of 7.5–15 cm despite 12 cm of rainfall that occurred during the first 60 days post-application 
(Williams 1975a). Furthermore, when the granular formulation was applied at a depth of 7.5 cm, there 
was little movement of chlorfenvinphos below a depth of 10 cm.  In a similar study by Agnihotri et al. 
(1981), when chlorfenvinphos granules were applied to the 0–15 cm soil layer, no leaching of the 
compound occurred below the 15 cm depth over a period of 120 days. 
Chlorfenvinphos is also transported from the soil of one area to soil of another area or from soil to 
surface water (rivers, lakes, and streams) via runoff. Pesticides with a water solubility >10 mg/L move 
mainly in solution phase in runoff water (Racke 1992). Chlorfenvinphos with a water solubility of 
145 mg/L (Merck 1989) is expected to be found mainly in runoff water. This does not seem to be 
completely substantiated, however, by results of several field studies conducted in agricultural 
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watersheds. In one field study, only 0.3–0.6% of the applied chlorfenvinphos was found in runoff water 
after a rainfall event (Racke 1992). Braun and Frank (1980) analyzed pesticide residues in surface 
water samples over a 3-year period (1975–77) collected in 11 agricultural watersheds in Southern 
Ontario, Canada. Although chlorfenvinphos was known to have been used as a soil pesticide in at least 
one of the watersheds, it was not detected in any surface water samples (detection limit 1 µg/L [1 ppb]). 
In a more recent study, Frank et al. (1991) analyzed pesticide residues in surface water samples over a 
5-year period (1986–90) collected from the mouths of the 3 major agricultural watersheds, the Grand, 
the Saugeen, and the Thames Rivers in Ontario, Canada. All three rivers flow into Lake Erie. Although 
it was known to have been used as a soil pesticide in the Thames River basin in 1988, no 
chlorfenvinphos residues were detected in any surface water samples during the study period 
(detection limit <1.0 µg/L [ppb]). Most recently, Wan et al. (1994) studied residues of several 
organophosphate pesticides including chlorfenvinphos in farm ditch water, and sediments and farm 
soils in the lower Fraser Valley of British Columbia, Canada, from July through December 1991. The 
farm ditches drained into three rivers: the Fraser, the Niicomekl, and the Sumas. During the study 
period, no sales of chlorfenvinphos were reported. Chlorfenvinphos was used as a soil insecticide in 
1990, but was not recommended for this use in Canada in 1991. Although chlorfenvinphos was not 
detected in any of the farm ditch water or sediment samples analyzed at the 7 sampling sites, it was 
detected in 7% of the soil samples. Adsorption of chlorfenvinphos to particulate matter will transport the 
pesticide from the water column and partition it to suspended solids and sediment. From these results, 
it seems clear that surface water runoff and leaching of chlorfenvinphos into drainage water from 
treated agricultural fields is not likely to be a serious problem. 
Adsorption of chlorfenvinphos from water solutions of hydrogen, calcium, sodium, and potassium ions 
were studied (Barba et al. 1991). In all cases, the saturating cations influenced the Freundlich-type 
adsorption, with adsorption decreasing in the following sequence: H+> Ca2+> Na+> K+ for adsorption on 
two clays, kaolinite and bentonite. The extent of adsorption of chlorfenvinphos was generally slower in 
kaolinite than in bentonite. 
When it was first introduced, chlorfenvinphos was generally considered to be a non-systemic pesticide 
(i.e., when it is applied to soil it should not move into plants and when sprayed on plant foliage, it should 
not move from the treated leaves into other untreated parts of the plant) (Rouchaud et al. 1989b). This 
view was based on the fact that at plant maturity or at harvest, very low residues (<0.02 mg/kg [ 
0.02 ppm]) were found in turnips, carrots, cabbages, white radishes, and potatoes planted or sown in 
chlorfenvinphos-treated soil (Beynon and Wright 1968; Beynon et al. 1968). In addition, no 
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translocation of chlorfenvinphos from treated leaves to other parts of plants was observed (Beynon et 
al. 1973). Earlier work with potato tubers under recommended field conditions also confirmed this 
finding (Beynon et al. 1968). Rouchaud et al. (1989b), however, found that in the foliage of the spring 
cauliflower, the concentration of chlorfenvinphos increased, reaching a peak concentration 15 days 
after soil treatment, then progressively decreased until harvest. The presence of chlorfenvinphos and 
two metabolites, trichloroacetophenone and 2,4-dichlorobenzoic acid, was the result of their absorption 
by the plant from the soil and of their biodegradation by the plant. Two crops were studied for their 
chlorfenvinphos uptake (Rouchaud et al. 1991). The periods of time required for chlorfenvinphos 
foliage concentrations to attain residues of 1 mg/kg (1 ppm) fresh weight were: cauliflower, 
24–37 days; and Brussels sprouts, 41–45 days. Suett (1974, 1975a) also reported that carrots 
accumulated high residue concentrations of chlorfenvinphos applied to the soil and continued to 
accumulate the pesticide during the entire period of active plant growth. Thirty weeks after carrot seed 
was sown in soil treated with chlorfenvinphos at a depth of 10 cm, the peel of the carrots contained 
88% of the total chlorfenvinphos residues found in the carrots. The upper 6 cm of carrot root always 
contained most of the chlorfenvinphos residue irrespective of the application mode. Significant residues 
of chlorfenvinphos were detected in immature onion bulbs (64–76 days after seeding), with the level of 
chlorfenvinphos residue being much higher in the roots and outer skin (Ritcey et al. 1991). The 
chlorfenvinphos concentrations in the bulbs dropped below the detection limit (unspecified) by 96 days 
after seeding (2 months before harvesting). 
In recent experiments, plant cuticle was investigated as the first and rate-limiting barrier in foliar uptake 
of chlorfenvinphos. Mobility studies of chlorfenvinphos across the cuticular membranes of bitter orange 
(Citrus aurantium) leaves and green pepper (Capsicum annuum) fruits gave first-order rate constants of 
6.7 (±3.3)x108/second and 10.2 (±3.4)x107/second, respectively (Bauer and Schönherr 1992). These 
correspond to penetration half-lives of 120 days (2,874 hours) and 7.8 days (189 hours), respectively. 
5.3.2 Transformation and Degradation 
5.3.2.1 Air 
One of the important reactions for most organic pollutants in the atmosphere is with hydroxyl radicals. 
No rate constant for the reaction of hydroxyl radicals with chlorfenvinphos in air has been 
experimentally determined. Using an estimation method, the estimated rate constant value for the 
vapor-phase reaction of chlorfenvinphos with hydroxyl radicals is 5.31x10-11 cm3/radical-sec at 25 EC 
(Atkinson 1988; Meylan and Howard 1993). Based on this value, and assuming an average annual 
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atmospheric concentration of hydroxyl radicals in the northern hemisphere of 4.8x105 radicals/cm3 
(Lyman et al. 1990), the estimated half-life value (first-order kinetics) of chlorfenvinphos in the 
atmosphere due to this reaction is 7 hours. Thus, chlorfenvinphos is short-lived in the atmosphere. 
Chlorfenvinphos can also be degraded by ozonation in the atmosphere. However, no rate constant for 
the reaction of ozone with chlorfenvinphos in air has been experimentally determined. An estimated 
value of the rate constant is 3x10-18cm3/molecule-sec at 25 EC (Atkinson and Carter 1984; Meylan and 
Howard 1993). Based on this value and assuming an average atmospheric ozone concentration of 
9.6x1011 molecules/cm3 (Lyman et al. 1990), the estimated half-life value (first-order kinetics) of 
chlorfenvinphos in the atmosphere due to this reaction is 92 hours (3.4 days). Photolysis is probably 
the least significant of the atmospheric degradation processes. Chlorfenvinphos is not susceptible to 
direct photolysis in sunlight because its maximum absorption for ultraviolet light is 228 nm (Schlett 
1991), which is less than the 290 nm wavelength limit for sunlight absorption to occur. 
5.3.2.2 Water 
The processes that can result in the transformation and degradation of chlorfenvinphos in water are 
hydrolysis, photosensitized oxidation, and biodegradation.  Hydrolysis pathways for chlorfenvinphos in 
water are shown in Figure 5-2. Chlorfenvinphos is most stable in water at ambient temperatures and 
neutral pH. Chlorfenvinphos hydrolyzed slowly in water resulting in a half-life (first-order kinetics) value 
of 170 days at pH 6 and 80 days at pH 8 at 20–30 EC (Beynon et al. 1971). In laboratory studies, 
hydrolysis was observed under conditions of high temperature and extreme pH (highly alkaline or highly 
acidic), resulting in a half-life of >400 hours (>33 days) at pH 9.1, and >700 hours (58 days) at pH 1.1 at 
38 EC (Agrochemicals Handbook 1991; Beynon et al. 1973; Hayes 1982). Hydrolysis probably does 
not contribute much to the initial disappearance of chlorfenvinphos from natural waters (Beynon et al. 
1971). Based on hydrolysis studies (Ruzicka et al. 1967) conducted at 70 EC and correcting for 
temperature differences assuming an environmental temperature of 20 EC, the aqueous hydrolysis half-
life (first-order kinetics) value of chlorfenvinphos is approximately 1–1.3 years (Harris 1990).  Direct 
photolysis of chlorfenvinphos is negligible, since the compound does not significantly absorb ultraviolet 
wavelength light >290 nm. No information was found in the literature regarding the photosensitized 
reaction of chlorfenvinphos in water with ozone, hydroxyl radicals or singlet oxygen. Therefore, 
biodegradation appears to be the dominant degradation process in natural waters. This is likely, as 
microbial degradation is the dominant degradation process in soils (Miles et at. 1979, 1983; Rouchaud 
et al. 1988). 

136 CHLORFENVINPHOS 
5. POTENTIAL FOR HUMAN EXPOSURE 
5.3.2.3 Sediment and Soil 
Chlorfenvinphos in soil and sediment may undergo degradation and transformation by hydrolysis, and 
biotic processes. Various screening studies have demonstrated that microbial degradation is the 
dominant degradation process in soil (Miles et al. 1979, 1983; Rouchaud et al.1988, 1989a, 1989b). 
The hydrolysis of chlorfenvinphos may occur in the soil/sediment-water phase, as opposed to the soil/ 
sediment-sorbed phase. As a result, the rate of hydrolysis is expected to be comparable to that in 
water. Based on the slow hydrolysis rates observed in water (see Section 5.3.2.2), hydrolysis of 
chlorfenvinphos in soil is not expected to be significant. In the laboratory, chlorfenvinphos was 
incubated in sterilized and unsterilized soil for more than 2 months at 20 EC. The rate of 
disappearance of chlorfenvinphos from the sterilized soil was more than 15 times slower than that 
observed in unsterilized soil. The persistence of chlorfenvinphos was examined in sterile and natural 
mineral (sandy loam/organic matter = 2.7%, pH = 7.2) and organic (muck, organic matter = 48%, 
pH = 6.5) soils at a range of temperatures (3–28 EC) for 24 weeks (Miles et al. 1979, 1983). In general, 
chlorfenvinphos is less stable in sandy loam than in muck, less stable at higher temperatures (the 
exception was the stability of chlorfenvinphos in sterile sandy loam at all temperatures studied), and 
considerably less stable in natural soils (half-lives #11 weeks at 15 and 28 EC) compared to sterile soils 
(half-lives >24 weeks at all temperatures), indicating the major role microbes play in degrading 
chlorfenvinphos in soil. A summary of degradation pathways of chlorfenvinphos in soil is presented in 
Figure 5-3. 
Chlorfenvinphos is degraded in soil to trichloroacetophenone, 2,4-dichloroacetophenone, α-(chloro­
methyl)-2,4-dichlorobenzyl alcohol, and 1-(2',4'-dichlorophenyl)-ethan-1-ol (Rouchaud et al. 1988, 
1991). Other degradation products identified are 2,4-dichlorobenzoic acid, 2-hydroxy-4-chlorobenzoic 
acid, and 2,4-dihydroxybenzoic acid. None of the degradation products retain any pesticide 
characteristics. Trichloroacetophenone is the main transformation product; when hydrolyzed, oxidized 
and decarboxylated, it becomes 2,4-dichlorobenzoic acid. Reduction of trichloroacetophenone to 
α-(chloromethyl)-2,4-dichlorobenzyl alcohol is a slow process, and replacement of a chlorine atom by a 
hydrogen atom to become 2,4-dichloroacetophenone and 1(-2',4'-dichlorophenyl)-ethan-1-ol is also 
slow. The degradation products 2-hydroxy-4-chlorobenzoic acid and 2,4-dihydroxybenzoic acid are 
produced from 2,4-dichlorobenzoic acid by replacement of chlorine atoms by hydroxyl groups. 
Biodegradation of chlorfenvinphos is influenced by several factors: soil type, presence of organic 
matter, moisture content, soil temperature, and a history of chlorfenvinphos use. Chlorfenvinphos 
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sandy soils and slowest in peat, probably because of its degree of adsorption to organic matter (Beynon 
et al. 1973; Williams 1975a). Because the rate of degradation by hydrolysis is greater than expected, 
breakdown is assumed to be mainly biotic. Initial half-life values of 4–30 weeks have been determined 
for sandy soils. In peat, chlorfenvinphos persists longer.  Chlorfenvinphos was found to be very slowly 
degraded in a peat soil (47.8% organic matter), but was much less persistent on several sandy soils 
(1.6–2.2% organic matter) (Williams 1975a). In the peat (soil water pH = 6.0), 70% of the applied 
chlorfenvinphos remained after 21 weeks and 30% remained after nearly 12 months. In sandy soil (soil 
water pH = 6.9–7.5) only 3–15% of the applied chlorfenvinphos remained after a period of 15 weeks. 
The persistence in peat was attributed to strong adsorption rendering the pesticide unavailable to 
microorganisms and to plant roots. In sandy soil, rainfall was also correlated to increased loss of 
chlorfenvinphos. 
Chlorfenvinphos was more stable and had increased persistence in soils that had been treated with 
organic fertilizer such as pig slurry, cow manure, city refuse, or mushroom cultivation composts 
compared to untreated control plots (Rouchaud et al. 1992a, 1992b). For example, the half-life of 
chlorfenvinphos at the Gembloux site was 18, 36, 35, and 43 days for the control, city refuse compost, 
cow manure, and mushroom compost plots, respectively. At another site (St. Katelijne-Waver), both a 
spring and summer application study were conducted. In the spring study, the half-life of 
chlorfenvinphos was 9, 13, 14, and 21 days and in the summer study, the half-life was 23, 42, 46, and 
53 days for the control, city refuse compost, cow manure, and mushroom compost plots respectively. 
The humic acid concentrations and the total soil organic matter content were always higher in the 
organic fertilizer treated plots. 
Rates of chlorfenvinphos loss from soil also appear to be related to soil moisture conditions. In dry 
seasons, although the initial rate of loss was high, the subsequent rate of degradation was slower than 
in wetter seasons of higher soil moisture content (Williams 1975a). Under conditions of average 
summer rainfall and relatively moist soils, the residues were less than 5% of applied dose, but when the 
soils were much drier than normal, residues were higher at 15% of applied dose after the same period 
of time (Miles et al. 1984). 
Degradation of chlorfenvinphos ceases in soil at low temperatures (below 6–7 EC) (Suett 1975b). A 
granular formulation of chlorfenvinphos was broadcast at 2 kg active ingredient per hectare and 
incorporated to 10 cm into sandy-loam soil in May and in September 1971. When applied in 
September, the chlorfenvinphos persisted for a longer period than when applied in May. Degradation 
was slower during the winter while the mean soil temperature remained below 6–7 EC. Rising soil 
temperature during the following spring rapidly increased the rate of degradation. The late summer­
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early fall applications to control carrot flies would leave appreciable residues of chlorfenvinphos in the 
soil at the beginning of the next growing season which might contribute to the terminal crop residues. 
Residues of chlorfenvinphos applied in May declined to less than 20% of the initially applied dose, and 
there was little loss subsequent to the December sampling. In the September application, more than 
60% of the chlorfenvinphos applied still remained when the loss rates decreased in October. The 
relatively high concentration of chlorfenvinphos remaining then continued to decline only slowly 
throughout the winter until March when the rate of loss of chlorfenvinphos residues increased to rates 
similar to those of the previous September. 
The catalytic degradation of chlorfenvinphos on H+, Ca2+, Na+, and K+ mono-ionic kaolinite and 
bentonite was found to be influenced by the nature of the exchange cations and their degree of 
hydration in the order K+> Na+> Ca2+> H+/Al3+ (Cámara et al. 1992). In both types of clays, the process 
of hydrolysis occurred in two stages involving first-order kinetics, giving different hydrolysis rates. The 
first stage is characterized by a rapid hydrolysis rate of short duration; the second phase is long with a 
slow but continuous hydrolysis rate. 
An inverse relationship between the history of chlorfenvinphos use in the soil and foliage concentrations 
was found that suggested enhanced biodegradation (Rouchaud et al. 1991). The longer the history of 
chlorfenvinphos use in a field, the lower the chlorfenvinphos residues and residues of its metabolites 
that were found; this suggests that specific soil microbial fauna adaptation was due to previous soil 
treatments. In soil from cauliflower, Brussels sprouts, and Chinese cabbage fields, the half-life of 
chlorfenvinphos was found to vary from 9 to 35 days; for chlorfenvinphos plus degradation products, the 
half-life ranged from 50 to 80 days (Rouchaud et al. 1989a). The fields in which chlorfenvinphos 
exhibited the shorter half-lives were those with the longer histories of chlorfenvinphos use in the soil, 
suggesting enhanced biodegradation was occurring. 
Environmental transformation pathways for chlorfenvinphos in plants are summarized in Figure 5-4. A 
trans to cis rearrangement of chlorfenvinphos sprayed on plant foliage has been observed (Beynon et 
al. 1973). This conversion has been attributed to photochemical processes. The same conversion has 
not been observed for chlorfenvinphos applied directly to soil. The initial half-life value of 
chlorfenvinphos on foliage is 2–3 days, and the rate of degradation decreases thereafter. Over 50% of 
the radioactivity from 14C-(vinyl)-trans-chlorfenvinphos disappeared from foliage in 4–7 days. It is not 
known whether it is released as chlorfenvinphos or as a degradation product. The major breakdown 
product of chlorfenvinphos on plant foliage is a conjugate of the ethan-1-ol [8], probably with a sugar. 
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5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Reliable evaluation of the potential for human exposure to chlorfenvinphos depends on the reliability of 
supporting analytical data from environmental samples and biological specimens.  In reviewing data on 
chlorfenvinphos levels monitored in the environment, it should also be noted that the amount of 
chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. 
5.4.1 Air 
No information was located on the ambient concentrations of chlorfenvinphos in the atmosphere or on 
concentrations associated with domestic or occupational indoor air exposures in the United States. 
5.4.2 Water 
No information was located on the ambient concentrations of chlorfenvinphos in drinking water, surface 
water, or groundwater in the United States. Chlorfenvinphos was detected (concentration unspecified) 
in surface water and groundwater samples collected at the only hazardous waste site where it was 
detected in some environmental media (HazDat 1996). 
Environmental monitoring data are available for surface waters from Canadian studies in the Great 
Lakes region and from British Columbia. Braun and Frank (1980) analyzed pesticide residues in 
surface water samples collected over a 3-year period (1975–77) in 11 agricultural watersheds in 
Southern Ontario, Canada. Although chlorfenvinphos was known to have been used as a pesticide in 
at least one of the watersheds, it was not detected in any surface water samples (detection limit 1 µg/L 
[1 ppb]). Frank et al. (1991) analyzed pesticide residues in water samples collected over a 5-year 
period (1986–90) from the mouths of the three major agricultural watershed rivers in Ontario, Canada: 
the Grand, the Saugeen, and the Thames. All three rivers flow into Lake Erie. Although it was known 
to have been used as a soil pesticide in the Thames River basin in 1988, no chlorfenvinphos residues 
were detected in any water samples during the study period (detection limit <1.0 µg/L [<1 ppb]). Most 
recently, Wan et al. (1994) studied residues of several organophosphate pesticides including 
chlorfenvinphos in farm ditch water and farm soils in the lower Fraser Valley of British Columbia, 
Canada, from July through December 1991. The farm ditches drained into three rivers: the Fraser, the 
Niicomekl, and the Sumas. During the study period, no sales of chlorfenvinphos were reported. 
Chlorfenvinphos was used as a soil insecticide in 1990, but was not recommended for this use in 
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Canada in 1991. Although chlorfenvinphos was not detected in any of the farm ditch water or sediment 
samples analyzed at the 7 sampling sites, it was detected in 7% of the soil samples. Residue results 
obtained in these Canadian studies may be inappropriate for estimating water residues in the United 
States, as chlorfenvinphos was never registered for use as a soil insecticide in the United States (REFS 
1995). 
5.4.3 Sediment and Soil 
Chlorfenvinphos was detected (concentration not specified) in topsoil and subsoil samples (>3 inches 
deep) collected at one NPL hazardous waste site where it was detected in some environmental media 
(HazDat 1996). No other information was located on the concentrations of chlorfenvinphos detected in 
soil or sediment samples collected in the United States. 
Environmental monitoring data are available, however, for agricultural soils from Canadian studies in 
the Great Lakes region and from British Columbia. Chlorfenvinphos residues in organic farm soils of 
the Holland Marsh in Ontario, Canada, were analyzed each fall from 1972 to 1975 and residue levels 
generally exceeded 0.1 ppm (Miles et al. 1978). The annual mean residues (dry weight basis) of 
chlorfenvinphos sampled in 13 farm soils were as follows: 1972, 0.12 ppm; 1973, 0.05 ppm; 1974, 
0.36 ppm; and 1975, 0.13 ppm. Wan et al. (1994) studied residues of several organophosphate 
pesticides including chlorfenvinphos in farm soils from seven different sites in the lower Fraser Valley of 
British Columbia, Canada, from July through December 1991.  Chlorfenvinphos was used as a soil 
insecticide in 1990, but was not recommended for this use in Canada, in 1991 (during the study period). 
Despite the fact that chlorfenvinphos was not used during the study period, it was detected in 7% of the 
soil samples analyzed. The mean chlorfenvinphos concentration found in soil at the Cloverdale site 
was 31 µg/kg (0.031 ppm), with a range of 12 to 60 µg/kg (0.012–0.060 ppm). The authors believed 
that these residues were a carryover from the previous years.  Residue results obtained in these 
Canadian studies may be inappropriate for estimating soil residues in the United States, as 
chlorfenvinphos was never registered for use as a soil insecticide in the United States (REFS 1995). 
5.4.4 Other Environmental Media 
Chlorfenvinphos was not monitored in many of the federal, regional, and state food studies conducted 
from the late 1960s through the mid-1980s (Corneliussen 1970; Duggan and Corneliussen 1972; 
Duggan et al. 1983; Gartell et al. 1986; Gunderson 1988; Hundley et al. 1988). The FDA's monitoring 
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program for domestic and imported food commodities detected chlorfenvinphos in unspecified foods at 
unspecified concentrations during fiscal years 1978–82 (Yess et al. 1991a) and during fiscal years 
1983–86 (Yess et al. 1991b). During 1982–86, the FDA Los Angeles District Laboratory analyzed 
19,851 samples of domestic and imported food and feed commodities (Luke et al. 1988). 
Chlorfenvinphos was not detected in any sample of the 6,391 domestic agricultural commodities or in 
any of the 12,044 imported agricultural commodities analyzed. Chlorfenvinphos was detected in 
unspecified foods at unspecified concentrations and at an unspecified detection frequency in 
14,492 domestic and imported food samples analyzed as part of the FDA pesticide monitoring program 
for 1986–87 (FDA 1988). In a pesticide residue screening program conducted in 1989–91 in San 
Antonio, Texas, on 6,970 produce samples, chlorfenvinphos was detected (0.75 ppm detection limit) in 
one produce sample of tomatoes (frequency of <0.5%) (Schattenburg and Hsu 1992). In a similar 
study conducted by Agriculture Canada of 13,230 domestic and imported food items analyzed during 
the same period (1989–91), chlorfenvinphos was not detected in any domestic foods, but was detected 
in 13 imported food samples (frequency <0.1%) (Neidert et al. 1994). Detectable residues were found 
in fresh oranges, peppers, pineapples, and spinach. As part of the FDA's Pesticide Monitoring Program 
for domestic and imported foods, chlorfenvinphos residues have been detected in unspecified foods at 
unspecified concentrations and at unspecified detection frequencies during 1988–89, 1989–90, 
1990–91, 1991–92, 1992-93 (FDA 1990, 1991, 1992, 1993, 1994), but residues were not detected in 
1993–94 during the most recent regulatory monitoring period (FDA 1995). 
The effect of cooking on chlorfenvinphos concentrations in raw foods was examined by Askew et al. 
(1968). These authors spiked samples of raw potato and cabbage mash with 2 ppm of chlorfenvinphos 
and boiled the samples for 30 minutes to simulate the effect of cooking raw vegetables contaminated 
with chlorfenvinphos. Total residues were reduced by 37–53% for potato and 56–86% for cabbage 
mash. A cooking process such as boiling leads to a partial reduction of chlorfenvinphos residues, but 
does not completely eliminate the pesticide. A similar study examined the effects of milk processing 
procedures on organophosphate residues in milk (Skibniewska and Smoczynski 1985).  These authors 
reported that boiling in an enamel vessel to simulate home cooking, and three pasteurization 
procedures involving heating for 30 minutes at 62 EC, for 2 minutes at 72 EC, and for 5 seconds at 
85 EC, resulted in about a 20% decrease in the residues of organophosphates including 
chlorfenvinphos. Reduction of the pesticide residues was more affected by the duration of heating 
rather than the temperature to which the milk was heated. 
Nagayama et al. (1989) studied the residue levels of chlorfenvinphos on commercial tea leaves grown 
in Japan and the leaching of the pesticide into tea. Chlorfenvinphos was detected at concentrations 
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ranging from trace to 3.4 ppm on tea leaves and more that 12% of the chlorfenvinphos was found to 
leach from the leaves into the tea. 
Heikes and Craun (1992) analyzed the residues of several pesticides including chlorfenvinphos in 
anhydrous lanolin and lanolin-containing pharmaceutical preparation sampled from 1988 through 1992. 
Concentrations of chlorfenvinphos in anhydrous lanolin samples collected in 1989 ranged from 0.60 to 
5.9 mg/kg; those collected in 1991 ranged from 0.81 to 10 mg/kg. In 1988, chlorfenvinphos was 
detected in a wide range of pharmaceutical preparations including A & D ointment, analgesic balm, 
nitroglycerin cream, atropine sulfate ointment, and dibucaine ointment at concentrations ranging from 
0.08 to 1.1 mg/kg (ppm). In 1992, chlorfenvinphos was detected in antibiotic, cold sore, and ophthalmic 
ointments at concentrations ranging from trace to 0.32 mg/kg (ppm). 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Currently, the general population is primarily exposed to chlorfenvinphos by ingesting food containing 
chlorfenvinphos, particularly fresh fruits and vegetables imported from countries where this pesticide still 
is used. In addition, the general population may be dermally exposed to chlorfenvinphos concentrations 
in lanolin and lanolin-containing pharmaceutical products. 
No information is available on the concentrations of chlorfenvinphos in ambient air. However, because 
this pesticide currently has no registered uses in the United States, the extent of exposure of the 
general population to chlorfenvinphos from inhalation is probably insignificant. No information is 
available on the concentrations of chlorfenvinphos in drinking water. Because chlorfenvinphos was not 
used as an agricultural pesticide on crops in the United States, it was not monitored extensively in 
groundwater. As a result of its relatively limited use, current exposure of the general population to 
chlorfenvinphos from consumption of drinking water is probably negligible. 
Chlorfenvinphos has been detected in both domestic and imported foods, but especially in imported 
fresh fruits and vegetables (see Section 5.4.4). Thus, consumers can be exposed to chlorfenvinphos 
by ingesting contaminated food. No information was available on the FDA-estimated daily food intakes 
of chlorfenvinphos for different age/sex groups in the United States for fiscal years 1982–84 
(Gunderson 1988) or 1986–91 (FDA 1993). However, because exposure to the general population 
from consumption of chlorfenvinphos-contaminated foods comes primarily from imported foods and 
145 CHLORFENVINPHOS 
5. POTENTIAL FOR HUMAN EXPOSURE 
because residues in raw vegetables and fruits are reduced during food preparation by washing and 
cooking procedures, the risk to the general U.S. population appears negligible. 
Workers who were involved in the manufacture, formulation, handling, or application of chlorfenvinphos 
are likely to have been exposed to higher concentrations by dermal exposure and inhalation of 
chlorfenvinphos particles than the general population. Workers who are currently involved in the 
disposal of chlorfenvinphos-contaminated wastes are likely to be exposed to higher concentrations by 
dermal contact and inhalation of chlorfenvinphos particles or chlorfenvinphos-contaminated soil 
particles than the general population. Occupational exposure to chlorfenvinphos was reported to have 
occurred in workers in California who handled flea control products. However, chlorfenvinphos was not 
associated with statistically elevated symptom frequency (Ames et al. 1989). 
No information was found in the National Occupational Exposure Survey (NOES) conducted by NIOSH 
from 1981 to 1983 on the number of workers and the number of facilities where workers could be 
potentially exposed to chlorfenvinphos in the United States (NOES 1990). NIOSH (1992) did not 
provide recommendations for occupational exposure levels to chlorfenvinphos for a 10-hour time 
weighted average (TWA) workday. An Occupational Safety and Health Administration (OSHA) 
permissible exposure limit (PEL) for workplace air does not exist (OSHA 1974). 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In the past, individuals who were occupationally exposed to chlorfenvinphos during its production, 
formulation, packaging, distribution, use, or disposal, were exposed to higher-than-background 
concentrations of chlorfenvinphos. 
At the present time, several groups within the general population may receive potentially high 
exposures to chlorfenvinphos. These groups include individuals living near chemical manufacturing or 
processing sites or those currently involved in the disposal of chlorfenvinphos or chlorfenvinphos­
contaminated materials, those living on dairy, beef, sheep, or poultry farms where chlorfenvinphos was 
extensively used, and those living near hazardous waste sites.  Individuals living near these sites may 
be exposed to potentially higher concentrations of chlorfenvinphos or its metabolites in their drinking 
water if they obtain tap water from wells near these sources. Children playing in chlorfenvinphos­
contaminated soils may consume this pesticide or its degradation products from their exposed hands. 
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5.7 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of chlorfenvinphos is available. Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of 
a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of chlorfenvinphos. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met 
would reduce the uncertainties of human health assessment. This definition should not be 
interpreted to mean that all data needs discussed in this section must be filled. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda will 
be proposed. 
5.7.1 Identification of Data Needs 
Physical and Chemical Properties.  As seen in Table 3-2, the relevant physical and chemical 
properties of chlorfenvinphos are known (Bowman and Sans 1983; Domine et al. 1992; HSDB 1994; 
Kenaga 1980; Merck 1989; Worthing 1983) and predicting the environmental fate and transport of 
this compound based on the Koc, Kow, and Henry's law constant is possible. No further information is 
required. 
Production, Import/Export, Use, Release, and Disposal.  Chlorfenvinphos was introduced into 
the United States in 1963 (Hayes 1982) by the Shell International Chemical Company, Ciba-Geigy 
AG, and by Allied Chemical Corporation (Worthing 1983).  No historic import/export information was 
available for this chemical. In the United States, chlorfenvinphos use appears to have been limited to 
uses in dairies, feedlots, or poultry yards to reduce adult fly populations; in manure containment 
areas to reduce adult and larval fly populations; as a cattle and sheep dip to reduce ectoparasites, 
and as a wettable powder (WP), granular form, or contained in a collar for killing fleas and ticks in 
dogs (EPA 1994; REFS 1995). While chlorfenvinphos has been extensively used in agricultural 
applications in other countries, especially for root and cole crops, this pesticide was not used for crop 
applications in the United States (Farm Chemicals Handbook 1984, 1993; Spencer 1982; The 
Agrochemicals Handbook 1991; Worthing 1983). More complete information on the production and 
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import/export of chlorfenvinphos would be useful to assess the possible routes of exposure, potential 
for environmental contamination and human exposure.  Information on the number of producers and 
production sites, locations of production facilities, years of production, and the volume of production 
in the United States would be helpful. Information on import/export volumes and estimates of yearly 
usage during those years prior to the cancellation of its pesticide registration would also be useful. 
While adequate information on disposal procedures exists (IRPTC 1985), more recent information 
would be helpful. 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 
11023, industries are required to submit chemical release and off-site transfer information to the EPA. 
The Toxics Release Inventory (TRI), which contains this information for 1993, became available in 
May of 1995. This database will be updated yearly and should provide a list of industrial production 
facilities and emissions. No information is available from TRI93 because chlorfenvinphos is not one 
of the toxic chemicals that producers currently are required to report (EPA 1995). 
Environmental Fate.  Information regarding the fate of chlorfenvinphos in the air was not located in 
the literature. Given a vapor pressure ranging from 4x10-6 to 7.5x10-6 mm Hg (Merck 1989; Worthing 
1983), chlorfenvinphos should exist in the atmosphere in the vapor phase, but will also partition to 
available airborne particulates (Eisenreich et al. 1981). The solubility of 145 mg/L (Merck 1989) 
ensures that at least partial removal of atmospheric chlorfenvinphos will occur by wet deposition. 
Based on these chemical and physical properties, the atmospheric concentrations of chlorfenvinphos 
are expected to be low because chlorfenvinphos is not highly volatile. Additional information would 
help predict the residence time and distance of its aerial transport. The fate of chlorfenvinphos in 
water has been more extensively studied (see Section 5.3.1) (Barba et al. 1991; Beynon et al. 1971, 
1973; Braun and Frank 1980; Frank et al. 1991; Wan et al. 1994), including information on its 
degradation under various environmental conditions. The fate of chlorfenvinphos in soil, including 
information on its mobility and biodegradation, has also been well documented (see Section 5.3.1) 
(Beynon et al. 1973; Edwards et al. 1971; Miles et al. 1979, 1983; Racke 1992; Rouchaud et al. 1988, 
1989a, 1989b, 1989c, 1991, 1992a, 1992b; Williams 1975a). Additional information on the 
degradation of chlorfenvinphos in air and groundwater would be helpful in estimating exposure to 
chlorfenvinphos under various conditions of environmental release for purposes of planning and 
conducting meaningful follow-up exposure and health studies. 
Bioavailability from Environmental Media.  Available information regarding the rate of 
chlorfenvinphos absorption following inhalation, oral, and dermal contact has been discussed in the 
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Toxicokinetics section (see Section 2.3) (Hunter 1969; Hutson and Wright 1980; Pach et al. 1987). 
Although no data on chlorfenvinphos' bioavailability from contaminated air are available, the 
bioavailability from inhalation exposure is expected to be relatively low because the compound is 
likely to partition to available particulates. No data are available on the bioavailability of 
chlorfenvinphos from water, soil, or plant material. Chlorfenvinphos is adsorbed moderately to soil 
(Beynon et al. 1973; Edwards et al. 1971; Racke 1992). Chlorfenvinphos is expected to have 
reduced bioavailability from soil and water, since the part that remains adsorbed to soil or sediment 
may be only partially bioavailable. Additional data on the bioavailability of chlorfenvinphos from 
environmental media and the difference in bioavailability from different media would be helpful in 
assessing the potential body burdens that may occur as a result of exposure to environmental 
concentrations. 
Food Chain Bioaccumulation.  The only information on bioconcentration factors for 
chlorfenvinphos was derived from equations based on information on physical and chemical 
properties (see Section 5.3.1) Estimated whole-body concentration factors calculated for 
chlorfenvinphos were significant, but relatively low, ranging from 37 to 460 (Mackay 1982; Veith et al. 
1979; Veith et al. 1980 in Bysshe 1990). No measured BCFs for any aquatic organisms were found 
in the literature. Available data indicate that chlorfenvinphos applied to plant foliage is transported 
across the cuticular membrane (Bauer and Schönherr 1992). Chlorfenvinphos applied to the soil is 
accumulated in the roots, stem and leaves of plants (Ritcey et al. 1991; Rouchaud et al. 1989b; Suett 
1974, 1975b). No information was found on the biomagnification of chlorfenvinphos in aquatic or 
terrestrial food chains. These data would be helpful in assessing the potential for human exposure as 
a result of consuming contaminated food. 
Exposure Levels in Environmental Media.  No data were located on the concentrations of 
chlorfenvinphos in ambient air or in occupational settings; therefore, no estimate of inhalation 
exposure to chlorfenvinphos can be obtained for the general population, or for any occupationally 
exposed groups. No data on the concentration of chlorfenvinphos in drinking water, surface water, or 
groundwater in the United States were located in the literature. Monitoring data for surface waters 
are available from several Canadian studies conducted in the Great Lakes region and British 
Columbia; however, monitoring results from these Canadian studies may be inappropriate for 
estimating water residues in the United States, as chlorfenvinphos was never registered for 
agricultural use as a soil insecticide. Current monitoring data on the concentrations of 
chlorfenvinphos in ambient air, in drinking water, surface water, groundwater, and in soil from the 
United States would be helpful. Many of the federal, regional, and state food studies conducted from 
the late 1960s through the mid-1980s did not monitor chlorfenvinphos concentrations in foods 
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(Corneliussen 1970; Duggan and Corneliussen 1972; Duggan et al. 1983; Gartell et al. 1986; 
Gunderson 1988; Hundley et al. 1988), despite the fact that chlorfenvinphos was most extensively 
used in the United States during this period (see Section 4.3). Recent FDA monitoring studies on 
imported and domestic foods have detected chlorfenvinphos residues; however, the foods in which 
chlorfenvinphos was detected and the residue concentrations were not specified (FDA 1990, 1991, 
1992, 1993). Additional quantitative information on chlorfenvinphos concentrations in food and the 
estimated daily human intake of chlorfenvinphos from foods would be helpful in assessing current 
exposure levels to this pesticide. 
Reliable monitoring data for the concentrations of chlorfenvinphos in contaminated media at 
hazardous waste sites are needed so that the information obtained on levels of chlorfenvinphos in the 
environment can be used in combination with the resulting body burden of chlorfenvinphos to assess 
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 
sites. 
Exposure Levels in Humans.  No data on chlorfenvinphos levels in various human tissues and 
body fluids of unexposed populations, populations near hazardous waste sites, or occupationally 
exposed groups in the United States are available.  Although chlorfenvinphos is a hydrophilic 
substance, it has not been widely found in human tissues because of its relatively short half-life. 
However, in a recent study conducted in the Federal Republic of Germany, chlorfenvinphos was 
found in some of the 41 specimens of cervical mucus, follicular and sperm fluids, and human milk that 
were examined. Chlorfenvinphos concentrations of 13.66, 1.69, 2.02, and 1.89 µg/kg were detected 
in 4 of the 11 samples of cervical mucus. Chlorfenvinphos was also detected at concentrations of 
0.42 µg/kg in 1 of the 10 sperm fluid samples and 1 of the 10 human milk samples, respectively 
(Wagner et al. 1990). Additional data on the concentrations of chlorfenvinphos and its metabolites in 
body tissues and fluids are needed to estimate the extent of exposure to chlorfenvinphos. This 
information is necessary for assessing the need to conduct health studies on these populations. 
Exposure Registries.  No exposure registries for chlorfenvinphos were located. This substance is 
not currently one of the compounds for which a subregistry has been established in the National 
Exposure Registry. The substance will be considered in the future when chemical selection is made 
for subregistries to be established. The information that is amassed in the National Exposure 
Registry facilitates the epidemiological research needed to assess adverse health outcomes that may 
be related to exposure to this substance. 
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5.7.2 Ongoing Studies 
A search of the Federal Research in Progress database (FEDRIP 1995) indicated that no research 




The purpose of this chapter is to describe the analytical methods that are available for detecting, 
and/or measuring, and/or monitoring chlorfenvinphos, its metabolites, and other biomarkers of 
exposure and effect to chlorfenvinphos. The intent is not to provide an exhaustive list of analytical 
methods. Rather, the intention is to identify well-established methods that are used as the standard 
methods of analysis. Many of the analytical methods used for environmental samples are the 
methods approved by federal agencies and organizations such as EPA and the National Institute for 
Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are 
approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American 
Public Health Association (APHA). Additionally, analytical methods are included that modify 
previously used methods to obtain lower detection limits, and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
Few methods are available for the determination of chlorfenvinphos in biological samples. Some 
methods which may be applicable to biological media are summarized in Table 6-1. Most methods 
involve an extraction step followed by one or more purification and fractionation procedures, then 
analysis, usually by gas chromatography (GC). Two detection methods are commonly used, nitrogen-
phosphorus detection (NPD) (Thier and Zeumer 1987; Wagner et al. 1990) and flame photometric 
detection (FPD) (Ivey et al. 1973). Both of these methods are specific for phosphorus-containing 
compounds and are very sensitive (low- to sub-ppb levels).  Recovery, where reported, is very good 
(>80%). 
Several cautions should be noted. First, the stability of chlorfenvinphos in biological media is 
unknown. The cold-storage stability (5 to –20 EC) of chlorfenvinphos in crops and soil has been 
reported (Kawar et al. 1973). However, enzymes present in biological media may reduce levels of 
organophosphate pesticides (Singh et al. 1986). Second, it is difficult to eliminate or reduce interfering 
compounds and maintain acceptable recovery of chlorfenvinphos. Quality control procedures are 
recommended to assure that the method performance is acceptable. Third, other organophosphorus 
pesticides may co-elute with chlorfenvinphos (Sasaki et al. 1987), so a confirmatory method is 
recommended A few methods are available for measuring metabolites of chlorfenvinphos. 
Chlorfenvinphos undergoes biotransformation to a variety of polar metabolites including diethyl 
phosphate. Methods for measurement of dialkyl phosphates involve extraction from urine using an ion 
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performance of the methods is variable; extraction is not always complete, and GC interferences often 
present problems. 
6.2 ENVIRONMENTAL SAMPLES 
Representative analytical methods for determining chlorfenvinphos in environmental samples are 
summarized in Table 6-2. Methods involve solvent extraction, purification and fractionation, and gas 
chromatographic analysis. Although most methods for measuring chlorfenvinphos in environmental 
samples involve GC coupled with specific detectors (including MS), other methods are available, 
including high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection (Bagon and 
Warwick 1982; Schlett 1991), and thin layer chromatography (TLC) (Roberts and Stoydin 1976). 
Methods for determining chlorfenvinphos in aqueous samples include solvent extraction (EPA 1992b; 
Wan et al. 1994) or isolation using solid phase extraction (SPE) (Schlett 1991). Further clean-up of 
the extract may not be required prior to analysis by HPLC (Schlett 1991) or GC (EPA 1992b; Wan et 
al. 1994). For GC analysis, confirmation using a second column is recommended (EPA 1992b; Wan 
et al. 1994). Detection limits are in the sub-ppb range; recovery was not reported. 
Similarly, methods for determining chlorfenvinphos in sediments, solid wastes, and soils use a solvent 
extraction procedure. A variety of clean-up procedures are used, including Florisil column purification 
(Beynon et al. 1966), solvent partition (Miles et al. 1979; Williams 1975b), and gel permeation 
chromatography (Wan et al. 1994). Extracts are analyzed by GC with electron capture detection 
(ECD) (Beynon et al. 1966; Edwards et al. 1968) or phosphorus-specific detectors (Wan et al. 1994; 
Williams 1975b). Detection limits are in the low-ppb range (1–20); recovery is excellent ($95%). 
A chemiluminscence assay has been developed that should be a useful screening tool for 
environmental media. It is not as sensitive as GC methods, but is inexpensive, fast, and may be used 
as a portable detection system (Moris et al. 1995). Capillary electrophoresis is a relatively new 
technique for environmental analysis. It is rapid, but does not yet achieve detection limits needed for 
environmental analysis (Süsse and Müller 1995). 
Methods for determining chlorfenvinphos on a variety of foods and crops have been reported. Most 
involve solvent extraction followed by clean-up using adsorption column techniques (FDA 1979; 
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1992; Leoni et al. 1992) or solvent partitioning (Frank et al. 1990; Stijve 1984). Chlorfenvinphos is 
determined by GC with phosphorus-specific detectors (flame photometric [FPD]; and nitrogen-
phosphorus [NPD]) (Agüera et al. 1993; Leoni et al. 1992; Kadenczki et al. 1992; Stijve 1984). 
Chlorfenvinphos in sample extracts is confirmed using GC with MS (Agüera et al. 1993; Leoni et al. 
1992) or TLC (Stijve 1984). Detection limits are in the low-ppb range; recovery is acceptable (>80%). 
A summary of methods for determination of chlorfenvinphos environmental degradation products is 
shown in Table 6-3. The breakdown products 2,4-dichloroacetophenone, 1-(2,4-dichlorophenyl)­
1-ethan-1-ol, and 2,4-dichlorophenacyl chloride can be determined in soil and earthworms using 
solvent extraction and GC/ECD (Edwards et al. 1968).  Detection limits are approximately 0.05 ppm 
and recovery is excellent (95–115%). The hydrolysis product 2,2',4'-trichloroacetophenone has been 
determined in corn extracts using GC/ECD and GC/FPD.  Detection limits are 0.02 ppm (ECD) and 
0.002 (FPD), and recovery is excellent (Beroza and Bowman 1966). Free and conjugated degradation 
products have been determined in soils and crops by GC/ECD (Beynon et al. 1968). Free products 
are extracted with solvent; conjugated products are hydrolyzed with sulfuric acid. Recovery is 
acceptable (80–100% for soils, 50–90% for crops); detection limits range from 0.01 to 0.2 ppm for soils 
(varies with compound) and from 0.005 to 0.05 ppm for crops.  Degradation products, including soil-
bound (polar) compounds, were determined by GC/ECD of soil extracts. The polar compounds were 
methylated prior to GC analysis. Recovery is acceptable (65–105%); detection limits are 
approximately 0.02 ppm. 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of chlorfenvinphos is available. Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of 
a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of chlorfenvinphos. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
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all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.  Few methods are available for 
measuring exposure to chlorfenvinphos. These are summarized in Table 6-4. Blood levels of 
chlorfenvinphos were determined in a case of human poisoning (Klys 1985); however, sensitivity and 
reliability were not reported. Chlorfenvinphos is metabolized in the body to esters of phosphoric acid, 
and methods are available for determining urine levels of these metabolites (Bradway et al. 1981; 
Lores and Bradway 1977). However, these phosphate compounds are not specific for 
chlorfenvinphos, but are common to all organophosphate pesticides. Decreased levels of 
acetylcholinesterase in plasma or erythrocytes have been reported to be indicative of chlorfenvinphos 
poisoning (Zwiener and Ginsberg 1988). Again, this assay is not specific for chlorfenvinphos. An 
increase in the level of tryptophan after exposure to chlorfenvinphos has been reported in rats (Dudka 
and Szczepaniak 1993). Good precision and accuracy were reported for the method; however, 
specific values were not given. It is not known if the available analytical methods will be sensitive 
enough to measure chlorfenvinphos levels in body tissues and fluids of the background population. 
Since chlorfenvinphos is apparently not produced or imported into this country, it should not be 
necessary to determine these background levels. It would be helpful to have methods which would 
permit assessment of the severity of exposure of a highly exposed population. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.  Methods are available for determining chlorfenvinphos in water, soils and sediments, and 
foods (Table 6-2). A summary of available methods for determining the environmental degradation 
products of chlorfenvinphos in soils (Beynon et al. 1968; Rouchaud et al. 1988), crops (Beynon et al. 
1968; Beroza and Bowman 1966), and worms (Edwards et al. 1968) is shown in Table 6-3. Sensitive 
methods (sub-ppb levels) are available for determining chlorfenvinphos in water; however, better 
information is needed regarding the recovery and precision of the methods (EPA 1992b; Schlett 1991; 
Wan et al. 1994). Methods for determining chlorfenvinphos in soils and sediments are sensitive (low 
ppb levels) and good recovery ($95%) has been reported (Beynon et al. 1966; Edwards et al. 1968; 
Wan et al. 1994). Methods for measuring chlorfenvinphos in some foods are sensitive (low ppb levels) 
with acceptable recovery (72–105%) (Agüera et al. 1993; FDA 1979; Frank et al. 1990; Kadenczki et 
al. 1992; Leoni et al. 1992; Stijve 1984). Available methods have 
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sufficient sensitivity for measuring chlorfenvinphos in water, soils and sediments, and foods at 
background levels. Information on the precision of these methods would be helpful. No methods are 
available for measuring chlorfenvinphos in ambient air.  Given its low volatility, chlorfenvinphos is not 
likely to be detected in ambient air. Methods are available for monitoring occupational exposure to 
chlorfenvinphos (Bagon and Warwick 1982). Research investigating the relationship between levels of 
chlorfenvinphos measured in water, soils and sediments, and food and health effects would be helpful. 
6.3.2 Ongoing Studies 
No ongoing studies involving chlorfenvinphos were located. 
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The national regulations and guidelines regarding chlorfenvinphos in air, food, and other media are 
summarized in Table 7-1. No international or state regulations were identified for chlorfenvinphos, nor 
were regulations and guidelines identified for chlorfenvinphos in air or water. 
ATSDR has not derived MRLs for inhalation exposure for any duration of exposure. 
An acute oral MRL of 0.002 mg/kg/day for chlorfenvinphos has been developed from a LOAEL of 
2.4 mg/kg/day, based on adverse neurological effects in rats (Barna and Simon 1973). 
An intermediate oral MRL of 0.002 mg/kg/day for chlorfenvinphos has been developed from a LOAEL 
of 1.5 mg/kg/day, based on adverse immunological/lymphoreticular effects in mice (Kowalczyk-Bronisz 
et al. 1992). 
A chronic oral MRL of 0.0007 mg/kg/day for chlorfenvinphos has been developed from a LOAEL of 
0.7 mg/kg/day, based on adverse neurological effects in rats (Ambrose et al. 1970). 
No reference concentration or dose exists for chlorfenvinphos, and no IARC or EPA cancer 
classification exists. 
Chlorfenvinphos is one of the chemicals regulated under "The Emergency Planning and Community 
Right-to-Know Act of 1986" (EPCRA) (EPA 1987). Section 313 of Title III of EPCRA requires owners 
and operators of certain facilities that manufacture, import, process, or otherwise use the chemicals on 
this list to report annually their release of those chemicals to any environmental media. 
An Occupational Safety and Health Administration (OSHA) permissible exposure limit (PEL) for 
chlorfenvinphos does not exist, nor is it regulated by the Clean Water Effluent Guidelines contained in 
Title 40, Sections 400-475, of the Code of Federal Regulations. 
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Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 
phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid 
phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per 
gram of soil or sediment. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic 
organisms at a specific time or during a discrete time period of exposure divided by the concentration 
in the surrounding water at the same time or during the same period. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may 
result from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any 
point in the life span of the organism. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure 
to a chemical; the distinguishing feature between the two terms is the stage of development during 
which the insult occurred. The terms, as used here, include malformations and variations, altered 
growth, and in utero death. 
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance 
based on health effects information. A health advisory is not a legally enforceable federal standard, 
but serves as technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 min without any escape-impairing symptoms or 
irreversible health effects. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result 
from exposure to environmental agents such as chemicals. 
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In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal 
population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation 
that is expected to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or 
group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level—An estimate of daily human exposure to a dose of a chemical that is likely to be 
without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen—A substance that causes mutations. A mutation is a change in the genetic material in a 
body cell. Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen 
between the exposed population and its appropriate control. Effects may be produced at this dose, 
but they are not considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL)—An allowable exposure level in workplace air averaged over an 
8-hour shift. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by 
the multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of 
the daily exposure of the human population to a potential hazard that is likely to be without risk of 
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deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal 
and human studies) by a consistent application of uncertainty factors that reflect various types of data 
used to estimate RfDs and an additional modifying factor, which is based on a professional judgment 
of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as 
cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable 
under CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an 
amount established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. 
Quantities are measured over a 24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may 
result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the 
related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed 
for up to 15 min continually. No more than four excursions are allowed per day, and there must be at 
least 60 min between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—A concentration of a substance to which most workers can be 
exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8­
hour workday or 40-hour workweek. 
Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data. 
UFs are intended to account for (1) the variation in sensitivity among the members of the human 
population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in 
extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the 





ATSDR MINIMAL RISK LEVEL 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 
99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly 
with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare 
toxicological profiles for each substance included on the priority list of hazardous substances; and 
assure the initiation of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available 
toxicological information and epidemiologic evaluations of a hazardous substance. During the 
development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and 
sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a 
specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to 
a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects 
over a specified duration of exposure. MRLs are based on noncancer health effects only and are not 
based on a consideration of cancer effects. These substance-specific estimates, which are intended 
to serve as screening levels, are used by ATSDR health assessors to identify contaminants and 
potential health effects that may be of concern at hazardous waste sites. It is important to note that 
MRLs are not intended to define clean-up or action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty 
factor approach. They are below levels that might cause adverse health effects in the people most 
sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate 
(15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of 
exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not 
yet identified a method suitable for this route of exposure. MRLs are generally based on the most 
sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects 
(such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for 




MRLs are intended only to serve as a screening tool to help public health professionals decide where 
to look more closely. They may also be viewed as a mechanism to identify those hazardous waste 
sites that are not expected to cause adverse health effects. Most MRLs contain a degree of 
uncertainty because of the lack of precise toxicological information on the people who might be most 
sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of 
hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this 
uncertainty consistent with the public health principle of prevention. Although human data are 
preferred, MRLs often must be based on animal studies because relevant human studies are lacking. 
In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the 
effects of hazardous substance than animals and that certain persons may be particularly sensitive. 
Thus, the resulting MRL may be as much as a hundredfold below levels that have been shown to be 
nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within 
the Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change 
as new information becomes available concomitant with updating the toxicological profiles. Thus, 
MRLs in the most recent toxicological profiles supersede previously published levels. For additional 
information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances 
and Disease Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333. 
A-3 CHLORFENVINPHOS 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical name: Chlorfenvinphos 
CAS number: 470-90-6 
Date: August 21, 1996 
Profile status: Final 
Route: [] Inhalation [x] Oral 
Duration: [x] Acute []Intermediate [] Chronic 
Key to figure: 13 
Species: Rat 
MRL: 0.002 [x] mg/kg/day [] ppm [] mg/m3 
Reference:  Barna J, Simon G. 1973. The effect of chlorfenvinphos insecticide in small often repeated 
dose. Cereal Research Commun. Vol.1, No. 3: 33-44. 
Experimental design (human study details or strain, number of animals per exposure/control group, 
sex, dose administration details): 
Two groups (55/group) of adult female albino (Wistar) rats weighing 208 g were orally administered 
Birlane® (chlorfenvinphos) at dose of 0 or 2.4 mg/kg/day in the diet for 10 days. The study was 
designed to investigate the effects of oral chlorfenvinphos on body weight increase, the 
gastrointestinal absorption of glucose, Na+, and Ca2+, as well as he effects of oral chlorfenvinphos on 
plasma and erythrocyte cholinesterase activity levels. 
Effects noted in study and corresponding doses: 
Plasma cholinesterase activity was inhibited by 52% while erythrocyte cholinesterase activity level was 
inhibited by 30% at a dose of 2.4 mg/kg/day (the only dose tested). Gastrointestinal (g.i.) absorption of 
glucose was increased by 30% over control values while Na+ absorption was decreased by 32% below 
control values. Gastrointestinal absorption of Ca2+ and body weight increases were unaffected by 
chlorfenvinphos exposure. These changes in the gastrointestinal absorption of glucose and Na+ were 
not considered statistically significant (P>0.05) by the investigators. 
Dose endpoint used for MRL derivation: 
[] NOAEL [x] LOAEL 
2.4 mg/kg/day; 30% decrease in erythrocyte cholinesterase activity in female rats. 
Uncertainty factors used in MRL derivation: 
[] 1 [] 3 [x] 10 (for use of a LOAEL)
 
[] 1 [] 3 [x] 10 (for extrapolation from animals to humans)
 
[] 1 [] 3 [x] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
If so, explain: No, the doses used are author-provided.
 





Was a conversion used from intermittent to continuous exposure?
Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: 
Neurological effects, mediated by cholinesterase inhibition, is the principal and most sensitive 
toxicological consequence of acute-duration exposure to chlorfenvinphos in humans (Cupp et al. 1975; 
Pach et al. 1987). Chlorfenvinphos also inhibits noradrenaline in the central nervous system 
(Brzezinski 1978). Human subjects, exposed to large acute doses of chlorfenvinphos, exhibited 
severe cholinergic signs. These cholinergic signs were relieved by the administration of atropine 
and/or pralidoxime, indicating cholinesterase inhibition etiology (Cupp et al. 1975; Pach et al. 1987). In 
rats, relatively moderate to low doses (2.4–30 mg/kg) of oral chlorfenvinphos significantly inhibited 
cholinesterase activities in a number of tissue including the brain, erythrocyte, and plasma (Osumi et 
al. 1975; Osicka-Koprowska et al. 1984; Puzynska 1984). An acute-duration oral study also found 
alterations in noradrenaline level in rat brain following exposure to chlorfenvinphos. A chlorfenvinphos 
dose of 13 mg/kg decreased noradrenaline levels in rat brains by 20%, as compared to control rats. 
According to the investigators, chlorfenvinphos accelerated the rate of NA disappearance from the 
brain (Brzezinski 1978). 
Therefore, it is appropriate to base the acute oral MRL for chlorfenvinphos on cholinesterase inhibition. 
It should be noted that a study by Osumi et al. (1975) which determined a NOAEL of 1 mg/kg/day and 
a LOAEL of 2 mg/kg/day for 38% inhibition of brain cholinesterase in rats was not used to calculate an 
acute oral MRL because of the gavage (oral) route of administration of the test substance which was 
deemed less appropriate by the ATSDR MRL Workgroup. An oral feeding study is preferred by the 
ATSDR MRL Workgroup. 
Agency Contact (Chemical Manager):  Alfred Dorsey. 
A-5 CHLORFENVINPHOS 
APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical name: Chlorfenvinphos 
CAS number: 470-90-6 
Date: August 21, 1996 
Profile status: Final 
Route: [] Inhalation [x] Oral 
Duration: [] Acute [x]Intermediate [] Chronic 
Key to figure: 23 
Species: Mouse 
MRL: 0.002 [x] mg/kg/day [] ppm [] mg/m3 
Reference:  Kowalczyk-Bronisz S, Gieldanowski J, Bubak , Kotz J. 1992. Studies on the effect of 
pesticide chlorfenvinfos on mouse immune system. Arc Immunol Ther Exp (Warsz) 40(5-6):283-289. 
Experimental design (human study details or strain, number of animals per exposure/control group, 
sex, dose administration details): 
The authors investigated the effect of chlorfenvinphos on mouse immune system.  In the study, male 
and female inbred C57BL/6 mice and (C57BL/6 x DBA/2)F1 (BDF1/Iiw) hybrids mice (6-8 weeks old) 
were orally dosed with chlorfenvinphos (suspended in 1% methylcellulose solution) and evaluated for 
5 days for the effect of chlorfenvinphos exposure on the mouse immune system.  The rats were 
exposed to oral chlorfenvinphos doses of 0, 1.5, 3, and 6 mg/kg (0, 1/100, 1/50, and 1/25 LD50) daily 
for 3 months; control group was given 1% methylcellulose. Then exposed and control mice were 
immunized by intraperitoneal injections of 0.2 mL 10% SRBC. IgM-PFC (plaque-forming or 
antibody-producing cells) number in spleen cell suspension was tested on day 4 after immunization 
and the procedure repeated 3 weeks after the exposure to chlorfenvinphos had been ceased. 
Exposed and control groups were subjected to immunological tests and hematological examinations. 
Lymphatic organs were histologically examined. 
Effects noted in study and corresponding doses: 
A dose-related decrease in number of hemolysin producing cells was observed: plaque-forming cells 
(PFC) were 58% at the 6 mg/kg dose group and 85% at the 3 mg/kg dose level as compared to 
control values. Chlorfenvinphos treatment also caused reduction in E rosettes forming cell number by 
30% at the 6 mg/kg dose level and by 25% at the 3 mg/kg dose level. Increases in Interlukin-1 (Il-1) 
activity and DTH reaction were observed 24 hours after challenge. Spleen colonies were stimulated 
as evidenced by the increase of endogenous spleen colonies and exogenous spleen colonies (CFU-S) 
increased 190% at the 1.48 mg/kg dose level and 137% at the 6 mg/kg dose level, and 162% at 
1.5 mg/kg dose level and 70% at the 6 mg/kg dose level, respectively). When the IgM PFC number 
was tested 3 weeks latter, after the exposure to chlorfenvinphos in the small dose (1.5 mg/kg), and 
increase (about 40%) in plaques number was observed. There was a 50% reduction in thymus weight 
at the 1.5 mg/kg dose level as compared to controls as well as significant involution of thymus was 
noted. 
Dose endpoint used for MRL derivation: 




1.5 mg/kg/day; 190% increase of spleen endogenous colonies; 162% increase of spleen exogenous 
colonies; 50% reduction in thymus weight. 
Uncertainty factors used in MRL derivation: 
[] 1 [] 3 [x] 10 (for use of a LOAEL)
 
[] 1 [] 3 [x] 10 (for extrapolation from animals to humans)
 
[] 1 [] 3 [x] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
If so, explain: Doses were provided as 1/100, 1/50, and 1/25 of the LD50 (148 mg/kg) by the authors,
 
resulting in doses of 1.5, 3, and 6 mg/kg, respectively.
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Not applicable. 
Was a conversion used from intermittent to continuous exposure?
Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: 
In other studies, adverse immunolymphoreticular effects has been associated with exposure to oral 
chlorfenvinphos. In an intermediate-duration dietary study with albino (Wistar) rats, there was a 
significant and irreversible reduction in relative spleen weight of female rats given $3 mg/kg/day 
chlorfenvinphos for 12 weeks (Ambrose et al. 1970). A study was undertaken to evaluate selected 
serological and cytoimmunological reactions in rabbits subjected to a long-term poisoning with 
subtoxic oral doses (10 mg/kg in a soya oil solution with a small amount of food) of chlorfenvinphos for 
90 days. Chlorfenvinphos treatment significantly elevated serum hemagglutinin level (16%) and 
hemolysin activity (66%, P<0.05) as well as increased the number of nucleated lymphoid cells 
producing hemolytic antibody to sheep erythrocytes as compared to controls (treated 906, P<0.05 and 
controls 618). Spleen cytomorphology changes, manifested mainly as transformation of primary 
follicles into secondary ones with well developed germinal centers, were also observed (Roszkowski 
1978). 
Therefore, it is appropriate to base the intermediate oral MRL for chlorfenvinphos on immunological 
effects. 
Agency Contact (Chemical Manager):  Alfred Dorsey. 
A-7 CHLORFENVINPHOS 
APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical name: Chlorfenvinphos 
CAS number: 470-90-6 
Date: August 21, 1996 
Profile status: Final 
Route: [] Inhalation [x] Oral 
Duration: [] Acute []Intermediate [x] Chronic 
Key to figure: 34 
Species: Rat 
MRL: 0.0007 [x] mg/kg/day [] ppm [] mg/m3 
Reference:  Ambrose AM, Larson PS, Borzelleca JF, Hennigar GR. 1970. Toxicologic studies on 
diethyl-1-(2,4-dichlorophenyl)-2-chlorovinyl phosphate.  Toxicology and Applied Pharmacology, 
17:323-336. 
Experimental design (human study details or strain, number of animals per exposure/control group, 
sex, dose administration details): 
The authors conducted toxicological studies with chlorfenvinphos in weaning albino (Wistar) rats. In 
the study, four matched groups of weaning albino (Wistar) rats (30 rats/sex/group) were culled to a 
narrow starting weight range and fed daily GC-4072 (technical chlorfenvinphos) doses of 0, 0.7, 2.1, 7, 
or 21 mg/kg/day (males) or 0, 0.8, 2.4, or 8, or 24 mg/kg/day (females) in the diet for 104 weeks. An 
additional group of non-littermate rats (30/sex) were administered 21 mg/kg/day (males) or 
24 mg/kg/day (females) chlorfenvinphos for 104 weeks. Plasma and erythrocyte cholinesterase (ChE) 
activity levels were obtained from 4 rats of each sex per dose group at 1, 4, 8, and 12 weeks. At 
13 weeks, 4 rats/sex/dose group were sacrificed for histopathologic examination. At 13 weeks, 
4 rats/sex/dose group were sacrificed for histopathologic examination. The rats in the 21 mg/kg/day 
(males) and 24 mg/kg/day (females) were sacrificed on the 95th week while all other dose group 
animals were sacrificed on the end of the study (104 weeks). At each autopsy, relative organ weights 
were determined for heart and kidneys. All animals sacrificed in moribund condition as well as those 
sacrificed at week 13, 95, and 104 weeks were examined grossly and microscopically and organs 
(heart, lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, 
skin, bone marrow, pancreas, thyroid, adrenal, pituitary) from these animals were histopathologically 
examined. Chlorfenvinphos significantly decreased body weight gain of females at the 8 and 
24 mg/kg/day dose groups from the 26th week till towards the end of the study, although, the 
decreased body weight gain became not statistically significant at the end of the study.  Increased 
relative liver weights were observed in males at the 7 mg/kg/day dose level but no other signs of 
hepatopathology was reported. No consistent difference in body weight gains in males, survival of the 
test animals, food consumption, or mortality was evident at all dose levels tested, as compared to 
undosed controls. Essentially, no gross or microscopic histopathology were evident in all the organs 
(heart, lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, 
skin, bone marrow, pancreas, thyroid, adrenal, pituitary) tissues examined. No changes in 
organ-to-body weight were observed in the heart, kidney, spleen and testes (Ambrose et al. 1970). 
Dose endpoint used for MRL derivation: 
[] NOAEL [x] LOAEL 
A-8 CHLORFENVINPHOS 
APPENDIX A 
0.7 mg/kg/day; 45% inhibition of plasma cholinesterase activity; 33% inhibition of erythrocyte 
cholinesterase activity 
Uncertainty factors used in MRL derivation: 
[] 1 [] 3 [x] 10 (for use of a LOAEL)
 
[] 1 [] 3 [x] 10 (for extrapolation from animals to humans)
 
[] 1 [] 3 [x] 10 (for human variability)
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
If so, explain: Doses, provided as food concentrations (10, 30, 100, or 300 ppm), were converted to
 
doses in mg/kg/day using rat daily food intake factor for chronic Wistar rat obtained from EPA (1988).
 
CALCULATIONS: 10 ppm =10 mg/kg; Male - 10 mg/kg x 0.07 mg/kg/day (chronic male Wistar rat food 
factor) = 0.7 mg/kg/day; 30 ppm = 2.1 mg/kg/day; 100 ppm =  7 mg/kg/day; 300 ppm = 21 mg/kg/day: 
Female - 10 mg/kg x 0.08 mg/kg/day (chronic female Wistar rat food factor) = 0.8 mg/kg/day; 30 ppm 
= 2.4 mg/kg/day; 100 ppm = 7 mg/kg/day; 300 ppm = 24 mg/kg/day. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Not applicable. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: 
Although the neurological effects of human prolonged exposure to low oral doses of chlorfenvinphos is 
not known due to a dearth of studies, acute-duration exposure data indicate that neurological effects, 
mediated by cholinesterase inhibition, is the most sensitive toxicological consequence of human 
exposure to chlorfenvinphos(Cupp et al. 1975; Pach et al. 1987; Taitelman 1992). Similarly, 
chlorfenvinphos significantly inhibited both plasma and erythrocyte cholinesterase activities in Beagle 
dogs (2/sex) fed daily chlorfenvinphos doses of 0, 0.3, 2, or 10 mg/kg/day (males), or 0, 1.5, 10, or 
50 mg/kg/day (females) in the diet (moist) for 104 weeks.  Plasma cholinesterase activities were 
significantly inhibited at all dietary levels through week 39 of the study; 49% inhibition at the 
0.3 mg/kg/day (males) and 1.5 mg/kg/day (females) dose levels.  Erythrocyte cholinesterase activity 
was significantly and consistently inhibited (36%) during the first 12 weeks only in the 10 mg/kg/day 
(males) and 50 mg/kg/day (females) dose levels (Ambrose et al. 1970). 
Therefore, it is considered appropriate to use this endpoint for developing a chronic oral MRL for 
chlorfenvinphos. 





Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it 
would still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence 
that will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-1 and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects. These levels cover health effects 
observed at increasing dose concentrations and durations, differences in response by species, 
minimal risk levels (MRLs) to humans for noncancer endpoints, and EPA's estimated range associated 
with an upper- bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE 
tables and figures for a quick review of the health effects and to locate data for a specific exposure 
scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in 
these tables and figures represent studies that provide reliable, quantitative estimates of 
No-Observed-Adverse- Effect Levels (NOAELs), Lowest-Observed- Adverse-Effect Levels (LOAELs), 
or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 2-1 and Figure 2-1 are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-1 
(1)	 Route of Exposure  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. When 
sufficient data exists, three LSE tables and two LSE figures are presented in the document. The 
three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and 
dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE 
Figure 2-1) and oral (LSE Figure 2-2) routes. Not all substances will have data on each route of 
exposure and will not therefore have all five of the tables and figures. 
(2)	 Exposure Period  Three exposure periods - acute (less than 15 days), intermediate 
(15–364 days), and chronic (365 days or more) are presented within each relevant route of 
exposure. In this example, an inhalation study of intermediate exposure duration is reported. 
For quick reference to health effects occurring from a known length of exposure, locate the 
applicable exposure period within the LSE table and figure. 
B-2 CHLORFENVINPHOS 
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(3)	 Health Effect  The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer. 
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4)	 Key to Figure  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the 2 "18r" data points in Figure 2-1). 
(5)	 Species  The test species, whether animal or human, are identified in this column. Section 2.5, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 
2.3, "Toxicokinetics," contains any available information on comparative toxicokinetics.  Although 
NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human 
doses to derive an MRL. 
(6)	 Exposure Frequency/Duration  The duration of the study and the weekly and daily exposure 
regimen are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to toxaphene via inhalation for 
6 hours per day, 5 days per week, for 3 weeks. For a more complete review of the dosing 
regimen refer to the appropriate sections of the text or the original reference paper, i.e., Nitschke 
et al. 1981. 
(7)	 System  This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not 
covered in these systems. In the example of key number 18, 1 systemic effect (respiratory) was 
investigated. 
(8)	 NOAEL  A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which 
no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 
3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation 
MRL of 0.005 ppm (see footnote "b"). 
(9)	 LOAEL  A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect. LOAELs have been classified into "Less Serious" and 
"Serious" effects. These distinctions help readers identify the levels of exposure at which 
adverse health effects first appear and the gradation of effects with increasing dose. A brief 
description of the specific endpoint used to quantify the adverse effect accompanies the LOAEL. 
The respiratory effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 
10 ppm. MRLs are not derived from Serious LOAELs. 
(10) Reference  The complete reference citation is given in Chapter 8 of the profile. 
(11) CEL	 A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12) Footnotes	 Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to 




See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period	 The same exposure periods appear as in the LSE table. In this example, 
health effects observed within the intermediate and chronic exposure periods are illustrated. 
(14) Health Effect	 These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15) Levels of Exposure	 concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported 
in mg/kg/day. 
(16) NOAEL	 In this example, 18r NOAEL is the critical endpoint for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol 
indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in 
the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level 
of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). 
(17) CEL	 Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The 
diamond symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 
corresponds to the entry in the LSE table. 
(18) Estimated Upper-Bound Human Cancer Risk Levels	 This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are 
derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope 
of the cancer dose response curve at low dose levels (q1*). 
(19) Key to LSE Figure  The Key explains the abbreviations and symbols used in the figure. 
SAMPLE
 







(ppm) Less serious (ppm) 
LOAEL (effect) 
Serious (ppm) Reference 
2 6 INTERMEDIATE EXPOSURE 
5  6  7  8  9  10 

6 Systemic 9 9 9 9 9 9
 








38 Rat	 18 mo 20 (CEL, multiple Wong et al. 1982 
5d/wk organs) 
7hr/d 
39 Rat	 89–104 wk 10 (CEL, lung tumors, NTP 1982 
5d/wk nasal tumors) 
6hr/d 
40 Mouse	 79–103 wk 10 (CEL, lung tumors, NTP 1982 
5d/wk hemangiosarcomas) 
6hr/d 
a The number corresponds to entries in Figure 2-1. 
6 b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5 x 10
-3 ppm; dose adjusted for intermittent exposure and divided by12 an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability). 
CEL = cancer effect level; d = days(s); hr = hour(s); LOAEL = lowest-observed-adverse-effect level; mo = month(s); NOAEL = no-observed­

































































Figure 2-1. Levels of Significant Exposure to [Chemical X] – Inhalation 
Acute Intermediate 


























30r 34r20m 35m17r 20m 31r16r 24g 18r 22g 21r 28m 29r 27r18r 22m 34r33r 
18r 
* Doses represent the lowest dose tested per study that produced a tumorigenic response and do not imply 





g Guinea Pig 
k Monkey 
The number next to each point 
corresponds to entries in the 
accompanying table. 
Minimal risk level for effects 
other than cancer 
LOAEL for serious effects (animals) 
LOAEL for  less serious effects (animals) 
NOAEL (animals) 





































Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of existing 
toxicologic, epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, 
weight-of-evidence discussions for human health endpoints by addressing the following questions. 
1.	 What effects are known to occur in humans? 
2.	 What effects observed in animals are likely to be of concern to humans? 
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous waste 
sites? 
The section covers endpoints in the same order they appear within the Discussion of Health Effects by Route of 
Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are presented first, 
then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro data and data from 
parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this section.  If data are 
located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing 
toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform 
cancer risk assessments.  Minimal risk levels (MRLs) for noncancer endpoints (if derived) and the endpoints 
from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health 
are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for inhalation 
and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action; but to acquaint health professionals with exposure levels at which adverse 
health effects are not expected to occur in humans.  They should help physicians and public health officials 
determine the safety of a community living near a chemical emission, given the concentration of a contaminant in 
air or the estimated daily dose in water.  MRLs are based largely on toxicological studies in animals and on 
reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2.5, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such as 2.7, 
"Interactions with Other Substances," and 2.8, "Populations that are Unusually Susceptible" provide important 
supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a modified 
version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes and 
Dourson 1988) to determine reference doses for lifetime exposure (RfDs). 
To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, represents 
the most sensitive human health effect for a given exposure route and duration.  ATSDR cannot make this 
judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential 
systemic, neurological, and developmental effects.  If this information and reliable quantitative data on the 




multiple species is available) with the highest NOAEL that does not exceed any adverse effect levels.  When a 
NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and 
an uncertainty factor (UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for 
human variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In deriving an 
MRL, these individual uncertainty factors are multiplied together.  The product is then divided into the inhalation 
concentration or oral dosage selected from the study.  Uncertainty factors used in developing a 




ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ADME Absorption, Distribution, Metabolism, and Excretion 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
BCF bioconcentration factor 
BSC Board of Scientific Counselors 
C Centigrade 
CDC Centers for Disease Control 
CEL Cancer Effect Level 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
CLP Contract Laboratory Program 
cm centimeter 
CNS central nervous system 
d  day  
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DOL Department of Labor 
ECG electrocardiogram 
EEG electroencephalogram 
EPA Environmental Protection Agency 
EKG see ECG 
F Fahrenheit 
F1 first filial generation 
FAO Food and Agricultural Organization of the United Nations 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
fpm feet per minute 
ft foot 
FR Federal Register 
g  gram  
GC gas chromatography 
gen generation 
HPLC high-performance liquid chromatography 
hr hour 
IDLH Immediately Dangerous to Life and Health 
IARC International Agency for Research on Cancer 
ILO International Labor Organization 
in inch 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LCLo lethal concentration, low 
LC50 lethal concentration, 50% kill 
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LDLo lethal dose, low 
LD50 lethal dose, 50% kill 
LOAEL lowest-observed-adverse-effect level 






mm Hg millimeters of mercury 
mmol millimole 
mo month 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
ng nanogram 
nm nanometer 
NHANES National Health and Nutrition Examination Survey 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPL National Priorities List 
NRC National Research Council 
NTIS National Technical Information Service 
NTP National Toxicology Program 
OSHA Occupational Safety and Health Administration 
PEL permissible exposure limit 
pg picogram 
pmol picomole 
PHS Public Health Service 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
REL recommended exposure limit 
RfD Reference Dose 
RTECS Registry of Toxic Effects of Chemical Substances 
sec second 
SCE sister chromatid exchange 
SIC Standard Industrial Classification 
SMR standard mortality ratio 
STEL short term exposure limit 
STORET STORAGE and RETRIEVAL 
TLV threshold limit value 
TSCA Toxic Substances Control Act 
TRI Toxics Release Inventory 
TWA time-weighted average 
U.S. United States 




WHO World Health Organization 
wk week 
> greater than 
> greater than or equal to 
= equal to 
< less than 
< less than or equal to 
% percent 
α alpha 
β beta 
δ delta 
γ gamma 
µm micrometer 
µg microgram 
